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ABSTRACT

DOPAMINE TRANSPORTER (DAT) AND METABOTROPIC GLUTAMATE
RECEPTOR 5 (MGLU5) IRREVERSIBLE PROBES FOR IDENTIFYING
ANTI-PSYCHOSTIMULANT THERAPEUTICS

By
Ranganadh Velagaleti
May 2014

Dissertation supervised by Dr. David J. Lapinsky
Numerous behavioral studies indicate that dopamine transporter (DAT) inhibitors
and metabotropic glutamate receptor 5 (mGlu5) negative allosteric modulators (NAMs)
possess promising anti-addiction therapeutic properties. However, the lack of human
DAT (hDAT) and mGlu5 X-ray crystal structures makes it difficult to understand how
these promising anti-addiction compounds interact with their major drug targets at the
molecular level. This knowledge gap represents an important problem towards rationally
designing new therapeutics for numerous addiction disorders. The objective of this
research was to develop irreversible chemical probes based on select DAT inhibitors and
mGlu5 NAMs in order to map the corresponding binding sites and poses of these
compounds within their major drug targets.

The central hypothesis was that these

compounds could be derivatized, without significant loss in pharmacological activity,
with a functional group capable of forming a covalent bond to their target protein and, if

iv

necessary, a tag functional group. These probes would then allow proteomic experiments
to be coupled with computational modeling in order to directly map the ligand-binding
sites of these promising anti-addiction compounds within their target proteins. The
central hypothesis was tested by pursuing two specific aims: 1) identification of nontropane DAT inhibitor photoprobes suitable for DAT structure-function studies, and 2)
identification of irreversible mGlu5 NAM ligands as chemical probes suitable for mGlu5
structure-function studies. Under the first aim, methylphenidate (MP) and GBR-12909 as
non-tropane DAT inhibitors were structurally modified to contain a photoreactive group
(e.g., aryl azide, benzophenone) and a tag (e.g.,

125

I, terminal alkyne, aliphatic azide).

These compounds were then subjected to DAT pharmacological evaluation in order to
identify suitable candidates for DAT structure-function studies. Under the second aim,
thiazole- and pyridine-based mGlu5 NAMs were structurally modified to contain either a
photoreactive group (e.g., aryl azide, benzophenone) or an affinity labeling group (e.g.,
methanethiosulfonate, maleimide) and a tag (e.g.,

125

I, terminal alkyne, aliphatic azide).

These compounds were then subjected to mGlu5 pharmacological evaluation in order to
identify suitable chemical probe candidates for mGlu5 structure-function studies. At
present, several irreversible chemical probes from these specific aims have advanced to
the proteomics stage of the experimental research strategy.
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CHAPTER ONE
1. Biological Literature Review
1.1.

The Problem of Cocaine Abuse
Cocaine (1.1, Figure 1.1) abuse and addiction represent a major problem not only

in the United States (U.S.), but worldwide (Degenhardt and Hall, 2012). Cocaine abuse
is not only a significant health problem, but this disease also imposes a huge economic
burden to society (Corlett, 2013). According to the 2011 National Survey on Drug Use
and Health, 37.8 million Americans over the age of 11 have reported use of cocaine at
least

once

in

their

lifetime

(http://www.drugabuse.gov/drugs-abuse/cocaine).

Additionally, the number of current cocaine users over the age of 11 is estimated to be
1.4 million (http://www.drugabuse.gov/publications/drugfacts/nationwide-trends).

Figure 1.1. The chemical structure of cocaine, an abused psychostimulant.

Historically, cocaine is a tropane alkaloid that was extracted from the leaves of
the coca plant Erythroxylum coca in 1855 (Stolberg, 2011). The compound was initially
used for treatment of depression and morphine addiction, then later as a local anesthetic
in ophthalmology during the 19th and early 20th centuries. Cocaine can be used in its
hydrochloride salt or free base form. The hydrochloride salt is typically administered
intravenously, whereas the free base, or a mixture of the free base with an ammonium salt
impurity (so-called crack), is used for inhalation. Since cocaine is the most potent
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stimulant of natural origin (Avois et al., 2006), it is categorized as a Schedule II drug by
the

U.S.

Drug

Enforcement

Administration

(http://www.justice.gov/dea/druginfo/ds.shtml), and its medical use is strictly regulated
by the U.S. federal government.
Cocaine addiction causes severe medical, psychiatric, and psychosocial problems.
Cocaine traditionally elicits euphoria, increased cardiovascular activity, hypothermia, and
hypertension upon administration (Zimmerman, 2012). Consequently, individuals who
abuse cocaine are at high risk for stroke, heart, and pulmonary diseases. In addition,
cocaine addicts are much more susceptible to infectious diseases such as HIV/AIDS,
Hepatitis B, and Hepatitis C (Parikh et al., 2012).

Furthermore, these individuals

experience financial instability and ultimately destroy their wellbeing, eventually leading
to social devastation and the alienation of loved ones (Vijayakumar et al., 2011).
Cocaine withdrawal leads to many symptoms including decreased energy, limited
ability to experience pleasure, depression, paranoia, hallucinations, and a strong desire to
use cocaine again (Zimmerman, 2012). As a result, overcoming cocaine dependence
requires tremendous will power and a sincere desire to quit. To date, no effective
pharmacotherapy for cocaine addiction exists, and behavioral therapies often represent
the only available method of treatment (Herdener et al., 2012). It has been hypothesized
that a correct combination of behavioral and pharmacological treatments may ultimately
provide the most effective approach for treating cocaine abuse and addiction (Haile et al.,
2012).
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1.2.

Cocaine and the Dopaminergic System

1.2.1. The Dopaminergic System
The dopaminergic system refers to dopaminergic neurons that synthesize and
release dopamine (1.2, Figure 1.2) as a chemical messenger. Dopamine is a major
catecholamine neurotransmitter that plays an important role in regulating brain processes
associated with reward, attention, locomotor activity, and cognition (Tritsch and Sabatini,
2012).

Figure 1.2. The chemical structure of dopamine as a neurotransmitter.

Dopamine is produced in several areas of the brain, including the substantia nigra
and the ventral tegmental area.

It is biosynthesized from tyrosine by tyrosine

hydroxylase and stored in vesicles of presynaptic neurons. In response to a presynaptic
action potential, dopamine is released into the synaptic cleft via calcium-mediated
exocytosis. Dopamine can then interact with postsynaptic dopamine receptors to produce
chemical impulses signaling satisfaction or reward (Arias-Carrion et al., 2010).
The DAT is a neuronal membrane protein that functions to regulate extracellular
dopamine levels by transporting dopamine back into presynaptic neurons, wherein
dopamine can then be degraded by monoamine oxidase (MAO) (Figure 1.3). As a result
of its function, the DAT plays a critical role in regulating both the signal amplitude and
duration of dopaminergic neurotransmission (Jaber et al., 1997).
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Figure 1.3. Dopaminergic neurotransmission (Reprinted with permission from
http://www.cnsforum.com/imagebank/item/MAO_cocaine/default.aspx. Copyright 2014, accessed on
02/26/2014)

1.2.2. Effects of Cocaine on the Dopaminergic System
The rewarding properties of cocaine and amphetamine have been explained via a
dopamine hypothesis, and multiple studies have identified the DAT protein as the
primary drug target associated with abuse and addiction of these psychostimulants
(Woolverton and Johnson, 1992; Fleckenstein et al., 2007). Cocaine has been shown to
bind to the DAT within presynaptic neuronal membranes of the dopaminergic system and
inhibit dopamine reuptake from the synaptic cleft. This leads to increased extracellular
dopamine levels that can continuously stimulate dopamine receptors on postsynaptic
neurons (Woolverton and Johnson, 1992; Fleckenstein et al., 2007).

In turn, this

phenomenon causes an increased activation of the dopaminergic reward pathways
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resulting in the euphoria and traditional ‘high’ associated with cocaine use (Figure 1.4)
(Schmitt and Reith, 2010).
Since cocaine bound to the DAT hinders the dopamine reuptake process, the
concentration of dopamine can be reduced by either metabolic removal from the synaptic
cleft or an increase in the number of DAT proteins. As a result, dopamine levels in the
synaptic cleft will eventually become reduced and lead to decreased euphoric or
rewarding effects. In turn this leads to craving, wherein cocaine users chronically selfadminister the drug in order to reactivate dopamine-mediated pathways that lead to the
‘high’ associated with cocaine use (Schmitt and Reith, 2010).

Figure 1.4. Inhibition of dopamine reuptake upon binding of cocaine to the DAT (Reprinted with
permission from http://www.cnsforum.com/imagebank/item/MAO_cocaine/ default.aspx. Copyright
2014, accessed on 02/26/2014)
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1.3.

The DAT

1.3.1. Chemical Composition and Structure of the DAT
The hDAT is an 80 kDa integral membrane protein of 620 amino acids that
belongs to the neurotransmitter/sodium symporter (NSS), or solute carrier 6 (SLC6),
family of proteins (Pramod et al., 2013). This protein features 12 transmembrane (TM)
domains connected by both intracellular and extracellular loops, and the amino and
carboxyl termini are located on the intracellular side of the protein (Figure 1.5). The
large extracellular loop linking TM 3-4 has several potential glycosylation sites that are
important for the stability and plasma membrane trafficking of the DAT, while TMs 1
and 6 are considered to be critical for both substrate and cocaine binding (Volz and
Schenck, 2005; Wang and Lewis, 2010).

Figure 1.5. Diagram of the membrane topology of the hDAT based upon bacterial leucine
transporter (LeuT) crystal structures. Full TM helices are numbered 1–12 and intra- and extracellular
loops are numbered 1–5 with prefixes either ‘i’ or ‘e’ respectively (Schmitt et al., 2008. Reprinted
with permission from J. Neurochem. 2008, 107, 928-940. Copyright 2008, International Society for
Neurochemistry).
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The precise tertiary structure of the hDAT remains unknown.

Nonetheless,

crystal structures of homologues of the NSS/SLC6 family of transporters such as the
bacterial (Aquifex aeolicus) LeuT (Yamashita et al., 2005; Zhou et al., 2007 and 2009;
Singh et al., 2007 and 2008; Quick et al., 2009; Nyola et al., 2010; Wang et al., 2012;
Krishnamurthy and Gouaux, 2012; Piscitelli and Gouaux, 2012; Wang and Gouaux,
2012; Kantcheva et al., 2013) and the fly (Drosophila melanogaster) DAT (dDAT)
(Penmatsa et al., 2013) have been recently solved. These high-resolution structures of
LeuT and dDAT have provided insight into the hDAT tertiary structure of this class of
proteins, especially hDAT. In turn, 3-D molecular models of hDAT have been generated
via sequence homology with LeuT (Indarte et al., 2008; Manepalli et al., 2012), and
several laboratories have performed site-directed mutagenesis experiments in order to try
and predict the precise location of the cocaine-binding pocket relative to the substratebinding site (Beuming et al., 2008; Stockner et al., 2013). Simultaneously, studies
employing photoreactive analogs of cocaine have also suggested approximate ligandbinding regions in the DAT (Vaughan et al., 2005 and 2007; Parnas et al., 2008).
Despite decades of intense research, the molecular mechanism, and exact binding site(s)
of cocaine and other DAT inhibitors remain unknown due to the lack of an accurate
tertiary structure of the hDAT.
1.3.2. Proposed Mechanism of Dopamine Reuptake by the DAT
Dopamine reuptake is an energy-dependent process reliant on ion gradient created
by Na+ K+-ATPase (Figure 1.6). This process drives the opening of the DAT and cotransport of dopamine, Na+, and Cl- from the synaptic cleft.

7

Figure 1.6. Na+K+-ATPase induced concentration gradient in the DAT (Reprinted with permission
from http://www.cnsforum.com/imagebank/item/rcpt_sys_DA_ reup/default.aspx. Copyright 2014,
accessed on 02/26/2014).

Figure 1.7. Dopamine influx coupled with inward flow of Na+ and Cl- ions as part of
the reuptake process (Reprinted with permission from
http://www.cnsforum.com/imagebank/item/rcpt_sys_DA_ reup/default.aspx. Copyright 2014,
accessed on 02/26/2014).
.
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Figure 1.8. The DAT returns to an outward-facing conformation in
order to facilitate another transport cycle (Reprinted with permission from
http://www.cnsforum.com/imagebank/item/rcpt_sys_DA_ reup/default.aspx. Copyright 2014,
accessed on 02/26/2014).

Jardetzky has proposed an alternate accessing model in which dopamine, Na+, and
Cl- first bind to the DAT in an outward-facing conformation (Figure 1.9) (Jardetzky,
1966). This binding is proposed to induce a conformational change in the transporter
such that the dopamine-binding site becomes exposed to the intracellular side of the
membrane (i.e., an inward-facing conformation), allowing dopamine, Na+, and Cl- to be
released into the cell (Figure 1.7). Subsequently, the DAT returns to an outward-facing
conformation in order to facilitate another transport cycle (Figure 1.8).
Jardetzky’s alternate access model, featuring transitions between outward- and
inward-facing DAT conformations, was further corroborated by single-molecule
dynamics studies, molecular simulations, and crystal structures of the LeuT (Yamashita
et al., 2005). In addition to the two low-energy conformations (i.e., the outward- and
inward-facing conformations), these studies have also revealed a third-low energy state
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termed the dually occluded, substrate-bound conformation (Figure 1.9) (Yamashita et al.,
2005; Schmitt et al., 2013).
Most recently, three conformational states have been suggested to occur during
dopamine (DA, Figure 1.9) transport: an outward-facing conformation for dopamine and
ion pickup, an occluded conformation featuring dopamine and ion bound, and an inwardfacing conformation allowing dopamine and ion release (Figure 1.9) (Schmitt et al.,
2013).

First, Na+ and Cl- ions are proposed to bind to an ion/substrate-free (apo)

outward-facing state of the DAT (Figure 1.9) and promote a more stabilized outwardfacing conformation featuring a fully open extracellular gate ready to bind substrate
(Krishnamurthy and Gouaux, 2012). Next, dopamine is proposed to bind at the primary
substrate (S1) site (Figure 1.9) and close the extracellular gate via salt-bridge formation
between extracellular gating residues Arg85 and Asp476 and aromatic bridge formation
between Tyr156 and Phe320 to give rise to the occluded state. Moreover, dopamine
binding at the S1 site also induces conformational changes thereby shifting the DAT
towards an inward-facing conformation. Simultaneously, a second dopamine molecule
has been proposed to bind to a secondary allosteric site (S2) in order to activate the
conformational shift from the occluded to inward-facing state (Figure 1.9) (Shi et al.,
2008). However, the nature of the S2 site and its relevance to DAT (NSS protein)
function is highly controversial (Rudnick, 2007; Quick et al., 2012 and the rebuttal of
Wang and Gouaux, 2012). Finally, dopamine, Na+, and Cl- ions are released into the
cytosol from the inward-facing state of the DAT due to hydration of its binding sites.
Subsequent DAT changes from the inward- to outward-facing state allow another
dopamine transport cycle to commence (Figure 1.9; Schmitt et al., 2013).
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Figure 1.9. Putative DAT conformational cycle (DA = dopamine) (Schmitt et al., 2013. Reprinted
with permission from J. Pharmacol. Exp. Ther. 2013, 346, 2-10. Copyright 2013, JPET Online by
American Society for Pharmacology and Experimental Therapeutics).

1.4.

DAT Ligands

1.4.1. DAT Substrates
Amphetamines (1.3-1.8; Figure 1.10) are a class of drugs notorious for high abuse
and addiction potential. Since these compounds are structurally similar to dopamine,
amphetamines behave as DAT substrates and get transported into the presynaptic neuron,
leading to an increased number of “inward-facing” transporter binding sites (Volz et al.,
2007). Concomitantly, these drugs are also VMAT-2 substrates, releasing vesicular
dopamine stores resulting in increased intracellular dopamine levels that enhance
dopamine reverse transport into the synaptic cleft (Kahlig and Galli, 2003). In addition,
a channel-like mode of the DAT has been indicated with respect to amphetaminemediated dopamine efflux (Sonders et al., 1997; Kahlig et al., 2005). The resulting
excessive dopaminergic neurotransmission in the reward areas of the brain leads to
amphetamine abuse and addiction (Fleckenstein et al., 2007).
11

Figure 1.10. Chemical structures of amphetamines as DAT substrates.

1.4.2. DAT Inhibitors
A suggested treatment for cocaine addiction has been the pursuit of DAT
inhibitors that act as cocaine antagonists without inhibiting dopamine uptake.

In

particular, it has been suggested that the ideal DAT inhibitor for treatment of cocaine
abuse should gradually eliminate craving for cocaine and help users maintain abstinence
from cocaine (Rothman et al., 1989; Carroll et al., 1999). However, the rational design
of such compounds has been challenging due to limited 3-D structural information and
poor understanding of dopamine- and inhibitor-binding sites within the DAT. As a
result, essentially all DAT inhibitors to date have been discovered either by serendipity or
ligand-based drug design.

In particular, these compounds have been traditionally

classified as either “cocaine-like” or “atypical” inhibitors due to their distinct behavioral
effects. In particular, given there are structural and behavioral differences between DAT
inhibitors, it has been suggested this protein exhibits ligand-specific pleotropic functional
qualities (Schmitt et al., 2013).
1.4.2.1.

“Cocaine-Like” DAT Inhibitors

1.4.2.1.1. Tropanes
Cocaine (1.1, Figure 1.1) is a pyschostimulant tropane analog that binds to the
DAT and inhibits dopamine reuptake. A large number of tropane analogs have been
thoroughly investigated in the hope of finding a cocaine antagonist that does not inhibit
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dopamine uptake to a significant extent (Carroll et al., 1999; Runyon and Carroll, 2006).
However, the overwhelming majority of tropane analogs exhibit cocaine-like behavioral
effects in vivo (Schmitt et al., 2013). Nevertheless, studies of these compounds have led
to the identification of several important tropane analogs including WIN-35,428 (1.9,
Figure 1.11; IC50 = 18 nM; Ki = 6.5 nM), which functions as a competitive inhibitor of
cocaine and displays 8-fold higher DAT binding affinity than cocaine (Clarke et al.,
1973; Madras et al., 1989). WIN-35,428 is a stable, long-lasting cocaine analog because
of the absence of the metabolically labile benzoate ester found within cocaine. As a
result, [3H]-WIN-35,428, a radiolabeled form of WIN-35,428, is extensively used in
determination of binding affinities of DAT ligands (Carroll et al., 1991).

Figure 1.11. Structural comparison between cocaine and WIN-35,428.

1.4.2.1.2. Methylphenidate (MP)
Methylphenidate (1.10, MP, Figure 1.12) is a highly potent DAT inhibitor
approved by the U.S. Food and Drug Administration (FDA) for the treatment of attention
deficit hyperactivity disorder (ADHD) (Hodgkins et al., 2012). MP displays 2-fold
higher DAT binding affinity when compared to cocaine (Pan et al., 1994) and has similar
pharmacophoric features (a basic nitrogen, methyl ester, and an aromatic ring).
Predictably, MP has reinforcing effects similar to that of cocaine in animal models.
However, these reinforcing effects in humans are substantially lower, and this drug has
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been shown to reduce cocaine craving (Yano and Steiner, 2007). In addition, MP has
been used for decades and is considered relatively safe upon oral administration.
Moreover, unlike cocaine, MP is not a sodium channel blocker at therapeutic levels and
does not have harmful effects on nerve conductance when taken in excess. As a result,
MP and its analogs are currently being pursued as potential candidates for the treatment
of cocaine dependence (Misra et al., 2010).

Figure 1.12. Structural comparison of cocaine versus MP.

1.4.2.2.

“Atypical” DAT Inhibitors

1.4.2.2.1. Benztropines
Benztropine

(1.11,

Figure

1.13)

is

a

centrally

acting

anticholinergic/antihistamine agent whose anticholinergic effects have been established
as therapeutically significant in the symptomatic management of Parkinsonism
(Katzenschlager et al., 2003).

Benztropine antagonizes the effect of acetylcholine,

decreasing the imbalance between the neurotransmitters acetylcholine and dopamine,
which may improve symptoms of parkinsonian tremor. Benztropine also functions as
a DAT inhibitor, which makes it useful for people with extrapyramidal symptoms who
take antipsychotics through a similar mechanism in the striatum (Soares and McGrath,
2000). Structurally, benztropine is a cocaine analog that lacks the methyl ester at the 2position of the tropane system, and contains a 3α-diphenylmethoxytropane in place of a
3β-benzoyl ester.

Although benztropines have high affinity for the DAT, these
14

compounds demonstrate unique behavioral profiles that are significantly different from
that of cocaine.

For example, benztropines did not stimulate locomotor activity as

effectively as cocaine, and did not fully substitute for cocaine in rats trained to
discriminate cocaine from saline injections (Newman et al., 1995; Katz et al., 1999 and
2004; Vela´zquez-Sa´nchez et al., 2010).

Moreover, benztropines were not self-

administered to the same degree as cocaine (Woolverton et al., 2000; Ferragud et al.,
2009; Hiranita et al., 2009) and have a relatively slow onset and reduced maximal effects
compared to cocaine (Tanda et al., 2009). As a result of these non-addictive behavioral
properties, benztropine analogs have garnered significant attention as potential agents for
the treatment of cocaine addiction (Rothman et al., 2008).

Figure 1.13. Structural comparison of cocaine versus benztropine as DAT inhibitors.

1.4.2.2.2. GBR-12909
Modified analogs of benztropine featuring a piperazine ring in place of the
bicyclic tropane skeleton have been termed GBR analogs (Rothman et al., 2008). GBR12909 (1.12, Figure 1.14) was initially envisioned as an antidepressant, but later was
found to be a highly selective DAT inhibitor that is structurally distinct from cocaine
(Esumi et al., 2013). Similar to the benztropines, GBR-12909 and its analogs have also
shown unique behavioral profiles that are significantly different from that of cocaine
(Villemagne et al., 1999).

Pharmacological studies of GBR-12909 indicate this
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compound has a higher affinity for, and slower dissociation rate from, the DAT in
comparison to cocaine.

Moreover, GBR-12909 was shown to antagonize cocaine’s

ability to increase extracellular dopamine levels (Rothman et al., 1991). Additionally,
GBR-12909 has a slower onset and longer duration of action than that of cocaine
(Rothman et al., 1992).

As a result of its promising pharmacodynamic and

pharmacokinetic profile, GBR-12909 was advanced into clinical trials for the treatment
of cocaine abuse, but later was withdrawn due to long QT syndrome (Goldsmith et al.,
2007).

Figure 1.14. Structural comparison of GBR-12909 versus benztropine and cocaine
as DAT inhibitors.

1.4.3. Unique Behavioral Responses of DAT Inhibitors
There is abundant evidence that different structural classes of DAT inhibitors
preferentially bind to unique transporter conformational states, which are suggested to
dictate the addictive liability of a particular DAT ligand (Loland et al., 2008). This type
of conformation-specific activity was first observed with differential effects for cocaine
and benztropine with respect to an extracellular-facing DAT cysteine residue’s reactivity
towards membrane-impermeable sulfhydryl reducing agents.

This experimental

observation suggests that these particular DAT inhibitors stabilize different transporter
conformations (Reith et al., 2001). These observations have been further corroborated by
several site-directed mutagenesis studies.

In particular, DAT mutations W84L and
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D313N in the extracellular vestibule have been shown to stabilize an outward-facing
DAT conformation (Chen et al., 2004). Each of these mutations resulted in an increased
DAT affinity for both cocaine and MP, whereas negligible or opposite effects on binding
affinity of atypical inhibitors such as GBR-12909 and benztropine was observed.
Additionally, these mutations did not affect the binding affinity of DAT substrates such
as dopamine and amphetamine. As a result, it has been suggested that preferential
interaction of cocaine-like compounds with an outward-facing DAT conformational state
may be responsible for the abusive or cocaine-like rewarding effects associated with
these compounds (Schmitt et al., 2008).
In contrast, Y335A mutation of the DAT has been shown to stabilize an inwardfacing DAT conformation (Kniazeff et al., 2008). In the Y335A DAT mutant, binding of
cocaine-like compounds was completely destroyed, whereas binding of atypical
inhibitors such as GBR-12909 and benztropine was nominally impacted.

These

observations give further credibility to the hypothesis that atypical DAT inhibitors
display reduced, or even a complete lack of, cocaine-like rewarding effects due to their
preferential interactions with the inward-facing DAT conformational state (Loland et al.,
2008; Kopajtic et al., 2010; Schmitt and Reith, 2011). Moreover, it has been shown that
the rate at which a particular DAT inhibitor enters the brain and interacts with the DAT
significantly affects the addictive liability of the compound. It has been observed that
DAT inhibitors with a rapid onset of action tend to have greater addiction potential than
those with a slower onset rate (Wee et al., 2006). As a result, it is believed that the
behavioral response to a specific DAT inhibitor is the result of a complex interplay
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between the rate of delivery to the brain (pharmacokinetics) and the mode of interaction
with the transporter (pharmacodynamics) (Schmitt et al., 2013).
1.5.

Cocaine and the Glutamatergic System

1.5.1. The Glutamatergic System
Glutamate (1.13, Figure 1.15) is a major excitatory neurotransmitter in the brain
that regulates a variety of functions including cognition, memory, and learning
(Meldrum, 2000).

Glutamate is known to exert its neuronal effects by principally

interacting with two classes of receptors: ionotropic glutamate receptors (iGlus) and
metabotropic glutamate receptors (mGlus) (Kew and Kemp, 2005).

Figure 1.15. Structural representation of glutamate as an excitatory neurotransmitter.

iGlus are ligand-gated ion channels that are responsible for mediating fast
excitatory neurotransmission. This group of receptors consists of N-methyl-D-aspartate
(NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA), and kainate
receptors (Traynelis et al., 2010). In contrast, mGlus are Family C G-protein-coupled
receptors (GPCRs) that modulate the strength of synaptic transmission (Niswender and
Conn, 2010). Currently there are eight known members of the mGlu family that are
classified into three groups (Group I, II, and III) according to their sequence homology,
pharmacology, and signal transduction mechanism. Group I mGlus (mGlu1 and mGlu5)
are predominately located post-synaptically and enhance cell signaling by increasing
intracellular calcium levels (Koulen et al., 1997). In contrast, group II (mGlu2 and
mGlu3) and group III (mGlu4, mGlu6, mGlu7, and mGlu8) mGlus are located pre-
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synaptically and display inhibitory eﬀects on neurotransmitter release by decreasing
cyclic adenosine monophosphate (cAMP) levels (Muto et al., 2007).
1.5.2. Effects of Cocaine on the Glutamatergic System
Traditionally, scientific research on cocaine addiction has focused mainly on
alterations in dopaminergic neurotransmission. While dopamine is crucial for reward and
initiation of addiction, end-stage addiction is primarily due to cellular adaptations in
glutamatergic projections to the nucleus accumbens. In particular, repeated use of
addictive drugs induces reorganization in neuronal circuit (Figure 1.16) of glutamatergic
and dopaminergic interconnections among the basolateral amygdala, ventral tegmental
area, nucleus accumbens, and prefrontal cortex, which ultimately leads to characteristic
behaviors of addiction.

However, the mechanism by which the disruption of neuronal

circuit of glutamate and dopamine (Figure 1.16) leads to addiction is less clear (Kalivas
and Nora, 2005; Schmidt and Christopher, 2010).

Figure 1.16. Neuronal circuit of glutamate and dopamine

In addition to the disruption of neuronal circuit of glutamate and dopamine, there
is significant evidence indicating a pivotal role for glutamatergic neurotransmission in
mediating the addictive behaviors and long-term neuroplasticity associated with cocaine
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abuse (Olive et al., 2012). In rodent models of addiction, it has been shown that repeated
exposure to cocaine increases the expression of mGlu5, which could play an important
role in the behavioral effects of cocaine (Ghasemzadeh et al., 2009). Additionally,
mutant mGlu5-null mice have been shown to be insensitive to the locomotor-stimulating
effects of cocaine and do not self-administer cocaine (Chiamulera et al., 2001).
Analogously, a highly selective mGlu5 non-competitive antagonist/ (NAM), 2-methyl-6(phenylethynyl)-pyridine (MPEP, 1.14, Figure 1.17), has been shown to attenuatecocaine mediated behavioral effects including relapse to cocaine seeking (Chiamulera et
al., 2001).

These particular studies have provided initial evidence that either

pharmacological or genetic inhibition of mGlu5 can decrease the locomotor stimulant and
reinforcing effects of cocaine. In turn, several mGlu5 NAMs have been shown to reduce
self-administration, conditioned reward, and reinstatement of drug seeking associated
with cocaine (Cleva and Olive, 2012).

Despite a significant amount of promising

behavioral evidence, the exact mechanism of mGlu5’s contribution to cocaine
dependence remains unknown.

Figure 1.17. Structural representation of MPEP, a mGlu5 NAM.

1.6.

Structural and Functional Features of mGlu5
mGlu5 is the most abundant mGlu in the brain and is expressed mainly

throughout the striatum, cortex, hippocampus, caudate putamen, and nucleus accumbens
(Matosin et al., 2013). Structurally, mGlu5 contains three major domains: a large bi-
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lobal, venus flytrap extracellular N-terminal domain that hosts the orthosteric- /
glutamate-binding site, a heptahelical domain containing seven TM regions linked by
short loops, and an intracellular C-terminal domain (Figure 1.18, Wood et al., 2011).

Figure 1.18. Structural and functional representation of mGlu5 as a Family C GPCR (Wood et al.,
2011. Reprinted with permission from Biochemistry 2011, 50, 2403-2410. Copyright 2011, American
Chemical Society).

Binding of the orthosteric ligand, glutamate, to mGlu5 has been suggested to
induce closure of the “Venus fly trap” domain. Upon this binding, conformational
changes of the TM domains are proposed to facilitate coupling of Gq proteins to mGlu5,
which in turn leads to activation of protein kinase C (PKC) and phospholipase C (PLC),
ultimately catalyzing the production of 1,4,5-inositol triphosphate and an increase in
intracellular calcium levels (Pin and Acher, 2002).
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1.7.

mGlu5 Ligands

1.7.1. Orthosteric- / Glutamate-Binding Site mGlu5 Ligands
Development of ligands focused on the mGlu5 glutamate-binding site has yielded
a variety of competitive agonists and antagonists. However, the overwhelming majority
of these compounds (e.g., 1.15 and 1.16, Figure 1.19) display poor selectivity for mGlu5
due to the highly conserved nature of the glutamate-binding pocket found within all eight
mGlu subtypes. Furthermore, most of these orthosteric ligands are highly polar amino
acid derivatives that could potentially lack favorable pharmacokinetic properties
necessary for modulating CNS-based mGlu5s (Rocher et al., 2011).

Figure 1.19. Structural examples of compounds targeting the orthosteric- / glutamate-binding
site of mGlu5.

1.7.2. mGlu5 Allosteric Modulators
Given selectivity and pharmacokinetic challenges associated with developing
orthosteric ligands as viable CNS drug candidates, more recent mGlu5 research has
shifted to the development of allosteric modulators (Figure 1.18) (Emmitte, 2013).
Allosteric ligands are proposed to bind at distinct sites (e.g., within the TM domains) that
are topologically distinct from the glutamate-binding site (N-terminal domain) (Sheffler
et al., 2011). Binding of these compounds in turn are proposed to induce conformational
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changes that modulate the efficacy and binding aﬃnity of glutamate, as well as coupling
of the TM domains to the G-protein. Allosteric ligands that enhance glutamate-induced
activation or glutamate binding affinity, without triggering mGlu5 directly (i.e., mGlu5
activation in the absence of glutamate), are termed positive allosteric modulators
(PAMs). Conversely, compounds that reduce glutamate-induced activation or glutamate
binding affinity in a noncompetitive manner are termed NAMs. In general, the pursuit of
allosteric modulators has proven to be a justifiable approach for achieving greater mGlu5
subtype selectivity due to the less conserved nature of allosteric binding sites versus the
orthosteric-binding site (Conn et al., 2009). Additionally, mGlu5 allosteric modulators
are generally more hydrophobic than glutamate analogs targeting the orthosteric-binding
site.

As a result, allosteric modulators are anticipated to have more appropriate

physiochemical properties for CNS penetration.

Furthermore, mGlu5 allosteric

modulators are less likely to contribute to receptor desensitization, internalization, and
down regulation commonly associated with orthosteric ligands.
Despite these advantages, numerous challenges are associated with the discovery
and optimization of mGlu5 allosteric modulators as potential therapeutics (Conn et al.,
2009). The significant lack of accurate and reliable mGlu5 3-D structural information
makes structure-based design of allosteric modulators currently impossible. Moreover,
numerous mGlu5 allosteric modulators have been shown to exhibit unique
pharmacological behavior including ligand-biased signaling and trafficking effects
(Noetzel et al., 2013). Additionally, structure-activity relationships (SAR) of mGlu5
allosteric modulators are notoriously difficult or “flat”, wherein minimal changes to the
structure can result in significant loss of activity (Zhao et al., 2007). Furthermore, many
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mGlu5 modulator chemotypes display a disturbing “molecular switch” phenomenon
whereby a NAM can arise from a PAM scaffold (or vice versa) via minimal structural
modification to the chemotype (Wood et al., 2011). Additionally, mGlu receptor subtype
selectivity may also potentially be changed upon minimal structural change to the ligand.
As a result, the phenomenon of molecular switches raises concern over the pharmacology
of putative metabolites, and represents a true nightmare for medicinal chemists trying to
develop SAR for driving a program towards a clinical candidate with a single mode of
pharmacology.
1.7.2.1.

mGlu5 NAMs
The study of mGlu5 NAMs in cocaine abuse has been principally aided by the

discovery of MPEP (1.14, Figure 1.20) (Gasparini et al., 1999) and 3-[(2-methyl-1,3thiazol-4-yl)ethynyl]-pyridine (1.17, MTEP, Figure 1.20) (Cosford et al., 2003), which
have been shown to attenuate cocaine-mediated behavioral effects including relapse to
cocaine seeking (Olive et al., 2012). Although MTEP shows similar in vitro potency in a
calcium influx assay (IC50 = 5 nM) versus MPEP (IC50 = 2 nM), MTEP displays less offtarget effects especially at the norepinephrine transporter (NET) and MAO-A. Moreover,
due to its higher oral bioavailability and brain penetration, MTEP has shown better in
vivo efficacy in cocaine abuse animal models (Cleva and Olive, 2012). Since the initial
discovery of MPEP and MTEP, a plethora of alternative mGlu5 allosteric modulator
chemotypes have been pursued not only as anti-addiction therapeutics, but as candidates
for

numerous

other

disorders

associated

with

mGlu5

(e.g.,

anxiety,

pain,

gastroesophageal reflux disease, Parkinson’s disease, and fragile X syndrome) (Emmitte,
2011 and 2013).

Most recently, a substituted 1-phenyl-3-(pyridin-2-yl) urea
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(VU0463841, 1.18, Figure 1.20) was shown to attenuate drug seeking behaviors in
relevant rat models of cocaine addiction (Amato et al., 2013).

In short, given

encouraging results of MPEP-like compounds in behavioral models of drug addiction,
small molecule negative allosteric modulation of mGlu5 represents an area of high
interest towards the development of anti-addiction therapeutics.

Figure 1.20. Chemical structures of MPEP, MTEP, and VU0463841 as representative
mGlu5 NAMs.
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CHAPTER TWO
2. Irreversible Chemical Labeling of Protein Drug Targets with Small
Molecules: Literature Review
2.1.

Introduction
Lack of accurate three-dimensional structural information with respect to the

DAT and mGlu5 represents a critical barrier in the rational design of inhibitors and
modulators for therapeutic use. Although computer-generated homology models have
given some insight into DAT (Indarte et al., 2008; Manepalli et al., 2012) and mGlu5
(Pagano et al., 2000; Malherbe et al., 2003; Molck et al., 2012; Kaae et al., 2012)
structure-function relationships, these powerful tools require further refinement and
experimental validation in order to be confidently used in drug discovery and
development programs.

Site-directed mutagenesis and chemical labeling with

irreversible molecular probes represent traditional experimental approaches for validating
homology models (Foucaud et al., 2001 and 2007) in order to refine computer-aided drug
discovery methods such as virtual / in silico screening (Tanrikulu et al., 2013).
Site-directed mutagenesis has been used as an experimental approach to indirectly
determine ligand-target molecular interactions and validate DAT (Surratt et al., 2005;
Volz and Schenk, 2005; Beuming et al., 2008; Stockner et al., 2013) and mGlu5 (Pagano
et al., 2000; Malherbe et al., 2003; Molck et al., 2012; Kaae et al., 2012) homology
models. In this strategy, if an amino acid substitution results in a significant change of a
ligand’s pharmacological effect, it indicates the residue’s importance within the ligandbinding site. However, the question of how these mutated amino acid residues directly
affect the pharmacology of a ligand cannot be easily clarified, as mutations may have
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long-range structural or functional effects that in turn may alter ligand pharmacology
(Colquhoun, 1998; Cervantes et al., 2013). Nevertheless, when a site-directed mutation
does not significantly interfere with the pharmacological activity of the drug target, such
an indirect effect cannot be suspected. In particular, if the amino acid mutation is a
cysteine, this residue can be chemically derivatized and the modified drug target can be
subsequently assayed (Foucaud et al., 2001 and 2007).
Alternatively, site-directed chemical labeling with irreversible molecular probes
can provide unequivocal experimental results in determining direct ligand-target
molecular interactions towards validating computationally-derived drug target homology
models (Foucaud et al., 2001 and 2007). This strategy employs affinity and photoaffinity
labeling agents, which upon initial reversible binding to the requisite drug target can
ultimately form an irreversible covalent bond to the drug target within the ligand-binding
site, thus providing direct unambiguous structural information regarding ligand-target
molecular interactions. To date, employment of irreversible chemical probes has never
been attempted with respect to mGlu5 structure-function studies. However, this strategy
has been extensively used with the DAT (Sallee et al., 1989; Grigoriadis et al., 1989;
Carroll et al., 1992; Deutsch et al., 1992; Schweri et al., 1992; Agoston et al., 1997;
Husbands et al., 1997; Dutta et al., 2001; Zou et al., 2001 and 2003; Cao et al., 2004;
Lever et al., 2005; Newman et al., 2006; Murthy et al., 2007 and 2008; Lapinsky et al.,
2009, 2011, 2012a, and 2012b). In this regard, it should be noted that multiple attempts
to elucidate microlevel structural information regarding DAT ligand-binding sites by
mass-spectrometry (MS) has not been successful, prinicipally due to limited resolution in
proteolytic separation, labor intensive peptide mapping strategies, and low efficiency of
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photolabel incorporation (Vaughan et al., 2005). Nonetheless, site-directed chemical
labeling techniques utilizing molecular probes have significantly evolved over the past
decade in order to address the traditional shortcomings associated with this experimental
approach (Foucaud et al., 2007; He et al., 2009).

These improvements and their

applications to this research will be discussed in further detail in subsequent sections of
this dissertation.
2.2.

Affinity Labeling
Affinity labeling is a powerful biochemical technique to investigate the presence

of nucleophilic amino acid residues within the binding sites of drug targets. Affinity
labeling agents are ligands decorated with an electrophilic functional group (EFG,
Scheme 2.1), which upon close proximity to a nucleophile (Nu) within the drug target
binding site can form a reversible binary complex whose lifespan is long enough to
sustain a covalent bond-forming reaction. In this complex, the probability of a reaction
between the nucleophile within the ligand-binding site and the electrophile of the ligand
does not depend on a collision, but rather upon the geometry of these functional groups
and their intrinsic chemical reactivity. Irreversible occupancy of the drug target can be
then determined by a competitive radioligand binding assay, which subsequently
confirms the presence of a nucleophilic amino acid within close proximity to the
electrophilic functional group of the affinity labeling probe.

Next, the irreversible,

covalent probe-target complex is then typically digested or fragmented via protease
and/or chemical cleavage methods. Subsequently, the resulting probe-labeled fragments
can then be analyzed using epitope-specific immunoprecipitation, high performance
liquid chromatography (HPLC), and mass spectrometry (MS) in order to identify the
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amino acid composition / sequence peripheral to the covalent point of attachment of the
probe to the drug target (Chen et al., 2003; Foucaud et al., 2001 and 2007).

Scheme 2.1. Affinity labeling towards determining the binding site of a ligand within a drug target
(Adapted with permission from Bioorg. Med. Chem. 2012, 20, 6237-6247.
Copyright 2012, Elsevier).

2.2.1. Thiol-Reactive Affinity Labeling Agents
Thiol-reactive affinity labeling agents are ligands featuring electrophilic
functional groups that have high or specific reactivity towards nucleophilic cysteine
residues found within ligand-binding sites of a drug target. Methanethiosulfonates (2.1)
and maleimides (2.4) represent two of the most common electrophilic functional groups
employed in the design of thiol-reactive affinity labeling agents (Scheme 2.2). When a
affinity labeling probe derivatized with a methanethiosulfonate (2.1) functional group
initially binds to its drug target (2.2) reversibly, the methanethiosulfonate electrophile
could potentially react with a close proximity cysteine residue to form an irreversible
ligand-drug target complex (2.3) (Foucaud et al., 2007; Chalker et al., 2009). Similarly,
when an affinity labeling probe is derivatized with a maleimide (2.4) functional group
and this probe binds with its drug target (2.2) reversibly, the maleimide electrophile could
potentially react with a close proximity cysteine residue to form an irreversible liganddrug target complex (2.5) via conjugate addition (Foucaud et al., 2007; Chalker et al.,
2009).
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Scheme 2.2. Ligands derivatized with methanethiosulfonate and maleimide electrophilic functional
groups reacting with cysteine residues of drug targets.

In addition to methanethiosulfonate (2.1) and maleimide (2.4) functional groups
(Scheme 2.2), isothiocyanates (2.6), alkyl and aryl halides (2.7), fluorosulfonates (2.8),
aziridinium groups (2.9), and -halo carbonyl compounds (e.g., 2.10 and 2.11) represent
widely used electrophiles employed in the design of thiol-reactive affinity labeling agents
(Figure 2.1; Foucaud et al., 2007). However, most of these electrophilic functional
groups are not necessarily thiol specific. For example, although maleimides (2.4) have
higher specificity for thiols at normal physiological conditions, they tend to react with
nucleophilic amines under slightly basic conditions (Narain, 2014). In another instance,
isothiocyanates (2.6; Sletten and Bertozzi, 2009) and iodoacetamides (2.11, X = -I; Boja
and Fales, 2001; Nielsen et al., 2008) also react with nucleophilic amines, especially
lysine residues. Irrespective of these limitations, these common electrophilies have been
extensively employed in the design of thiol-reactive affinity labeling agents (Narain,
2014).
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Figure 2.1. Additional electrophilic functional groups commonly employed in the
design of thiol-reactive affinity labeling agents.

2.2.2. Engineered Affinity Labeling
Engineered affinity labeling is a chemical biology strategy that combines thiolreactive affinity labeling agents with molecular modeling-guided site-directed
mutagenesis of putative binding site residues into cysteines (Foucaud et al., 2001 and
2007; Chalker et al., 2009). For this research, this strategy is being pursued as an
experimental approach to definitively validate mGlu5 homology models. The strategy
begins with an anti-addictive mGlu5 MPEP-binding site NAM derivatized with a thiolreactive functional group (TRFG) (Scheme 2.3). These affinity labeling chemical probes
can be subsequently docked into a mGlu5 homology model. Next, a series of cysteinesubstituted mGlu5 mutants, rationally designed according to their position in the mGlu5
homology model, will be prepared and pharmacologically tested for activity compared to
wildtype mGlu5.

Upon incubation of an appropriate mGlu5 thiol-reactive affinity

labeling probe with its cysteine-modified mGlu5 receptor partner, the rationally
introduced cysteine is expected to covalently react with the thiol-reactive affinity labeling
probe only if: 1.) the introduced cysteine belongs to the mGlu5 NAM binding site, and 2.)
the introduced cysteine is in close proximity to the thiol-reactive electrophilic functional
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group upon reversible binding of the affinity labeling probe.

Finally, irreversible

occupancy of the MPEP-binding site within mGlu5 by a cysteine-reactive mGlu5 NAM
can be confirmed by a competitive radioligand binding assay using [3H]-methoxyPEPy
(Cosford et al., 2003a). This research approach (Scheme 2.3) is expected to provide a
mGlu5 homology model with experimental support and thereby enhance computer-aided
drug discovery methods such as virtual / in silico screening. Finally, this method can
potentially investigate protein dynamics of mGlu5 as a full-length membrane-inserted
protein, as well as modulator-induced conformational changes, in order to better
understand the pharmacology of this therapeutically important drug target (Foucaud et
al., 2007).

Scheme 2.3. Engineered affinity labeling approach for experimental validation of a mGlu5 homology
model.

2.3.

Photoaffinity Labeling
Photoaffinity labeling is a widely used technique for characterizing how a ligand

interacts with its drug target at the molecular level (Dorman and Prestwich, 2000;
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Geurink et al., 2012). A photoaffinity probe is a ligand that contains a photoreactive
functional group (PRG), which is essentially inert and chemically unreactive under
normal conditions (Scheme 2.4). Photoaffinity probes also generally contain a reporter
group (RG), which is important for the identification of drug target fragments covalently
modified by the photoaffinity probe. Upon reversible binding of the photoaffinity probe
to its drug target, UV irradiation at a defined wavelength is capable of converting the
PRG into a more reactive chemical species, which then initiates covalent bond formation
between the drug target and the photoaffinity probe. Next, the irreversible, covalent
probe-target complex is then typically digested or fragmented via protease and/or
chemical cleavage methods. Subsequently, the resulting probe-labeled fragments can
then be analyzed using epitope-specific immunoprecipitation, HPLC, and MS in order to
identify the amino acid composition / sequence peripheral to the covalent point of
attachment of the probe to the drug target (Dorman and Prestwich, 2000; Geurink et al.,
2012).

Scheme 2.4. Photoaffinity labeling towards determining the binding site of a ligand within a drug
target (Adapted with permission from Bioorg. Med. Chem. 2012, 20, 6237-6247.
Copyright 2012, Elsevier).
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2.3.1. Select Photoreactive Groups Traditionally Employed in Photoaffinity
Labeling
2.3.1.1.

Aryl Azides
Aryl azides have been extensively used in photoaffinity probes because of

their relatively small structural change (compared to their parent compound) and ease of
chemical synthesis.

Photolysis of an aryl azide (2.12) at a wavelength of 254 nm

traditionally forms a highly reactive singlet nitrene (2.13), which can directly react with
the drug target by simultaneous hydrogen-abstraction and insertion reactions resulting in
a stable nitrogen-carbon or labile nitrogen-heteroatom bond (2.16) (Scheme 2.5).
Simultaneously, singlet nitrenes (2.13) can form triplet nitrenes (2.14) by intersystem
crossing (ISC) to give the same product (2.16) via hydrogen abstraction (2.15) and
radical-radical combination.

Additionally, singlet nitrenes can also rearrange to

dehydroazepines (2.17) by ring expansion, which traditionally causes undesired
nonspecific labeling (2.18) by reacting with proximal nucleophiles on other biological
macromolecules (Dorman and Prestwich, 2000; Geurink et al., 2012).
A major disadvantage of aryl azides in photoaffinity labeling is that their
maximum absorption wavelength is <300 nm, which is a relatively high amount of
energy that could potentially damage the biological system upon photoirradiation.
Moreover, lack of reaction specificity and rearrangement of nitrenes (e.g., 2.13 to 2.17)
traditionally results in low crosslinking yields (<30%) being observed.

In order to

address these disadvantages and improve the efficiency of chemical cross-linking,
(per)fluorinated and iodinated aryl azides have been used to decrease the rearrangement
of nitrenes by their electron withdrawing nature. Despite these disadvantages, aryl azides
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continue to remain important photoreactive groups in photoaffinity labeling for mapping
drug-binding pockets at the molecular level (Dorman and Prestwich, 2000; Geurink et al.,
2012).

Scheme 2.5. Reaction pathways of aryl azides upon photoactivation.

2.3.1.2.

Benzophenones
Analogous to aryl azides, benzophenones are widely used photoreactive

groups in photoaffinity labeling, principally due to their commercial availability and high
chemical cross-linking efficiency with drug targets. Photolysis of a benzophenone (2.19)
at 350 nm wavelength forms a diradical (2.20), which can directly crosslink to a drug
target by hydrogen abstraction (2.21) and selective carbon-carbon bond formation by
radical combination (2.22) (Scheme 2.6).

An important feature of this chemical

mechanism is that diradical formation (2.20) is reversible. Moreover, diradicals (2.20)
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are highly stable in protic solvents. As a result of these advantages, higher drug target
cross-linking efficiency has been observed with benzophenones compared to other
photoreactive functional groups traditionally employed in photoaffinity labeling (e.g.,
aryl azides and diazirines) (Dorman and Prestwich, 2000; Geurink et al., 2012).
Additionally, although benzophenone diradicals can react with all types of amino acids,
benzophenones tend to show higher selectivity towards methionine due to the chemical
stability of the labeled product (Wittelsberger et al., 2006). As a result of this unique
methionine “magnet” effect (Wittelsberger et al., 2006), benzophenone groups have been
routinely used in methionine proximity experiments (Fillion et al., 2013), wherein amino
acids are systematically mutated into methionines, thus serving as “baits” with the goal of
identifying drug target residues that are in close proximity to the ligand.

Scheme 2.6. Activation pathway of benzophenone photoreactive groups.

Despite these numerous advantages, the bulky size of benzophenones can
negatively impact the proper pharmacodynamic interactions between the photoprobe and
its biological target. Irrespective of this drawback, benzophenones remain one of the
most preferred photoreactive groups in photoaffinity labeling, principally due to their
higher chemical cross-linking efficiency and commercial availability (Dorman and
Prestwich, 2000; Geurink et al., 2012)
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2.3.2. Select Reporter Groups Traditionally Employed in Photoaffinity Probes
2.3.2.1.

Radioactive Isotopes
Radioactive isotopes represent some the most popular reporter groups in

photoaffinity labeling studies because they provide a highly sensitive signal, require
minimal equipment for production, and are easy to detect using autoradiographic
methods. In particular, 125I is a widely used radioactive tag because of its relatively easy
synthetic incorporation into a molecule of any complexity via numerous methods.
Furthermore, the relatively small size of the iodine atom, when compared to other
traditional reporter groups such as biotin or ﬂuorophores, often results in minimum
structural modiﬁcation to the parent ligand.

Moreover, the ability of

125

I-labeled

molecules to be utilized in both in vitro and in vivo applications makes this reporter group
particularly attractive with respect to the covalent labeling of biological macromolecules
(Sadaghiani et al., 2007).
However, the short half-life of

125

I, t1/2 = ~60 days (Seevers and Counsell,

1982), indicates that radio-iodinated molecules are not suitable for long storage times and
can undergo relatively fast chemical degradation.

In addition, radiolabels are often

harmful, thus requiring additional care in their handling and use in a laboratory setting
(Sadaghiani et al., 2007; Lapinsky, 2012).
2.3.2.2.

‘Clickable’ Handles as Chemical Reporters
Towards addressing the disadvantages associated with radioactive isotopes as

reporter groups in photoaffinity labeling, a relatively new strategy has emerged wherein
either a terminal alkyne or aliphatic azide can be inserted into a photoprobe to serve as a
‘clickable’ handle / chemical reporter. These reporter groups are relatively small in size
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and can be easily installed into a parent ligand. Additionally, these functional groups are
bioorthogonal and less likely to negatively influence biological activity when compared
to the parent compound, principally by minimally disturbing key pharmacodynamic
interactions. As a result, these advantages make clickable handles the current reporter
group of choice in terms of experiments associated with covalent labeling of biological
macromolecules (Sadaghiani et al., 2007; Lapinsky, 2012).

Scheme 2.7. Tandem photoaffinity labeling-bioorthogonal conjugation (Lapinsky, 2012. Reprinted
with permission from Bioorg. Med. Chem. 2012, 20, 6237-6247.
Copyright 2012, Elsevier).

Most recently, a routine chemical strategy has emerged wherein following
covalent ligation of a photoprobe to a drug target by photoirradiation (Scheme 2.7),
clickable handles are used for bioorthogonal conjugation / attachment of a wide variety of
tags (e.g., biotin, fluorophores, FLAG peptide), thereby making this strategy particularly
advantageous for the identification and isolation of probe-labeled biological targets. In
particular, bioorthogonal conjugation is traditionally performed using either a StaudingerBertozzi ligation (Saxon and Bertozzi, 2000) or copper-catalyzed Huisgen 1,3-dipolar
cycloaddition (so called ‘click’ reaction) (Rostovtsev et al., 2002) chemical reaction
(Scheme 2.8).

This combined approach, termed tandem photoaffinity labeling-
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bioorthogonal conjugation (Lapinsky, 2012), also allows for high-throughput analysis
and potential use in vivo (Sadaghiani et al., 2007).

Scheme 2.8. Bioorthogonal conjugation strategies traditionally employed after photoaffinity labeling.

The only apparent drawback of this labeling strategy is that bioorthogonal
chemical coupling yields can often vary in different systems. In particular, low yields
have been generally observed under Staudinger–Bertozzi ligation conditions when
compared to copper-catalyzed Huisgen 1,3-dipolar cycloadditions (Speers et al., 2003).
However, this variability in bioorthogonal conjugation yield is signiﬁcantly trumped by
the substantial advantages associated with the strategy (Lapinsky, 2012).
2.3.2.3.

Binding Ensemble Profiling with (f)Photoaffinity Labeling (BEProFL)
Binding ensemble proﬁling with (f)photoafﬁnity labeling (BEProFL) (He et

al., 2009) is a powerful strategy wherein photoaffinity labeling is coupled with traditional
proteomic techniques and molecular modeling studies in order to accurately determine
the three-dimensional structure of a ligand–target complex. In particular, this strategy
facilitates

identiﬁcation

of

key

ligand–target
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molecular

interactions

(i.e.,

pharmacodynamics)

thereby

unambiguously

validating

homology

models

via

experimental support. This strategy is being envisioned utilizing DAT and mGlu5 antiaddiction photoprobes generated via this research, principally to experimentally validate
and refine their respective homology models (Scheme 2.9). In short, a DAT or mGlu5
anti-addiction lead compound is derivatized with both a photoreactive group (PRG) and a
reporter group (RG).

Upon reversible binding to their respective drug targets and

subsequent photoaffinity labeling, an irreversible ligand-target complex is expected to be
formed, which can then be subjected to traditional proteomic experiments and
computational studies in order to map the ligand-binding poses and sites of DAT or
mGlu5 anti-addiction compounds within their protein targets. Utilization of the BEProFL
approach is expected to further refine and/or validate DAT or mGlu5 homology models
via experimental support, thereby enabling more confident computer-aided drug
discovery efforts aimed at these targets (e.g., virtual / in silico screening, structure-based
drug design) (Indarte et al., 2010; Mueller et al., 2010).

Scheme 2.9. Binding ensemble profiling with (f)photoaffinity labeling towards experimental
validation and refinement of DAT and mGlu5 homology models.
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CHAPTER THREE
3. Chemical Literature Review
3.1.

Review of Synthetic Approaches Towards Racemic threo-MP as a Lead
Compound
A chemical synthesis of racemic threo-MP ((±)-1.10, Scheme 3.1) was first

developed by Panizzon in 1944 (Panizzon, 1944) then later improved by Deutsch and
colleagues in 1996 (Deutsch et al., 1996).

This scheme begins with treatment of

phenylacetonitrile (3.1) with 2-bromopyridine (3.2) under basic conditions to provide
nitrile 3.3, which was then subjected to acidic hydrolysis to provide amide 3.4 in 45%
overall yield (Scheme 3.1).

Scheme 3.1. Synthesis of racemic threo-MP according to Deutsch et al., 1996.

Hydrogenation of the pyridine ring of 3.4 and subsequent treatment with HCl
provided a mixture of diastereomeric piperidine salts (3.5) in good yield (90%). Acidic
hydrolysis of the amide of 3.5, followed by epimerization under basic conditions and
subsequent salt formation provided a diastereomeric mixture of racemic threo-ritilanic

41

acid derivatives (3.6) in moderate yield (64%).

Finally, esterification of 3.6 with

methanolic HCl and subsequent recrystallization provided racemic threo-MP ((±)-1.10)
in 84% yield (Deutsch et al., 1996). This synthetic route by Deutsch and coworkers
(Deutsch et al., 1996) was rather poor in terms of yield (9 steps, 18% overall yield) and
often gave a mixture of products that required difficult chromatographic separations. In
turn, a relatively short and efficient synthesis of racemic threo-MP ((±)-1.10) was
developed by Axten and colleagues in 1998 (Axten et al., 1998), which was then further
improved by Gutman and colleagues in 2004 (5 steps, 56% overall yield) (Gutman et al.,
2004) (Scheme 3.2).

Scheme 3.2. Synthesis of racemic threo-MP according to Gutman et al., 2004.

Synthesis of racemic threo-MP ((±)-1.10) according to Gutman et al. (Gutman et
al., 2004) begins with treatment of α-keto ester 3.7 with piperidine (3.8) to provide α-keto
amide 3.9 in nearly quantitative yield (Scheme 3.2). Subsequent condensation of the
ketone with tosylhydrazine under acidic conditions provided tosylhydrazone 3.10 in 85%
yield. Next, thermal cyclization of tosylhydrazone 3.10 under aqueous basic conditions
using Aliquat 336 as a phase transfer catalyst, followed by column chromatography and
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recrystallization from diethyl ether, gives diastereomerically pure racemic threo-β-lactam
(±)-3.11 as the major product in moderate yield (68%). Finally, threo-β-lactam (±)-3.11
was converted to racemic threo-MP ((±)-1.10) in quantitative yield by ring opening with
MeOH under acidic conditions (Scheme 3.2).
Simultaneously, Dias and De Piloto Fernandes (Dias and De Piloto Fernandes,
2000) reported their improved synthesis (7 steps, 35% overall yield) of racemic threo-MP
((±)-1.10) from known precursors α-ethoxy carbamate 3.15 (Nagasaka et al., 1986) and
silyl ketene acetal 3.17 (Tanaka and Fuji, 1992) (Scheme 3.4). Their synthetic approach
features protection of lactam nitrogen 3.12 as its carbamate 3.14, which upon treatment
with NaBH4 and EtOH in HCl provided α-ethoxy carbamate 3.15 in 63% overall yield
(Scheme 3.3; Nagasaka et al., 1986). Simultaneously, treatment of benzylic ester 3.16
with LDA and TMSCl provided silyl ketene acetal 3.17 in 90% yield (Scheme 3.3;
Tanaka and Fuji, 1992).

Scheme 3.3. Synthesis of α-ethoxy carbamate (3.15, Nagasaka et al., 1986) and silyl ketene acetal
(3.17, Tanaka and Fuji, 1992) precursors.

Next, condensation between α-ethoxy carbamate 3.15 and silyl ketene acetal
3.17 in the presence of TESOTf gave an inseparable diastereomeric mixture of Nprotected racemic threo-MP derivatives (3.18) in 90% yield (Scheme 3.4).
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Hydrogenolysis of the carbamate within 3.18 afforded a mixture of racemic threo- and
erythro-MP free bases, which were separated by column chromatography.

Finally,

racemic threo-MP free base was treated with methanolic HCl to produce the
hydrochloride salt ((±)-1.10) in 69% yield.

Scheme 3.4. Synthesis of racemic threo-MP according to
Dias and De Piloto Fernandes, 2000.

Concomitantly, Deutsch and coworkers (Deutsch et al., 2001) reported a new
synthetic route for racemic threo-MP ((±)-1.10) (8 steps, 7% overall yield) based on a
Blaise reaction (Scheme 3.5). This synthetic route begins with conversion of 4-chloro-1butanol (3.19) to 4-cyano-1-butanol, whose alcohol was converted to the corresponding
mesylate (3.20) in 25% yield. Mesylate 3.20 was then subjected to a Blaise reaction with
methyl 2-bromo-2-phenylacetate (3.21) in presence of zinc to provide imine 3.22, which
rearranges to form Z-enamine 3.23 in 63% yield. Reduction of enamine 3.23 was readily
accomplished with sodium cyanoborohydride at pH 6, wherein piperidine formation
occurred spontaneously during the work-up under basic conditions to provide a
diastereomeric mixture of racemic threo- and erythro-MPs (3.25) in 78% yield. Finally,
epimerization of the diastereomeric mixture of racemic threo- and erythro-MPs (3.25)
under basic conditions and subsequent treatment with methanolic HCl followed by
recrystallization provided racemic threo-MP ((±)-1.10) in 55 % yield (Scheme 3.5).
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Scheme 3.5. Synthesis of racemic threo-MP according to Deutsch et al., 2001.

3.2.

Known Synthesis of Racemic threo-4-Iodo-MP as a Lead Compound
A synthesis of racemic threo-4-iodo-MP ((±)-3.31, Scheme 3.6) developed from

racemic threo-MP ((±)-1.10) has been described by Pan and coworkers (Pan et al., 1996).
This scheme begins with N-benzoylation of racemic threo-MP to provide amide (±)-3.26
in near quantitative yield. The amide was subsequently nitrated with nitric acid to give
predominantly the p-nitro isomer ((±)-3.27) in moderate yield (85%).

The nitro

functional group was then reduced with iron under acidic conditions to provide aniline
(±)-3.28 in 85% yield, followed by subsequent diazotization and displacement with
potassium iodide to produce p-iodo compound (±)-3.29 in 60% yield. In turn, global
hydrolysis of benzamide (±)-3.29 under strong acidic conditions provides racemic threo4-iodo-ritalinic acid ((±)-3.30) in 40% yield, which upon esterification with methanolic
HCl quantitatively leads to racemic threo-4-iodo-MP ((±)-3.31) (Scheme 3.6).
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Scheme 3.6. Synthesis of racemic threo-4-iodo-MP according to Pan et al., 1996.

3.3.

Review of Synthetic Approaches Towards Enantiopure (R,R)-MP as a Lead
Compound
The shortest and most efficient synthetic route for preparing the more

pharmacologically active enantiomer of threo-MP (Ding et al., 1997; Williard et al.,
2007), that is (R,R)-MP ((+)-1.10), has been developed via direct resolution of
commercially available racemic threo-MP ((±)-1.10) (Scheme 3.7) (Prashad et al., 1999a
and 2000).

This approach features treatment of racemic threo-MP ((±)-1.10) with

dibenzoyl-D-(-)-tartaric acid (3.32) in the presence of 4-methylmorpholine in a mixture of
MeOH and water (2:1 v/v). Such conditions provided the dibenzoyl-D-(-)-tartaric acid
salt of (R,R)-MP ((+)-3.33) in 44% yield with excellent enantiomeric purity (R,R : S,S =
99.54 : 0.46).

Subsequent basification of diastereomeric salt (+)-3.33 with sodium

hydroxide, followed by HCl salt formation and water-HCl recrystallization gives (R,R)MP ((+)-1.10) in 91% yield with excellent enantiomeric purity (R,R : S,S = >99.9 : <0.1)
(Scheme 3.7).
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Scheme 3.7. Preparation of (R,R)-MP via diastereomeric salt formation
(Prashad et al., 1999a).

A highly efficient enantioselective synthesis reported by Axten and coworkers
(Axten et al., 1999) features concomitant stereocontrol of two chiral centers directly from
commercially available starting materials (Scheme 3.8).

This strategy begins with

rhodium-catalyzed asymmetric C-H insertion of methyl phenyldiazoacetate (3.35) with
N-Boc-piperidine (3.34) leading to enantioselective formation of N-Boc-MP (+)-3.37 in
65% yield with 94% de and 69% ee. Removal of the Boc group of (+)-3.37 with HCl gas
in MeOH gave crude (R,R)-MP in 68% yield with 94% de and 69% ee. Next, crude
(R,R)-MP was recrystallized twice from ethanol-diethyl ether (1:1 v/v) to provide
optically pure (R,R)-MP ((+)-1.10) in 24% yield with 95% de and >95% ee (Scheme 3.8).

Scheme 3.8. Preparation of (R,R)-MP via rhodium-catalyzed C-H insertion
(Axten et al., 1999).

Other synthetic approaches towards enantiopure (R,R)-MP have been published a
comprehensive review (Prashad, 2001).

The most recently developed enantiopure

synthesis of (R,R)-MP, by Krishna and coworkers (Krishna et al., 2007), features a ringclosing metathesis protocol to construct the piperidine ring and Sharpless asymmetric
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epoxidation to efficiently generate two contiguous stereocentres (Scheme 3.9). This
approach begins with coupling of propargyl alcohol (3.38) with allyl bromide in the
presence of copper iodide, tetrabutyl ammonium iodide, and potassium carbonate to give
hex-5-en-2-yn-1-ol, whose triple bond was partially reduced in the presence of nickel
acetate and sodium borohydride to afford Z-alkene 3.39 in 77% yield.

Sharpless

asymmetric epoxidation of alkene 3.39 with cumene hydroperoxide in the presence of (–
)-diisopropyl D-tartrate and titanium(IV) isopropoxide afforded epoxide 3.40 (92% ee),
which was then subjected to chelation-assisted regioselective nucleophilic ring-opening
with phenyl lithium in the presence of copper iodide to provide 1,3-diol 3.41 in 60%
overall yield. Then primary alcohol of alkene 3.41 was then selectively protected with
TBDPS chloride, while the secondary alcohol was mesylated and subsequently displaced
with azide to provide intermediate 3.42 in 60% yield. Next, the azide of intermediate
3.42 was reduced to the primary amine under Staudinger reaction conditions followed by
acryloylation to afford bis-olefin 3.43 in 75% yield. Subsequent ring-closing reaction of
diene 3.43 using Grubbs’ first-generation catalyst 3.44 provided α,β-unsaturated lactam
3.45, which was then converted to piperidine 3.46 in 55% yield by first reducing the
olefin via hydrogenation and then the amide with BH3•DMS. Next, the secondary amine
within piperidine 3.46 was protected as its carbamate and the silyl group was removed to
produce the primary alcohol, which was subsequently oxidized to aldehyde 3.47 in 51%
yield via Dess–Martin periodinane. The final steps of this elaborate synthesis feature
oxidation of aldehyde 3.47 to the corresponding carboxylic acid, followed by treatment
with methanolic HCl to provide (R,R)-MP ((+)-1.10) in 61% yield with high optical
purity (Scheme 3.9).
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Scheme 3.9. Preparation of (R,R)-MP via ring-closing metathesis (Krishna et al., 2007).

3.4.

Known Synthesis of Racemic threo-3,4-Dichloro-MP as a Lead Compound
Racemic threo-3,4-dichloro-MP ((±)-3.53, Scheme 3.10) represented a lead

compound for photoprobe design because it displays a number of interesting DAT
pharmacological properties when compared to racemic threo-MP. For example, racemic
threo-3,4-dichloro-MP is equipotent as an inhibitor of [3H]-WIN 35,428 (1.9) binding
and [3H]-dopamine (1.2) uptake, whereas racemic threo-MP is threefold less potent as
inhibitor of [3H]-dopamine (1.2) uptake.
A synthesis of racemic threo-3,4-dichloro-MP has been reported by Deutsch and
coworkers (Deutsch et al., 1996). This synthesis is analogous to the chemistry depicted

49

in Scheme 3.1 and begins by reacting 3,4-dichlorophenylacetonitrile (3.48) with 2bromopyridine (3.2) to provide nitrile 3.49 (Scheme 3.10). Subsequent acidic hydrolysis
provided amide 3.50 in 40% overall yield. Hydrogenation of the pyridine ring of amide
3.50 followed by treatment with HCl provided a mixture of diastereomeric piperidine
salts (3.51) in 80% yield. Acidic hydrolysis of the amide of 3.51, epimerization under
basic conditions, then subsequent salt formation provided a diastereomeric mixture of
racemic threo-3,4-dichloro-ritilanic acid derivatives (3.52) in 54% yield.

Finally,

esterification of carboxylic acids 3.52 with methanolic HCl followed by recrystallization
provided racemic threo-3,4-dichloro-MP ((±)-3.53) in 80% yield (Deutsch et al., 1996).

Scheme 3.10. Synthesis of racemic threo-3,4-dichloro-MP
according to Deutsch et al., 1996.

3.5.

Review of Synthetic Approaches Towards GBR-12909 as a Lead Compound
GBR-12909 (1.12, Scheme 3.11) represents one of the most studied DAT

inhibitors to date as a potential cocaine abuse therapeutic. The original synthesis of this
compound was disclosed by Van der zee and coworkers in 1980 (Van der zee et al.,
1980). Their approach featured initial treatment of 4,4’-difluorobenzhydrol (3.54) with
2-chloroethanol (3.55) under acidic conditions to provide chloride 3.56 in moderate yield
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(85%) (Scheme 3.11).

Next, displacement of the chloride within 3.56 with excess

piperazine (3.57) provided mono-substituted piperazine derivative 3.58 in 55% yield,
which upon alkylation with 1-phenyl-3-bromopropane (3.59) provided GBR-12909
(1.12) in 80% yield. Finally, treatment of GBR-12909 (1.12) with maleic acid followed
by MeOH-DMF recrystallization provided GBR-12909 dimaleate (3.60) in 45% yield.

Scheme 3.11. Synthesis of GBR-12909 according to Van der zee et al., 1980.

Given its tremendous therapeutic promise, GBR-12909 (1.12) was needed in
large-scale (kilogram) quantities for clinical trials. For this purpose, a synthetic route
developed by the National Institute on Drug Abuse (NIDA) (Scheme 3.12) was evaluated
for scale-up by Ironside and coworkers (Ironside et al., 2002).

Analogous to that

previously described, this effort began with initial treatment of 4,4’-difluorobenzhydrol
(3.54) with 2-chloroethanol (3.55) under acidic conditions to provide chloride 3.56 in
moderate yield (65%) after column chromatography (Scheme 3.12).

In parallel,

treatment of 1-phenyl-3-bromopropane (3.59) with excess piperazine (3.57) in refluxing
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acetonitrile provided 1-(3-phenylpropyl)piperazine, which upon treatment with dioxaneHCl

and

subsequent

MeOH-acetone

recrystallization

afforded

phenylpropyl)piperazine dihydrochloride (3.61) in moderate yield (45%).

1-(3Next, a

coupling reaction between chloride 3.56 and mono-substituted piperazine derivative 3.61
was performed in refluxing acetonitrile to provide GBR-12909 (1.12), which was then
converted to dihydrochloride salt 3.62 in 30% yield by treatment with dioxane-HCl and
subsequent water-ethanol recrystallization.

Scheme 3.12. Attempted scale-up synthesis of GBR-12909 by Ironside et al., 2002.

A major obstacle in the scale-up of GBR-12909 via NIDA’s synthetic route
(Scheme 3.12) was chloride 3.56 formation, wherein extraction with EtOAc formed
emulsions and required tedious column chromatographic purification. Moreover, the
synthesis of dihydrochloride salts 3.61 and 3.62 employed 1,4-dioxane-HCl as an adverse
reagent and produced difficult to filter solids, which typically needed vacuum-drying
prior to proceeding to the next step. In addition, the coupling of intermediates 3.56 and
3.61 was low yielding and not reproducible.

As a result, Ironside and coworkers

(Ironside et al., 2002) pursued improvements to the synthetic route previously developed
by NIDA (Scheme 3.13).
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Scheme 3.13. Successful scale-up synthesis of GBR-12909 by Ironside et al., 2002.

In the optimized synthetic route, replacement of p-TsOH with catalytic H2SO4
during chloride 3.56 synthesis, and introduction of heptane as the extraction solvent,
eliminated the emulsion and tedious chromatographic purification problems, thus
resulting in an improved yield from 65% to 98% (Scheme 3.12 versus Scheme 3.13).
Moreover, undesirable 1,4-dioxane-HCl was replaced with ethanol and HCl during salt
formation reactions to provide piperazines 3.61 and 3.62 with improved filtration
properties, higher purity, and increased yield (from 45% to 62%; Scheme 3.12 versus
Scheme 3.13). Furthermore, utilization of a preformed iodoether (3.63), replacement of
acetonitrile (CH3CN) with methyl ethyl ketone (MEK), and use of an aqueous base in the
last coupling step was relatively high yielding and reproducible (Scheme 3.12 versus
Scheme 3.13). As a result of these improved scale-up conditions depicted in Scheme
3.13, GBR-12909 (1.12) was successfully synthesized in kilogram quantities for clinical
trials.
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3.6.

Review of Synthetic Approaches Towards MPEP as a Lead Compound
MPEP (1.14, Scheme 3.14) represents a prototype NAM of mGlu5.

This

compound was originally synthesized by Tsuchiya and coworkers (Tsuchiya et al., 1984)
by Sonogashira coupling 2-bromo-6-methylpyridine (3.64) with ethynyl benzene (3.65)
(Scheme 3.14). However, practical experimental conditions and the yield of MPEP
(1.14) were not reported as a result of this work.

Scheme 3.14. Synthesis of MPEP by Tsuchiya et al., 1984.

Given the importance of MPEP (1.14) as a lead compound with respect to mGlu5,
several alternative synthetic strategies have been subsequently reported to that of
Tsuchiya et al. 1984. One strategy developed by Sorensen and Pombo-Villar (Sorensen
and Pombo-Villar, 2005) features microwave-mediated one-pot desilylation of
trimethyl(phenylethynyl) silane (3.66) with tetrabutylammonium chloride (TBACl),
followed by copper-free palladium-mediated Sonogashira coupling with 2-bromo-6methylpyridine (3.64) to give MPEP (1.14) in 50% yield (Scheme 3.15).

Scheme 3.15. Synthesis of MPEP by
Sorensen and Pombo-Villar, 2005.
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Another strategy towards the synthesis of MPEP (1.14) begins with Sonogashira
coupling of 2-bromo-6-methylpyridine (3.64) with trimethylsilyl acetylene (3.67) to
provide alkyne-protected pyridine derivative 3.68 in 70% yield (Alagille et al., 2005)
(Scheme 3.16).

Subsequent one-pot desilylation of protected alkyne 3.68 with

tetrabutylammonium fluoride (TBAF) and palladium-mediated Sonogashira coupling
with iodobenzene (3.69) provided MPEP (1.14) in 78% yield (Jaeschke et al., 2007).

Scheme 3.16. Synthesis of MPEP by Jaeschke et al., 2007.

A different strategy developed by Saleh and coworkers (Saleh et al., 2011),
features Heck alkynylation of 2-bromo-6-methylpyridine (3.64) with ethynylbenzene
(3.65) to provide MPEP (1.14) in 90% yield (Scheme 3.17). It is noteworthy to mention
that 1-n-butyl-3-methylimidazolium tetrafluoroborate ([BMIM][BF4]) was chosen as the
reaction solvent due to its high compatibility with transition metals, low vapor pressure,
ease of handling, and potential for recycling, which are favorable for industrial-scale
synthesis.

Scheme 3.17. Synthesis of MPEP by Saleh et al., 2011.

Another strategy developed by Reddy and coworkers (Reddy et al., 2013) features
palladium-catalyzed decarboxylative coupling of 3-phenylpropiolic acid (3.70) with 2-
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bromo-6-methylpyridine (3.64) to give MPEP (1.14) in 70% yield (Scheme 3.18). This
synthetic route employing 3-phenylpropiolic acid (3.70) is valuable because homocoupled side products traditionally associated with using terminal alkynes (e.g., 3.65,
Scheme 3.14) are not observed during industrial-scale synthesis.

Scheme 3.18. Synthesis of MPEP by Reddy et al., 2013.

3.7.

Review of Synthetic Approaches Towards MTEP as a Lead Compound
MTEP (1.17, Scheme 3.19) represents another prototype NAM for mGlu5. This

compound was originally synthesized by Cosford and coworkers in 2003 (Cosford et al.,
2003).

Their strategy began with condensation of acid chloride 3.72 with

bis(trimethylsilyl)acetylene (3.73) to provide -chloro ketone derivative 3.74 in 70%
yield (Scheme 3.19). Subsequent cyclization with thioacetamide (3.75) provided alkyneprotected methylthiazole derivative 3.76 in 60% yield. Finally, subjection of alkyne 3.76
to one-pot desilylation with tetrabutylammonium ﬂuoride (TBAF) and Sonogashira
coupling with 3-bromopyridine (3.77) afforded MTEP (1.17) in 50% yield (Cosford et
al., 2003).

Scheme 3.19. Synthesis of MTEP by Cosford et al., 2003.
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Roppe and coworkers (Roppe et al., 2004) synthesized MTEP (1.17) analogous to
Cosford et al., 2003 with a minor modification in Sonogashira coupling between alkyneprotected methylthiazole derivative 3.76 and 3-bromopyridine (3.77) (Scheme 3.20).
Usage of Pd(PPh3)4 in place of PdCl2(PPh3)2 led to an increased yield of MTEP (1.17)
from 50% to 87% (Scheme 3.19 versus Scheme 3.20).

Scheme 3.20. Synthesis of MTEP by Roppe et al., 2004.

Iso and coworkers (Iso et al., 2006) synthesized MTEP (1.17) analogous to
Cosford et al., 2003 with the exception of using 3-iodopyridine (3.78) as the electrophile
and Pd(PPh3)4 as the catalyst during Sonogashira coupling of alkyne-protected
methylthiazole derivative 3.76 (Scheme 3.21). Although the reaction time significantly
decreased from 4 hours to 30 minutes, no significant improvement in yield was observed
as a result of these particular changes (Scheme 3.19 versus Scheme 3.21).

Scheme 3.21. Synthesis of MTEP by Iso et al., 2006.

Finally, McIldowie and coworkers (McIldowie et al., 2009) reported a mediumscale (5 grams) synthesis of MTEP (1.17, Scheme 3.22) with minor modifications to the
Sonogashira coupling between alkyne-protected methylthiazole derivative 3.76 and 3bromopyridine (3.77) versus the original route developed by Cosford et al., 2003. Usage
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of Pd(PPh3)4, diisopropyl amine, and slower generation of the terminal alkyne by
extended syringe-pump addition of tetrabutylammonium ﬂuoride (TBAF) provided
MTEP (1.17) in 78% yield (Scheme 3.22).

Scheme 3.22. Synthesis of MTEP by McIldowie et al., 2009.
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CHAPTER FOUR
4. Statement of Research Problems
4.1.

Current Knowledge Gaps

4.1.1. DAT Structure-Function Knowledge Gap
The discrete molecular / pharmacodynamic interactions between cocaine-like or
atypical DAT inhibitors with the DAT remain unknown. In particular, it is not clear how
structurally distinct DAT inhibitor classes (e.g., tropane versus non-tropane DAT
inhibitors) specifically interact with the DAT to generate specific behavioral and/or
phenomenological effects (e.g., addictive versus non-addictive behavioral responses).
4.1.2. mGlu5 Structure-Function Knowledge Gap
Notable advances have been made in characterizing the MPEP-binding site within
the TM domain of mGlu5 (Pagano et al., 2000; Malherbe et al., 2003; Molck et al., 2012;
Kaae et al., 2012). However, it is unclear how subtle changes to the chemical structure of
a mGlu5 MPEP-binding site allosteric modulator can lead to either an opposite mode of
mechanism of action (i.e., a “molecular switch” from a mGu5 NAM to a mGlu5 PAM, or
vice versa) or a change in the ligand’s mGlu receptor subtype selectivity profile.
4.2.

Long-Term Goal of This Research
The long-term goal of this research is to understand how promising anti-addiction

compounds interact with their major drug targets at the molecular level, and use that
information in rational drug discovery and drug development efforts.
4.3.

Overall Objective of This Research
The overall objective of this research was to develop irreversible chemical probes

based on promising DAT and mGlu5 anti-addiction compounds in order to map their
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corresponding binding sites and poses within their major drug targets.
4.4.

Central Hypothesis of This Research
The central hypothesis of this research (Scheme 4.1) was that promising DAT and

mGlu5 anti-addiction compounds could be derivatized, without significant loss in
pharmacological activity, with a functional group (FG) capable of forming a covalent
bond to its target protein and, if necessary, a reporter group (RG). These probes are
expected to allow DAT and mGlu5 proteomic experiments to be coupled with DAT and
mGlu5 computational modeling (i.e., engineered affinity labeling previously described in
Section 2.2.2 and BEProFL previously described in Section 2.3.2.3) in order to directly
map the ligand-binding poses and sites of these anti-addiction compounds within their
target proteins.

Scheme 4.1. Central hypothesis of this research.
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4.5.

Rationale of This Research
The rationale of this research is that once it is known how promising DAT and

mGlu5 anti-addiction compounds specifically interact within their major drug targets at
the molecular level, lead compounds can then be logically manipulated into novel drug
candidates that bind and modulate the function of these anti-addiction drug targets.
Furthermore, this research is expected to predict the pharmacological profile of existing
and novel DAT and mGlu5 anti-addiction compounds and their major metabolites,
ultimately allowing rational structure-based drug design and confident virtual / in silico
screening in order to identify novel chemotypes targeting the DAT or mGlu5 as antiaddiction drug target proteins.
4.6.

Rational Design of MP-Based Photoprobes Suitable for DAT StructureFunction Studies
MP ((±)-1.10, Figure 4.2) is a highly potent DAT inhibitor clinically approved by

the U.S. FDA for the treatment of ADHD (Hodgkins et al., 2012). MP displays 2-fold
higher DAT binding affinity when compared to cocaine (Pan et al., 1994) and has similar
pharmacophoric features (a basic nitrogen, methyl ester, and an aromatic ring).
Predictably, MP has reinforcing effects similar to that of cocaine in animal models;
however, these reinforcing effects in humans are substantially lower, and MP has been
shown to reduce cocaine craving (Yano and Steiner, 2007). Additionally, MP has been
used for decades and is considered relatively safe upon oral administration. Moreover,
unlike cocaine, MP is not a sodium channel blocker and does not have harmful effects on
nerve conductance when taken in excess (Schwartz et al., 2010). As a result, MP and its
analogs are currently being pursued as potential candidates for the treatment of cocaine
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dependence (Misra et al., 2010).

Despite MP’s clinical significance, its specific

molecular contacts with the DAT remain unknown. In order to address this knowledge
gap, several MP-based DAT inhibitor photoprobes were designed for potential use in
DAT structure-function studies.
4.6.1. Rational

Design

of

Racemic

threo-N-Azidobenzyl-4-Iodo/3-Iodo-MP

Photoaffinity Ligands for DAT Structure-Function Studies
With respect to DAT inhibitor photoafﬁnity probe design, an overwhelming
number of known compounds contain an aromatic 3-iodo-4-azido substituted ring motif
(Figure 4.1; Sallee et al., 1989; Grigoriadis et al., 1989; Carroll et al., 1992; Agoston et
al., 1997; Dutta et al., 2001; Zou et al., 2001 and 2003; Cao et al., 2004; Lever et al.,
2005; Newman et al., 2006; Chen et al., 2007; Lapinsky et al., 2009, 2012a, and 2012b).
In particular, the 3-iodine of this common photoaffinity labeling structural motif not only
represents a position for a radioisotope tag as I125, but also an electron-withdrawing group
that is proposed to stabilize the singlet nitrene (2.13, Scheme 2.5) of the aryl azide upon
photoreaction (Soundararajan and Platz, 1990). However, this aromatic 3-iodo-4-azidosubstituted ring motif has been proposed to inherently lead to low labeling efﬁciency
(e.g., <1%) of the aryl azide into the DAT protein due to its juxtaposition ortho to the
sterically bulky iodine atom (Vaughan et al., 2005). Towards addressing this potential
disadvantage, novel probes were designed in which the photoreactive aryl azide group
and the 125I radiotracer tag were placed on different parts of the MP ((±)-1.10, Figure 4.2)
scaffold (Lapinsky et al., 2011).

62

Figure 4.1. Photoaffinity probes containing an aromatic 3-iodo-4-azido-substituted ring motif.
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Figure 4.2. Rational design of racemic threo-N-azidobenzyl-4-iodo/3-iodo-MP compounds as DAT
photoaffinity ligands.

4-Iodo-MP ((±)-3.31, Figure 4.2) and 3-iodo-MP ((±)-4.18, Figure 4.2) were
chosen as lead compounds for MP photoprobe design since it is known these analogs
display 6-fold (Deutsch et al., 1996) and 18-fold higher DAT binding afﬁnity,
respectively, versus MP ((±)-1.10). As a result, the 3- and 4-positions of MP’s aromatic
ring were envisioned as logical places to anchor the bulky iodine atom as a future
radiotracer tag (i.e., I125) within rationally designed DAT photoafﬁnity probes.
Additionally, known N-benzyl-MP analogs ((±)-4.19 to (±)-4.23, Figure 4.2) were
considered as lead compounds for photoprobe design since these compounds are known
to display either improved or retained DAT binding afﬁnity versus MP ((±)-1.10) (Misra
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et al., 2010). Based on these established structure–activity relationships for (±)-threo-MP
analogs, a series of DAT photoafﬁnity ligands ((±)-4.24 to (±)-4.29, Figure 4.2) was
rationally designed via molecular hybridization of known iodo-MP analogs ((±)-3.31 and
(±)-4.18) with known N-benzyl-MP analogs ((±)-4.19 to (±)-4.23).

These target

photoprobes featured systematic placement of a photoreactive aryl azide on the aromatic
ring of the N-benzyl substituent and anchoring of an iodine atom at either the 3- or 4position of MP’s aromatic ring.
4.6.1.1.

Results of Racemic threo-N-Azidobenzyl-4-Iodo/3-Iodo-MP Photoaffinity
Ligands for DAT Structure-Function Studies
Target compounds ((±)-4.24 to (±)-4.29, Figure 4.2) were synthesized (see

Chapter 5) and submitted to Dr. Christopher K. Surratt’s pharmacology lab at Duquesne
University for determination of their DAT binding affinity in comparison to the known
MP analogs previously described.

Dr. Surratt’s laboratory determined that lead

compounds 4-iodo-MP ((±)-3.31) and 3-iodo-MP ((±)-4.18) displayed 2-fold and 5-fold
higher DAT binding afﬁnity, respectively, versus MP ((±)-1.10) (Table 4.1). However, it
was observed that substituting the piperidine nitrogen of these iodo-MPs with a N-benzyl
group bearing a photoreactive aromatic azide resulted in a signiﬁcant decrease in DAT
binding afﬁnity (15-fold to 110-fold lower DAT binding afﬁnity than (±)-MP; see Table
4.1). From this series of hybrid compounds, p-azido-N-benzyl-4-iodo-MP ((±)-4.26)
displayed the highest DAT binding afﬁnity (Ki = 363 ± 28 nM). This compound was
subsequently synthesized in its I125 form in the laboratory of Dr. John Lever (University
of Missouri – Columbia) and advanced to DAT photoaffinity labeling studies in the
laboratory of Dr. Roxanne Vaughan (University of North Dakota). (±)-[I125]-4.26 was
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shown to bind covalently to rat striatal DAT and hDAT expressed in cultured cells
(Lapinsky et al., 2011). Co-incubation of (±)-4.26 with nonradioactive D-(+)-MP or (-)2-β-carbomethoxy-3-β-(4-fluorophenyl)tropane (β-CFT, WIN-35,428, a cocaine analog)
blocked DAT labeling (see Appendix).

Compound (±)-4.26 represents the first

successful example of a DAT photoaffinity ligand based on the MP scaffold. Such
ligands are expected to assist in mapping non-tropane ligand-binding pockets within
plasma membrane monoamine transporters.
Table 4.1. DAT binding affinity for racemic threo-N-azidobenzyl-4-iodo/3-iodo-MP photoaffinity
ligands. Inhibition of [3H]-WIN-35,428 binding by compounds at hDAT N2A neuroblastoma cells.

[3H]-WIN binding inhibition,
No.

Compound
hDAT Ki (nM)*

(±)-1.10

MP

25 ± 1

(±)-3.31

4-Iodo-MP

14 ± 3

(±)-4.24

o-Azido-N-benzyl-4-iodo-MP

517 ± 65

(±)-4.25

m-Azido-N-benzyl-4-iodo-MP

2754 ± 169

(±)-4.26

p-Azido-N-benzyl-4-iodo-MP

363 ± 28

(±)-4.18

3-Iodo-MP

4.5 ± 1

(±)-4.27

o-Azido-N-benzyl-3-iodo-MP

1112 ± 163

(±)-4.28

m-Azido-N-benzyl-3-iodo-MP

2056 ± 73

(±)-4.29

p-Azido-N-benzyl-3-iodo-MP

658 ± 70

* Each Ki value represents data from at least three independent experiments with each data point on
the curve performed in duplicate. P < 0.05 versus Ki of (±)-threo-MP.

With respect to DAT binding afﬁnity and the position of the photoreactive azide
functional group on the N-benzyl aromatic ring (Table 4.1), the para position appears to
be about the same (15- and 26-fold lower binding afﬁnity than (±)-MP) as compared to
the ortho position (21- and 44-fold lower binding afﬁnity than (±)-MP). Substitution of
the photoreactive azide at the meta position resulted in a much greater decrease in DAT
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binding afﬁnity (110- and 82-fold lower binding afﬁnity than (±)-MP). There was no
obvious advantage in terms of DAT binding afﬁnity associated with the position of the
iodine in these hybrid analogs (average Ki: 3-iodo compounds = 1280 nM; 4-iodo
compounds = 1210 nM). As a result, these rationally designed azido-N-benzyl-iodo-MPs
(Lapinsky et al., 2011) behaved unlike previously reported MPs in which N-benzyl
substitution either increased or retained DAT afﬁnity (Misra et al., 2010).
4.6.2. Rational Design of Racemic threo-p-Azido-N-Benzyl-4-Iodo-Ritalinol as a
Potential Photoaffinity Ligand for DAT Structure-Function Studies
From the previous series of compounds, it was observed that N-benzylation of
iodo-MPs (±)-3.31 and (±)-4.18 (Figure 4.2) led to a significant decrease in DAT binding
affinity. Out of this series of hybrid compounds, p-azido-N-benzyl-4-iodo-MP ((±)-4.26,
Figures 4.2 and 4.3) displayed the highest DAT binding afﬁnity (Ki = 363 ± 28 nM). In
order to improve DAT binding affinity for MP-based photoprobes (i.e., target goal of Ki <
100 nM), p-azido-N-benzyl-4-iodo-ritalinol ((±)-4.33, Figure 4.3) was rationally designed
as a potential DAT photoaffinity ligand.

Support for the design of this particular

photoprobe stemmed from the observation that N-benzyl-ritalinols (i.e., wherein MP’s
methyl ester is reduced to its corresponding 1˚ alcohol) display higher binding affinity
than their respective N-benzyl-MP analogs (Misra et al., 2010).

When there is no

substituent (R1 = H) on the aromatic ring of the MP / ritalinol scaffold, there is moderate
(2-fold) improvement in DAT binding affinity for N-benzyl-ritalinol (±)-4.31 when
compared to N-benzyl- MP (±)-4.19. However, when there are halogen substituents (R1
= 3,4-diCl) on the aromatic ring of the MP / ritalinol scaffold, there is significant (28fold) improvement in DAT binding affinity for the N-benzyl-ritalinol scaffold (i.e., (±)-

67

4.32) versus the N-benzyl-MP scaffold (i.e., (±)-4.30). As a result of this known SAR, it
was envisioned that methyl ester reduction of photoprobe (±)-4.26, which carries an
iodine atom at the 4-position of MP’s aromatic ring and a p-azido-N-benzyl substituent,
to the corresponding ritalinol analog (i.e., p-azido-N-benzyl-4-iodo-ritalinol (±)-4.33,
Figure 4.3) would significantly improve DAT binding affinity versus that obtained for
previously successful methyl ester photoprobe (±)-4.26.

Figure 4.3. Rational design of racemic threo-p-azido-N-benzyl-4-iodo-ritalinol as a MP-based DAT
photoaffinity ligand.

4.6.2.1.

Results

of

Racemic

threo-p-Azido-N-Benzyl-4-Iodo-Ritalinol

as

a

Potential Photoaffinity Ligand for DAT Structure-Function Studies
Target photoprobe (±)-4.33 (Figure 4.3) was synthesized (see Chapter 5);
however, no improvement in DAT binding affinity for this compound ((±)-4.33; Ki = 379
± 73 nM) was observed when compared to parent methyl ester compound (±)-4.26 (Ki =
68

363 ± 28 nM) (Figure 4.3). Due to this discouraging DAT binding affinity result, no
other DAT photoprobes were pursued based on either 3- or 4-iodo-MP.
4.6.3. Rational Design of Racemic threo- and (R,R)-MP-Based Photoaffinity
Ligands Containing the Traditional 3-Iodo-4-Azido Labeling Motif

Figure 4.4. Rational design of racemic threo- and (R,R)-MP-based DAT photoaffinity ligands with
the traditional 3-iodo-4-azido labeling motif.

Due to discouraging DAT binding affinity results (Ki >100 nM) associated with
photoaffinity ligands based on 3- or 4-iodo-MP (Figures 4.2 and 4.3), MP DAT
photoaffinity ligands possessing the traditional 3-iodo-4-azido labeling motif (i.e., (±)4.35 and (±)-4.36, Figure 4.4) were pursued. Support for the rational design of these
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potential DAT photoprobes stemmed from the observation that N-benzyl-MP analogs
((±)-4.19 to (±)-4.23) display either improved or retained DAT afﬁnity versus MP ((±)1.10) (Misra et al., 2010). Moreover, N-benzyl-ritalinol analogs (e.g., (±)-4.31 and (±)4.34) are known to display enhanced DAT afﬁnity versus MP ((±)-1.10) and N-benzylMP analogs ((±)-4.19 to (±)-4.23) (Misra et al., 2010). Furthermore, the traditional 3iodo-4-azido labeling motif (e.g., found in 4.7, MFZ-2-24, Figure 4.4) has been used in a
number of successful tropane-based DAT photoprobes (see Figure 4.1) (Vaughan et al.,
2005). Simultaneously, it is well known that (R,R)-MP ((+)-1.10, Figure 4.4) represents
the active enantiomer of racemic threo-MP ((±)-1.10) (Ding et al., 1997; Williard et al.,
2007). Therefore, (R,R)-MP DAT photoaffinity ligands bearing the traditional 3-iodo-4azido labeling motif were also rationally designed (i.e., (-)-4.35 and (-)-4.36, Figure 4.4)
4.6.3.1.

Results of Racemic threo- and (R,R)-MP-Based Photoaffinity Ligands
Containing the Traditional 3-Iodo-4-Azido Labeling Motif
Target photoprobes ((±)-4.35, (-)-4.35, (±)-4.36 and (-)-4.36, Figure 4.4) were

synthesized (see Chapter 5) and submitted to the Surratt lab for pharmacological
determination of their DAT binding affinities. Probes (±)-4.35 (Ki = 3243 ± 803 nM) and
(-)-4.35 (Ki = 1911 ± 272 nM) displayed a significant loss in DAT binding affinity when
compared to lead compounds (±)-1.10 and (+)-1.10 (Figure 4.4). However, photoprobes
(±)-4.36 (Ki = 233 ± 91 nM) and (-)-4.36 (Ki = 218 ± 29 nM) proved superior and
displayed only a 3- to 4-fold loss in DAT binding affinity when compared to lead
compounds (±)-1.10 and (+)-1.10. As a result of its improved DAT binding affinity and
enantiomeric purity relative to previously successful MP-based photoprobe (±)-4.26
developed during this work (Lapinsky et al., 2011), photoprobe (-)-4.36 was advanced to
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radiosynthesis and preliminary photoaffinity labeling studies wherein this compound has
been shown to successfully covalently label the hDAT expressed in cultured cells (see
Appendix; Lapinsky et al., unpublished results).
4.6.4. Rational Design of Racemic threo-3,4-Dichloro-MP-Based Photoaffinity
Ligands Containing the Traditional 3-Iodo-4-Azido Labeling Motif

Figure 4.5. Rational design of racemic threo-3,4-dichloro-MP-based DAT photoaffinity ligands
containing the traditional 3-iodo-4-azido labeling motif.

It is known that 3,4-dichloro-MP ((±)-3.53, Figure 4.5) displays 16-fold higher
DAT binding affinity than MP ((±)-1.10) (Misra et al., 2010). Therefore, 3,4-dichloroMP photoaffinity ligands containing the traditional 3-iodo-4-azido labeling motif were
rationally designed ((±)-4.37 and (±)-4.38, Figure 4.5) in an attempt to obtain MP-based
irreversible molecular probes with high DAT binding affinity. The rational design of
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these compounds stemmed from the observation that N-benzyl-3,4-dichloro-MP ((±)4.30) retained appreciable DAT binding affinity relative to that of N-benzyl-MP ((±)4.19). Furthermore, it is known that N-benzyl-3,4-dichloro-ritalinol ((±)-4.32) displays
significantly higher DAT binding affinity versus N-benzyl-ritalinol ((±)-4.31), N-benzylMP ((±)-4.19), and lead MP analogs (±)-1.10 and (±)-3.53 (Misra et al., 2010).
4.6.4.1.

Results of Racemic threo-3,4-Dichloro-MP-Based Photoaffinity Ligands
Containing the Traditional 3-Iodo-4-Azido Labeling Motif
Upon synthesis of these target compounds (see Chapter 5) and determination

of their DAT binding affinities by the Surratt laboratory, methyl ester (±)-4.37 (Ki = 3446
± 469 nM) and primary alcohol (±)-4.38 (Ki = 1248 ± 746 nM) displayed a significant
loss in DAT binding affinity when compared to lead molecules (±)-1.10 and (±)-3.53
(Figure 4.5). As a result of their very poor DAT binding affinities (i.e., unable to achieve
a goal DAT Ki < 100 nM), methyl ester (±)-4.37 and primary alcohol (±)-4.38 were not
considered justifiable candidates for further development into radioiodo photoprobes for
DAT structure-function studies.
4.7.

Rational Design of GBR-12909-Based Photoprobes Suitable for DAT
Structure-Function Studies
GBR-12909 (1.12, Figure 4.6) was initially envisioned as an antidepressant, but

later was found to be a highly selective DAT inhibitor that is structurally distinct from
cocaine (Esumi et al., 2013). Similar to the benztropines, GBR-12909 and its analogs
display unique behavioral profiles that are significantly different from that of cocaine
(Villemagne et al., 1999). Pharmacological studies of GBR-12909 indicate that this
compound has a higher affinity for, and slower dissociation rate from, the DAT in
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comparison to cocaine.

Moreover, GBR-12909 was shown to antagonize cocaine’s

ability to increase extracellular dopamine levels (Rothman et al., 1991). Additionally,
GBR-12909 has a slower onset and longer duration of action than that of cocaine
(Rothman et al., 1992).

As a result of its promising pharmacodynamic and

pharmacokinetic profile, GBR-12909 was advanced into clinical trials for the treatment
of cocaine abuse, but later was withdrawn due to long QT syndrome (Goldsmith et al.,
2007). Despite its clinical significance and development as a potential cocaine abuse
therapeutic, the specific drug-DAT contacts responsible for eliciting GBR-12909’s
unique behavioral profile remain unknown. In order to address this knowledge gap,
several GBR-12909-based DAT inhibitor photoprobes were designed to be utilized in
future DAT structure-function studies.
4.7.1. Rational Design of a Clickable Benzophenone-Alkyne-Based GBR-12909
Photoprobe for DAT Structure-Function Studies
One of the most common ways to create a clickable photoaffinity ligand is to
utilize a benzophenone as a photoreactive group and a terminal alkyne as a click
chemistry handle (e.g., 4.39, Figure 4.6) (Van Scherpenzeel et al., 2009 and 2010; Chen
et al., 2010; Ban et al., 2010; Eirich et al., 2011 and 2012; Park et al., 2012; Cisar and
Cravatt, 2012; Saario et al., 2012). With this observation in mind, benzophenone-alkynebased GBR-12909 DAT photoprobe 4.40 (Figure 4.6) was rationally designed given the
SAR that bulky substituents at the para position of the N-phenylpropyl moiety of GBR12909 (1.12) are tolerated without a large reduction in DAT pharmacological activity
(Matecka et al., 1997).
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Figure 4.6. Rational design of a clickable benzophenone-alkyne-based
GBR-12909 DAT photoprobe.

4.7.1.1.

Results

of

a

Clickable

Benzophenone-Alkyne-Based

GBR-12909

Photoprobe for DAT Structure-Function Studies
As of the writing of this dissertation, target photoprobe 4.40 (Figure 4.6) was
successfully synthesized (see Chapter 5), and this compound is currently being evaluated
in DAT pharmacology experiments by the Surratt laboratory.
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4.7.2. Rational Design of a Diazido-Based GBR-12909 Photoprobe for DAT
Structure-Function Studies

Figure 4.7. Rational design of a diazido-based GBR-12909 DAT photoprobe.

Another common approach to turn lead compounds into clickable photoaffinity
ligands is to utilize a 1,3,5-trisubstituted phenyl moiety bearing an aryl azide as a
photoreactive group and a methylene aliphatic azide as a click chemistry handle (e.g.,
4.42, Figure 4.7) (Hosoya et al., 2004, 2005, and 2009; Sun et al., 2006; He et al., 2009;
Gandy et al., 2011; Neelarapu et al., 2011; Vaidya et al., 2012).

Based on this

information, target photoprobe 4.43 (Figure 4.7) was rationally designed by incorporating
the common 1,3,5-trisubstituted-phenyl diazide moiety into the terminal phenyl ring of
GBR-12909’s N-propylphenyl substituent. The design of this clickable DAT photoprobe
stems from previous success of radioactive 3-azido-[3H]-GBR-12935 (4.41), which after
UV photolysis of crude synaptosomal membranes led to a single radiolabeled polypeptide
suggested to be glycosylated DAT with an apparent molecular mass of 80 kDa (Berger et
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al., 1991). Compared to known radioactive DAT photoprobe 4.41, target nonradioactive,
clickable photoprobe 4.43 features incorporation of two para fluorine substituents on the
diphenoxy ether moiety analogous to that of GBR-12909 (1.12), and an azidomethylene
click chemistry handle meta to the photoreactive aryl azide.
4.7.2.1.

Results of a Diazido-Based GBR-12909 Photoprobe for DAT StructureFunction Studies
As of the writing of this dissertation, target photoprobe 4.43 (Figure 4.7) was

successfully synthesized (see Chapter 5), and this compound is currently being evaluated
in DAT pharmacology experiments by the Surratt laboratory.
4.8.

Rational Design of Irreversible mGlu5 NAMs as Chemical Probes Suitable
for mGlu5 Structure-Function Studies
Despite noteworthy advances in characterizing the MPEP-binding site within the

TM domain of mGlu5 (Pagano et al., 2000; Malherbe et al., 2003; Molck et al., 2012;
Kaae et al., 2012), a mechanistic and/or conformational rationale is unknown for how
subtle variations to a mGlu5 allosteric modulator can engender either the opposite mode
of pharmacology or a change in the mGlu receptor subtype selectivity profile. In order to
address this research question, irreversible mGlu5 NAMs are envisioned as valuable
compounds to be utilized in mGlu5 structure-function studies.
4.8.1. Rational Design of a Clickable Benzophenone Propargyl Ether mGlu5 NAM
Photoprobe for mGlu5 Structure-Function Studies
It is known that MPEP-binding site mGlu5 NAM 4.44 (Figure 4.8) displays very
high mGlu5 binding affinity (Ki = 6 nM) (Iso et al., 2006). Furthermore, derivitization of
the 3-position of the phenyl ring within 4.44 to either a phenol (4.45) or a benzylic ether
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(4.46) results in a 8- to 10-fold loss in mGlu5 binding affinity; however, these
compounds still retain their mGlu5 NAM functional activity.

Figure 4.8. Rational design of a MPEP-binding site clickable thiazole benzophenone propargyl ether
mGlu5 NAM photoprobe.

In addition, a mGlu5 responsive imaging probe (4.47, Figure 4.8) was recently
reported featuring a large gadolinium-DOTA moiety conjugated to the 3-position of
phenyl ring of 4.44 (Mishra et al., 2012). Although mGlu5 binding affinity was not
reported for this imaging probe, the observation that this conjugate retained pronounced
mGlu5 antagonistic activity suggested that the gadolinium-DOTA moiety within 4.47
could potentially be replaced with other chemical entities (e.g., an “all-in-one”
photoreactive click chemistry moiety) and still retain desired mGlu5 NAM
pharmacology. With these thoughts in mind, target clickable mGlu5 NAM photoprobe
4.49 (Figure 4.8) was rationally designed by replacing the gadolinium-DOTA moiety of
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conjugate 4.47 with a known (Van Scherpenzeel et al., 2010) “all-in-one” chemical
moiety featuring a benzophenone photoreactive functional group and a propargyl ether
clickable handle (i.e., see representative example probe 4.48, Figure 4.8) attached to the
3’-OH of MPEP-binding site NAM 4.45 via an ethyl diether linkage.
4.8.1.1.

Results of a Clickable Benzophenone Propargyl Ether mGlu5 NAM
Photoprobe for mGlu5 Structure-Function Studies
Target photoprobe 4.49 (Figure 4.8) was successfully synthesized (see

Chapter 5) and submitted to Dr. Karen Gregory’s laboratory (Vanderbilt University) for
mGlu5 pharmacological evaluation. Target probe 4.49 displays improved mGlu5 binding
affinity (Ki = 11 ± 0.8 nM; HEK293A cells; [3H]-methoxyPEPy) versus lead compounds
4.45 (Ki = 59 ± 0.9 nM) and 4.46 (Ki = 48 ± 0.8 nM), and retained mGlu5 NAM
functional potency (IC50 = 1 µM). As of the writing of this dissertation, clickable
photoprobe 4.49 is being subjected to mGlu5 tandem photoaffinity labelingbioorthogonal conjugation experiments in Dr. Gregory’s laboratory at Monash University
(see Appendix).
4.8.2. Rational Design of a Clickable MPEP-Binding Site Diazido mGlu5 NAM
Photoprobe for mGlu5 Structure-Function Studies
Using the same SAR as that for the design of conjugate photoprobe 4.49 via lead
compounds 4.44 – 4.47, target clickable mGlu5 photoprobe 4.50 (Figure 4.9) was
rationally designed by replacement of the benzyl ether of 4.46 with the common “all-inone” diazido benzylic ether moiety (e.g., see representative example probe 4.42, Figure
4.9, He et al., 2009), wherein the aryl azide represents a photoreactive functional group
and the aliphatic azide represents a click chemistry handle.
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Figure 4.9. Rational design of a thiazole MPEP-binding site diazido mGlu5 negative
allosteric modulator clickable photoprobe.

4.8.2.1.

Results of a Clickable MPEP-Binding Site Diazido mGlu5 NAM
Photoprobe for mGlu5 Structure-Function Studies
Target photoprobe 4.50 (Figure 4.9) was synthesized (see Chapter 5) and

submitted to Dr. Karen Gregory’s laboratory (Vanderbilt University) for mGlu5
pharmacological evaluation.

Target photoprobe 4.50 displayed 1.5-fold less mGlu5

binding affinity (Ki = 72 ± 15 nM; HEK293A cells; [3H]-methoxyPEPy) in comparison to
lead compound 4.46 and retained mGlu5 NAM function. Given target photoprobe 4.50
meets desired pharmacological criteria for identifying suitable probes for mGlu5
structure-function studies (i.e., Ki < 100 nM, no more than 10-fold lower mGlu5 binding
affinity compared to an appropriate lead compound, and retention of mGlu5 NAM
functional activity), this compound is currently being subjected to mGlu5 tandem
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photoaffinity labeling-bioorthogonal conjugation experiments in Dr. Gregory’s laboratory
at Monash University.
4.8.3. Rational Design of an Azido-Iodo Thiazole mGlu5 MPEP-Binding Site NAM
Photoprobe for mGlu5 Structure-Function Studies
In terms of optimum photoprobe design, compact photoprobes featuring
placement of a photoreactive group directly on the parent lead compound are most
desirable (Lapinsky et al., 2012a). In particular, upon photoaffinity labeling, the covalent
point of photoprobe attachment to a drug target, which is directly dictated by the location
of the photoreactive functional group within the photoprobe, can be somewhat removed
from the lead compound chemical scaffold when a chemical linker is used (e.g., often a
conformationally flexible, variable-length methylene linker).

For photoprobes that

feature utilization of a chemical linker between the photoreactive functional group and
the lead compound chemical scaffold, covalent photoprobe adduction to the drug target
may occur at a residue near, but not at, a direct ligand-drug target contact point, thus
representing a significant limitation when trying to delineate the discrete molecular
interactions between the photoprobe and the drug target.

Furthermore, compact

photoprobes bearing a photoreactive functional group directly on the lead compound
chemical scaffold are expected to result in a more conformationally restricted
photoprobe-drug target complex in 3-D drug target molecular modeling studies.
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Figure 4.10. Rational design of an azido-iodo mGlu5 negative allosteric
modulator thiazole photoprobe.

In an attempt to create compact photoprobes that avoid chemical linkers and
feature placement of a photoreactive group directly on a mGlu5 NAM scaffold, high
affinity cyano thiazole 4.51 (Simeon et al., 2011) (Figure 4.10) was selected as a lead
compound. Target photoprobe 4.52 was rationally designed by replacing the nitrile of
MPEP-binding site mGlu5 NAM 4.51 with a photoreactive aryl azide and retention of the
heteroaromatic iodide as a potential future radiotracer tag (i.e., I125). Moreover, the
fluorine atom on the phenyl ring meta to photoreactive aryl azide is envisioned to help
stabilize the desired singlet nitrene during mGlu5 photoaffinity labeling experiments
(Schnapp et al., 1993). As a result, target photoprobe 4.52 is significantly more compact
than conjugate mGlu5 NAM photoprobes 4.49 and 4.50. As a result, photoprobe 4.52 is
expected to covalently attach to amino acid residue(s) directly within the MPEP-binding
site of mGlu5 and result in a more conformationally restricted photoprobe-mGlu5
complex in 3-D mGlu5 molecular modeling studies.
4.8.3.1.

Results of an Azido-Iodo Thiazole mGlu5 MPEP-Binding Site NAM
Photoprobe for mGlu5 Structure-Function Studies
Target photoprobe 4.52 (Figure 4.10) was synthesized (see Chapter 5) and

submitted to Dr. Karen Gregory’s laboratory (Vanderbilt University) for mGlu5
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pharmacological evaluation. Target photoprobe 4.52 retained mGlu5 NAM functional
activity, but this compound displayed a 27-fold loss in mGlu5 binding affinity (Ki = 35 ±
0.7 nM; HEK293A cells; [3H]-methoxyPEPy) when compared to lead nitrile compound
4.51.

Despite the fact that target photoprobe 4.52 meets some of the desired

pharmacological criteria for identifying suitable probes for mGlu5 structure-function
studies (i.e., Ki < 100 nM and retention of mGlu5 NAM functional activity), its chemical
synthesis proved very challenging with respect to retaining the highly activated iodine
atom on the thiazole ring. As a result of the relatively easy loss of the iodine atom on the
thiazole ring during chemical synthesis, radiosynthesis of photoprobe 4.52 in its I125 form
towards eventual utilization in mGlu5 photoaffinity labeling experiments was not
pursued.
4.8.4. Rational Design of an Azido-Propargyl mGlu5 MPEP-Binding Site NAM
Clickable Photoprobe for mGlu5 Structure-Function Studies
Given the relative instability and synthetic challenges associated with azido-iodo
mGlu5 NAM thiazole photoprobe 4.52 (Figure 4.10), a high affinity cyano MPEP methyl
ether derivative (4.53, Figure 4.11) (Keck et al., 2012) was selected as a lead compound
in order to pursue a photoprobe that avoided chemical linkers and featured placement of a
photoreactive group directly on an mGlu5 NAM scaffold. Clickable photoprobe 4.54
(Figure 4.11) was rationally designed by isosterically replacing the nitrile of mGlu5
MPEP-binding site NAM 4.53 with a photoreactive aryl azide and slightly extending the
methyl ether into a clickable propargyl ether.

Once again, compared to conjugate

photoprobes 4.49 and 4.50, target photoprobe 4.54 is more compact and expected to
covalently attach to amino acid residue(s) directly within the mGlu5 MPEP-binding
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pocket and result in a more conformationally restricted photoprobe-mGlu5 complex in 3D mGlu5 molecular modeling studies.

Figure 4.11. Rational design of an azido-propargyl mGlu5 negative allosteric
modulator MPEP-binding site clickable photoprobe.

4.8.4.1.

Results of an Azido-Propargyl mGlu5 MPEP-Binding Site NAM
Clickable Photoprobe for mGlu5 Structure-Function Studies
Target clickable photoprobe 4.54 (Figure 4.11) was synthesized (see Chapter

5) and submitted to Dr. Karen Gregory’s laboratory (Vanderbilt University) for mGlu5
pharmacological evaluation. Target photoprobe 4.54 displays the highest mGlu5 binding
affinity the Lapinsky group has ever synthesized and pharmacologically evaluated to date
(Ki of 0.5 nM; 2.6-fold higher than lead compound 4.53). Given target photoprobe 4.54
meets all of the desired pharmacological criteria for identifying suitable probes for
mGlu5 structure-function studies (i.e., Ki < 100 nM, no more than 10-fold lower mGlu5
binding affinity compared to an appropriate lead compound, and retention of mGlu5
NAM functional activity), this compound is currently being subjected to preliminary
mGlu5 tandem photoaffinity labeling-bioorthogonal conjugation experiments in Dr.
Gregory’s laboratory at Monash University.
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4.8.5. Rational Design of a Methanethiosulfonate mGlu5 MPEP-Binding Site NAM
Thiol-Reactive Chemical Probe for mGlu5 Engineered Affinity Labeling
Experiments
As an alternative to photoaffinity labeling and previously described in Section
2.2.2, coupling drug target molecular modeling studies with cysteine-substituted drug
target mutants and thiol-reactive affinity labeling probes represents a powerful
experimental approach towards ultimately validating and refining 3-D homology models
of a drug target (Foucaud et al., 2007). In this regard, a potential thiol-reactive, MPEPbinding site affinity labeling probe (4.55, Figure 4.12) for mGlu5 cysteine-substituted
engineered affinity labeling was rationally designed analogous to that described for
conjugate clickable photoprobe 4.49 (Section 4.8.1). In particular, target affinity labeling
probe 4.55 was envisioned and accessed by functionalizing the 3’-OH position of known
MPEP-binding site mGlu5 NAM 4.45 (Figure 4.12) with an ethyl linker and a thiolspecific and reactive methanethiosulfonate electrophilic functional group (Foucad et al.,
2007).

Figure 4.12. Rational design of a thiazole methanethiosulfonate mGlu5 MPEP-binding site
NAM thiol-reactive affinity labeling probe.
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4.8.5.1.

Results of a Methanethiosulfonate mGlu5 MPEP-Binding Site NAM
Thiol-Reactive Chemical Probe for mGlu5 Engineered Affinity Labeling
Experiments
Target affinity labeling probe 4.55 (Figure 4.12) was synthesized (see Chapter

5) and submitted to Dr. Karen Gregory’s laboratory (Vanderbilt University) for mGlu5
pharmacological evaluation. Encouragingly, this potential thiol-reactive mGlu5 affinity
labeling probe retained appropriate mGlu5 binding affinity (Ki = 13 ± 0.8 nM, ~2-fold
lower than parent compound 4.44). Given target probe 4.55 meets all of the desired
pharmacological criteria for identifying suitable probes for mGlu5 structure-function
studies (i.e., Ki < 100 nM, no more than 10-fold lower mGlu5 binding affinity compared
to an appropriate lead compound, and retention of mGlu5 NAM functional activity), this
compound is currently being subjected to preliminary mGlu5 cysteine-substituted
engineered affinity labeling studies in Dr. Gregory’s laboratory at Monash University.
4.8.6. Rational Design of a Maleimide-Based mGlu5 MPEP-Binding Site NAM
Thiol-Reactive Chemical Probe for mGlu5 Engineered Affinity Labeling
Experiments
Analogous to the rational design of probe 4.55, another potential thiol-reactive
NAM probe (4.56) for mGlu5 cysteine-substituted engineered affinity labeling was
envisioned by functionalizing the 3-position of MPEP-binding site NAM 4.44 (Figure
4.13) with a maleimide electrophilic moiety (Foucad et al., 2007). It is well known that
maleimide-based electrophiles tend to undergo conjugate addition reactions preferentially
with thiol-based nucleophiles (e.g., cysteine) during affinity labeling versus other types of
nucleophiles (e.g., tyrosine) (Chalker et al., 2009).
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Figure 4.13. Rational design of a maleimide-based thiazole mGlu5 MPEP-binding site
NAM thiol-reactive affinity labeling probe.

4.8.6.1.

Results of a Maleimide-Based mGlu5 MPEP-Binding Site NAM ThiolReactive Chemical Probe for mGlu5 Engineered Affinity Labeling
Experiments
Target affinity labeling probe 4.56 (Figure 4.13) was synthesized (see Chapter

5) and submitted to Dr. Karen Gregory’s laboratory (Vanderbilt University) for mGlu5
pharmacological evaluation.

Unfortunately, Dr. Gregory experienced a number of

solubility issues while attempting to determine the mGlu5 binding affinity for this
compound.

As a result, currently no future experiments are envisioned with this

particular probe.
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CHAPTER FIVE
5. Chemical Discussion
5.1.

Synthesis of MP-Based Photoprobes Suitable for DAT Structure-Function
Studies

5.1.1. Synthesis of Racemic threo-N-Azidobenzyl-4-Iodo/3-Iodo-MP Photoaffinity
Ligands for DAT Structure-Function Studies
As previously described in Section 4.6.1, in order to overcome the labeling
efficiency drawback associated with photoprobes containing the traditional 3-iodo-4azido labeling motif, we desired racemic threo-N-azidobenzyl-4-iodo/3-iodo-MP analogs
as potential photoaffinity ligands for DAT structure-function studies. We envisioned the
synthesis of a series of racemic threo-N-azidobenzyl-4-iodo/3-iodo-MP (MP) analogs
((±)-4.24-4.29) as photoaffinity ligands for DAT structure-function studies via Nalkylation of either 4-iodo-MP ((±)-3.31) or 3-iodo-MP ((±)-4.18) with a known series of
azido benzyl bromides (5.1-5.3; Mornet et al., 1984) (Scheme 5.1). With this synthetic
strategy in mind, an efficient, relatively large-scale synthesis of 4-iodo-MP ((±)-3.31) and
3-iodo-MP ((±)-4.18) was initially desired and pursued.

Scheme 5.1. Proposed retrosynthesis of a series of racemic threo-N-azidobenzyl-4-iodo/3-iodo-MP
analogs as photoaffinity ligands for DAT structure-function studies.
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5.1.1.1.

Problems With the Known Synthetic Route for Preparing Racemic threo4-Iodo-MP
A synthetic route for preparing 4-iodo-MP ((±)-3.31, Scheme 5.3) is known in

the chemical literature (Pan et al., 1996). However, this synthetic route is not necessarily
desirable for generating 4-iodo-MP in relatively large quantities, principally because this
scheme is rather poor yielding (6 steps, 9% overall yield) and utilizes MP ((±)-1.10,
Scheme 5.2) as a relatively expensive substance controlled by the FDA.

Scheme 5.2. Synthesis of racemic threo-MP performed according to
Axten et al., 1998 and Gutman et al., 2004.

Racemic threo-MP ((±)-1.10) was first synthesized on a multi-gram scale
according to Axten et al. and Gutman et al. (Axten et al., 1998; Gutman et al., 2004)
(Scheme 5.2).

Briefly, commercially available α-keto ester 3.7 was treated with

piperidine (3.8) to provide α-keto amide 3.9 in nearly quantitative yield. Subsequent
condensation of ketone 3.9 with tosylhydrazine under acidic conditions provided
tosylhydrazone 3.10 in 85% yield. Next, thermal cyclization of tosylhydrazone 3.10
under aqueous basic conditions using Aliquat 336 as a phase transfer catalyst, followed
by

column

chromatography

and

recrystallization
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from

diethyl

ether,

gave

diastereomerically pure racemic threo-β-lactam (±)-3.11 as the major product in
moderate yield (68%). Finally, threo-β-lactam (±)-3.11 was converted to racemic threoMP ((±)-1.10) in quantitative yield by ring opening with MeOH under acidic conditions.

Scheme 5.3. Synthesis of racemic threo-4-iodo-MP performed
according to Pan et al., 1996.

Next, racemic threo-MP ((±)-1.10) was then converted to 4-iodo-MP ((±)3.31) according to Pan et al. (Pan et al., 1996) (Scheme 5.3). This synthesis began with
N-benzoylation of racemic threo-MP to provide amide (±)-3.26 in near quantitative yield.
The amide was then subsequently nitrated with nitric acid to give predominantly the pnitro isomer (±)-3.27 as the major product in moderate yield (85%). The nitro functional
group was then reduced with iron under acidic conditions to provide aniline (±)-3.28,
which was then diazotized and displaced with iodide to produce p-iodo compound (±)3.29 in 60% yield. In turn, global hydrolysis of benzamide (±)-3.29 under strong acidic
conditions then provided racemic threo-4-iodo-ritalinic acid ((±)-3.30) in 40% yield,
which upon esterification with methanolic HCl quantitatively provided racemic threo-4iodo-MP ((±)-3.31). The 4-iodo-MP product synthesized by this route was determined to

89

be ≥95% diastereomerically pure by 1H NMR upon comparison to the known data for
enantiomerically pure threo- and erythro-MP and its para-substituted derivatives (Thai et
al., 1998).
The synthetic route performed for 4-iodo-MP ((±)-3.31) via Schemes 5.2 and
5.3 was lengthy (10 steps) and very low yielding (9%). Furthermore, this route was
rather cumbersome on a large scale due to significant formation of the undesirable orthoand meta-nitro isomers of compound (±)-3.27 (detected via 1H NMR), which were
difficult to separate by column chromatography. In addition, benzamide deprotection /
global hydrolysis from (±)-3.29 to (±)-3.30 was rather harsh and time consuming,
typically taking several days for reaction completion on a large scale. As a result, a
shorter, more efficient large scale synthesis of 4-iodo-MP ((±)-3.31) was desired
involving cheap, readily available, non-controlled starting materials in order to synthesize
a variety of MP-based DAT photoprobes. The following strategies were attempted in
order to develop an improved synthetic route for 4-iodo-MP ((±)-3.31).
5.1.1.2.

Strategies Towards an Improved Large Scale Synthesis of Racemic threo4-Iodo-MP

5.1.1.2.1. Electrophilic Aromatic Iodination of a Racemic threo-β-Lactam Building
Block
Electrophilic aromatic iodination of known β-lactam (±)-3.11 (Axten et al.,
1998; Gutman et al., 2004) with N-iodosuccinimide (NIS) in H2SO4 (conditions adapted
from Chaikov et al., 2007) followed by lactam methanolysis under acidic conditions was
envisioned as a particularly short and attractive route to racemic threo-4-iodo-MP
(Scheme 5.4), particularly since β-lactam (±)-3.11 was synthetically accessible in large
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quantities in the lab via Scheme 5.2. Attempted electrophilic aromatic iodination of βlactam (±)-3.11 was complete in four hours based on the formation of a single non-polar
spot on TLC. However, 1H NMR revealed the presence of the ortho- and meta-iodo
isomers of (±)-5.4. Additionally, the presence of the erythro diastereomer of β-lactam
(±)-5.4 was also observed by 1H NMR. Given that it was extremely challenging to obtain
pure desired (±)-5.4 via silica gel chromatography after this chemical reaction (Scheme
5.4), this strategy was abandoned in favor of more practical routes (vide infra).

Scheme 5.4. Attempted electrophilic aromatic iodination of a racemic threo-β-lactam
building block towards 4-iodo-MP.

5.1.1.2.2. Application of Axten’s Racemic threo-MP Synthetic Methodology
Towards the Synthesis of Racemic threo-4-Iodo-MP
A synthesis of racemic threo-4-iodo-MP ((±)-3.31) was then investigated
(Scheme 5.5) via appropriate application of synthetic methodology previously described
to synthesize racemic threo-MP ((±)-1.10) (Axten et al., 1998; Gutman et al., 2004).
This strategy began with Friedel-Craft’s acylation of commercially available iodobenzene
(3.69) with commercially available ethyl chlorooxoacetate (5.5) to give known α-keto
ester 5.6 (Kiesewetter, 1993), which upon condensation with piperidine (3.8) provided
novel α-keto amide 5.7 in 63% yield.

Subsequent reaction of ketone 5.7 with

tosylhydrazine under acidic conditions then provided tosylhydrazone 5.8 in moderate
yield (85%). Thermal cyclization of tosylhydrazone 5.8 (i.e., the para-iodo derivative of
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known tosylhydrazone 3.10) under aqueous basic conditions using Aliquat 336 as a phase
transfer catalyst, column chromatography, then subsequent recrystallization from diethyl
ether provided diastereomerically pure racemic threo-β-lactam (±)-5.4 as the major
product in moderate yield (60%). In turn, diastereomerically pure racemic threo-βlactam (±)-5.4 was converted to 4-iodo-MP ((±)-3.31) in quantitative yield by ring
opening with MeOH under acidic conditions (Lapinsky et al., 2011). Racemic threo-4iodo-MP ((±)-3.31) synthesized by this chemistry was determined to be ≥95%
diastereomerically pure by

1

H NMR upon comparison to the known data for

enantiomerically pure threo- and erythro-MP and its para-substituted derivatives (Thai et
al., 1998).

Scheme 5.5. Novel synthesis of racemic threo-4-iodo-MP by application of methodology previously
described for the synthesis of racemic
threo-MP by Axten et al., 1998.

The chemistry described in Scheme 5.5 worked fairly well in the lab yielding
4-iodo-MP ((±)-3.31) in 5 steps and 5% overall yield.
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Although this represents a

significant improvement when compared to the known synthetic route (Schemes 5.2 and
5.3, 10 steps, 9% overall yield), synthesis of iodo keto ester 5.6 by Friedel-Craft’s
acylation (Kiesewetter, 1993) proved low yielding on a large scale (Table 5.1).
Table 5.1. Different reaction scales for the production of iodo keto ester 5.6.

Attempt

Solvent

Yield of 5.6

1
2

Scale
(mmol)
5
10

CS2
CS2

15 %
13 %

3

30

CS2

8%

4

150

CS2

3%

5

5

DCM

18 %

The reaction workup for formation of iodo keto ester 5.6 was rather
challenging due to formation of a sticky gum that was principally responsible for low
yields (Table 5.1, attempts 1 and 2). This problem became more significant on a larger
scale and led to a further decrease in product yield (Table 5.1, attempts 3 and 4).
Changing the reaction solvent from carbon disulfide (CS2) to dichloromethane (DCM)
(Table 5.1, attempts 1 versus 5) made reaction monitoring by TLC and the workup
process relatively easier. However, the product yield was comparable to that when CS2
was used as the reaction solvent (Table 5.1, attempts 1 versus 5). As a result of these
practical challenges, an alternative route was envisioned and pursued utilizing
commercially available nitro α-keto ester 5.9 in order to access the previously described
iodo keto amide 5.7 directly via an aniline precursor (Scheme 5.6).
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Scheme 5.6. An alternative, efficient synthesis of iodo keto amide 5.7 via diazotization
of an aniline precursor.

Treatment of commercially available nitro α-keto ester 5.9 with piperidine
(3.8) provided α-keto amide 5.10 in 95% yield and involved no column chromatography
purification (Scheme 5.6) (Lapinsky et al., 2012a).

The nitro group of 5.10 was

subsequently reduced with tin (II) chloride under acidic conditions to provide aniline
precursor 5.11 in 70% yield. The aniline was then subjected to diazotization and iodide
displacement to provide the previously described iodo keto amide 5.7 in good yield
(78%). This synthetic route proved very practical even on a large scale. Furthermore, a
significant improvement in product yield for iodo keto amide 5.7 was observed using this
strategy (Scheme 5.6, 3 steps, 52% overall yield versus Scheme 5.5, 2 steps, 10% overall
yield on a 10 mmol scale), which ultimately significantly improved the synthesis of 4iodo-MP ((±)-3.31). The optimized synthesis of 4-iodo-MP ((±)-3.31) (Scheme 5.7)
utilizes 6 steps and produces the target compound in 26 % overall yield. This represents
a significant improvement in terms of the number of synthetic steps and overall product
yield when compared to the known synthetic route for 4-iodo-MP (Pan et al., 1996; 10
steps, 9% overall yield, Schemes 5.2 and 5.3).
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Scheme 5.7. Optimized chemical synthesis of racemic threo-4-iodo-MP
developed as part of this dissertation work.

Simultaneous to this work on developing an enhanced route to 4-iodo-MP, an
efficient synthesis of 3-iodo-MP ((±)-4.18) (Scheme 5.8) was developed by Nageswari
Yarravarapu in the Lapinsky laboratory at Duquesne University (Lapinsky et al., 2011).
This material could then be utilized to subsequently produce desired MP-based DAT
photoprobes upon N-alkylation with a series of known azido benzyl bromides (5.1-5.3;
Mornet et al., 1984) (Scheme 5.10). The synthesis of 3-iodo-MP ((±)-4.18) begins with
regioselective meta-iodination of α-keto amide 3.9 to provide iodo α-keto amide 5.12 in
77% yield. Subsequent condensation of the ketone within 5.12 with tosylhydrazine under
acidic conditions provided tosylhydrazone 5.13 in moderate yield (72%). Next, thermal
cyclization of tosylhydrazone 5.13 (i.e., the meta-iodo derivative of known tosyl
hydrazine 3.10) under aqueous basic conditions using Aliquat 336 as a phase transfer
catalyst, followed by column chromatography and recrystallization from diethyl ether,
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provided diastereomerically pure racemic threo-β-lactam (±)-5.14 as the major product in
moderate yield (55%). Finally, diastereomerically pure racemic threo-β-lactam (±)-5.14
was converted to 3-iodo-MP ((±)-4.18) in quantitative yield by ring opening with MeOH
under acidic conditions. Racemic threo-3-iodo-MP ((±)-4.18) synthesized by this route
was determined to be ≥95% diastereomerically pure by 1H NMR upon comparison to the
known data for enantiomerically pure threo- and erythro-MP and its para-substituted
derivatives (Thai et al., 1998).

Scheme 5.8. Synthesis of racemic threo-3-iodo-MP performed
according to Lapinsky et al., 2011.

5.1.1.3.

Synthesis of Requisite Azido Benzyl Bromides Needed to Produce a
Series of Racemic threo-N-Azidobenzyl-4-Iodo/3-Iodo-MP Photoaffinity
Ligands for DAT Structure-Function Studies
In order to produce desired series of racemic threo-N-azidobenzyl-4-iodo/3-

iodo-MP photoaffinity ligands (Scheme 5.10) for DAT structure-function studies, a series
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of requisite azido benzyl bromides (5.1-5.3) were needed for N-alkylation of either 3- or
4-iodo-MP. Two of these azido benzyl bromides, 5.1 and 5.3, were accessed by their
known chemical literature procedures (Mornet et al., 1984). Specifically, commercially
available anilines 5.15 and 5.17 were subjected to diazotization and azide displacement to
provide known azido toluene derivatives 5.16 and 5.18 (Mornet et al., 1984), which were
subsequently converted to their azido benzyl bromide derivatives 5.3 and 5.1 by free
radical bromination (Scheme 5.9).

Scheme 5.9. Synthesis of requisite azido benzyl bromides needed to produce a series of racemic
threo-N-azidobenzyl-4-iodo/3-iodo-MP photoaffinity ligands.

Simultaneously, meta-azido toluene derivative 5.20 was successfully made
analogous to its ortho and para derivatives utilizing commercially available aniline 5.19
by employing diazotization followed by azide displacement conditions.

However,

synthesis of meta-azido benzyl bromide 5.2 by free radical bromination was not
reproducible according to the literature (Mornet et al., 1984), as this reaction appeared to

97

not proceed to completion and formed only the undesired dibrominated derivative 5.21
(Scheme 5.9).
5.1.1.4.

N-Alkylation of Racemic threo-4-Iodo/3-Iodo-MP with a Series of Azido
Benzyl Bromides Towards a Series of Racemic threo-N-Azidobenzyl-4Iodo/3-Iodo-MP Photoaffinity Ligands for DAT Structure-Function
Studies

Scheme 5.10. Synthesis of a target series of racemic threo-N-azidobenzyl-4-iodo/3-iodo-MP
derivatives as potential DAT photoaffinity ligands.

Ortho- ((±)-4.24 and (±)-4.27) and para-azido-substituted ((±)-4.26 and (±)4.29) target MP-based photoafﬁnity probes were synthesized in moderate yield (50% to
67%) by N-alkylation of either 3- or 4-iodo-MP with the corresponding ortho- (5.1) or
para-substituted (5.3) azido benzyl bromide (Scheme 5.10).

Simultaneously, meta-

substituted azido photoaffinity probes (±)-4.25 and (±)-4.28 were synthesized in 48% and
53% yield using 3- or 4-iodo-MP and a sequence of N-alkylation with commercially
available meta-nitro benzyl bromide (5.22), nitro reduction, and diazotization followed
by azide displacement (Lapinsky et al., 2011).
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5.1.1.5.

Stannylation of Racemic threo-p-Azido-N-Benzyl-4-Iodo-MP Towards
Radioiodination and DAT Covalent Ligation Via Photoaffinity Labeling
With respect to identifying candidate probes for photoaffinity labeling

experiments, ideal compounds are those that are bioactive in the same range as the parent
compound. However, compounds with as much as 1000-fold lower activity can still be
useful (Dorman and Prestwich, 2000). Given racemic threo-p-azido-N-benzyl-4-iodoMP ((±)-4.26) displayed modest DAT binding affinity, and the highest DAT binding
affinity (Ki = 363 ± 28 nM) in the series of racemic threo-N-azidobenzyl-4-iodo/3-iodoMP compounds (4.24-4.29), further development of this compound into a potential DAT
photoprobe was pursued.

Given that wash-resistant binding experiments involving

nonradioactive azido compounds frequently give false positives in the assessment of
covalent attachment (Agoston et al., 1997), synthesis of a radioiodinated (i.e., [125I])
version of racemic threo-p-azido-N-benzyl-4-iodo-MP ((±)-4.26) was pursued to
determine if photoactivation could produce covalent ligation to the DAT. In this regard,
racemic p-azido-N-benzyl-4-iodo-MP ((±)-4.26) was subjected to Stille coupling
(conditions adapted from Shu et al., 1996) with bis(tributyltin) to provide stannyl
derivative (±)-5.23 in 40% yield (Scheme 5.11). This compound was then converted to
radioactive iodide derivative [125I]-(±)-4.26 by Dr. John Lever at the University of
Missouri-Columbia (see Section A.1 in Appendix). Subsequently, the DAT was
irreversibly labeled ((±)-5.24, Scheme 5.11) succesfully with [125I]-(±)-4.26 by Dr.
Roxanne Vaughan’s group at the University of North Dakota (see Section A.1 in
Appendix). In summary, [125I]-(±)-4.26 represents the first successful example of a DAT
photoaffinity ligand based on a MP scaffold, thus representing an important contribution
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to the arsenal of probes for characterizing DAT function and 3-D structure (Lapinsky et
al., 2011).

Scheme 5.11. Stannylation of (±)-4.26 towards radioiodination by Dr. John Lever and DAT covalent
ligation by Dr. Roxanne Vaughan.

5.1.2. Synthesis of Racemic threo-p-Azido-N-Benzyl-4-Iodo-Ritalinol as a Potential
Photoaffinity Ligand for DAT Structure-Function Studies
As previously described in Section 4.6.2, since N-benzylation of iodo-MPs (±)3.31 and (±)-4.18 led to a significant decrease in DAT binding affinity, we desired
racemic threo-p-azido-N-benzyl-4-iodo-ritalinol ((±)-4.33) in order to potentially obtain a
MP-based photoprobe with improved DAT binding affinity (i.e., target goal of DAT Ki <
100 nM) relative to previously successful probe [125I]-(±)-4.26 (Lapinsky et al., 2011).
We envisioned the synthesis of racemic threo-p-azido-N-benzyl-4-iodo-ritalinol ((±)4.33) as a potential photoaffinity ligand for DAT structure-function studies via Nalkylation of 4-iodo-ritalinol ((±)-5.25) with known p-azido benzyl bromide (5.3; Mornet
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et al., 1984) (Scheme 5.12). With this strategy in mind, an efficient synthesis of 4-iodoritalinol ((±)-5.25) was desired and pursued.

Scheme 5.12. Retrosynthetic strategy towards racemic threo-p-azido-N-benzyl-4-iodo-ritalinol as a
potential photoaffinity ligand for DAT structure-function studies.

5.1.2.1.

Attempted Methyl Ester Reduction of Racemic threo-4-Iodo-MP with
LiAlH4 to Access Racemic threo-4-Iodo-Ritalinol
Methyl ester reduction of 4-iodo-MP ((±)-3.31) with LiAlH4 (conditions

adopted from Kim et al., 2007) was envisioned as the shortest route to 4-iodo-ritalinol
(Scheme 5.13) due to the availability of 4-iodo-MP previously described (Scheme 5.3).
This strategy began with basification of 4-iodo-methyphenidate ((±)-3.31) with 1M
aqueous NaOH to provide the free base (±)-5.26 in 72% yield. Subsequently, methyl
ester reduction was then attempted with 0.6 equivalents of LiAlH4 at 0 ˚C (Table 5.2,
attempt 1). Although TLC of this reaction indicated a complete reaction in 30 minutes
and generation of a single, more polar spot, 1H NMR indicated a minor amount of desired
4-iodo-ritalinol ((±)-5.25) alongside deiodinated side product (±)-5.27 as the major
product. Furthermore, it proved very challenging to separate these ritalinols by silica gel
chromatography due to their rather high polarity.
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Table 5.2. LiAlH4 reaction conditions employed for methyl ester
reduction of racemic threo-4-iodo-MP.

Attempt

LiAlH4

Reaction

Equivalents

Conditions

1

0.6

0 ˚C, 30 min

2

0.3

-10 ˚C, 15 min

Result
Concomitant
deiodination

Scheme 5.13. Methyl ester reduction of racemic threo-4-iodo-MP to access
racemic threo-4-iodo-ritalinol.

Attempts to eliminate the undesirable deiodinated side product ritalinol ((±)5.27) by decreasing the number of equivalents of LiAlH4 to 0.3 equivalents, alongside
lower reaction temperature (-10 ˚C) (Table 5.2, attempt 2) and time (15 min) yielded
similar results. At this stage, the crude mixture of 4-iodo-ritalinol ((±)-5.25) and ritalinol
((±)-5.27) was N-benzylated to determine whether the expected mixture of N-benzyl-4iodo-ritalinol ((±)-5.28) and N-benzyl-ritalinol ((±)-4.31) could be separated by silica gel
chromatography (Scheme 5.13). However, once again silica gel chromatography proved
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difficult in terms of separating these N-benzyl-ritalinols.

As a result, methyl ester

reduction using a strong reducing agent such as LiAlH4 was abandoned in favor of milder
reducing agents in order to avoid undesirable deiodination to produce side product
ritalinol ((±)-5.27).
It should be noted that at the time of this project, 4-iodo-MP (via Scheme 5.3)
was considered very valuable material by the Lapinsky lab since its synthetic route had
yet to be optimized. However, as previously delineated, Nageswari Yarravarapu from the
Lapinsky lab at Duquesne University had already developed an efficient large scale
synthetic route for 3-iodo-MP (Scheme 5.8). As a result, the following model reduction
reactions were performed using 3-iodo-MP and its readily available precursors.
5.1.2.2.

Attempted Methyl Ester Reduction of Racemic threo-3-Iodo-MP with
LiBH4 to Access Racemic threo-3-Iodo-Ritalinol: a Model Reaction for
Reduction of Racemic threo-4-Iodo-MP to Racemic threo-4-Iodo-Ritalinol
At this time, methyl ester reduction conditions reported by Lapinsky and

Bergmeier (Lapinsky and Bergmeier, 2001) using LiBH4 as a milder reducing agent was
attempted in order to address the previously observed undesirable deiodination using
LiAlH4. In this regard, 3-iodo-MP ((±)-4.18) was first treated with 1M aqueous NaOH
in order to provide the free base (±)-5.29 in 85% yield, then methyl ester reduction with
LiBH4 was attempted (Scheme 5.14). TLC of this reaction indicated a complete reaction
after 24 hours with formation an unexpected nonpolar spot. Although 1H NMR of this
isolated material did not indicate the desired 3-iodo-ritalinol ((±)-5.30), the methyl ester
of (±)-5.29 was observed with impurities, thus indicating a potentially stable borane
complex where the piperidine nitrogen may have prevented desired reduction of the
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methyl ester under these reaction conditions. All attempts to force this reduction reaction
to completion using excess LiBH4 (10 equivalents) and heating (60 ˚C) proved
unsuccessful, and as a result this strategy was no longer pursued.

Scheme 5.14. Attempted methyl ester reduction of racemic threo-3-iodo-MP with LiBH4 as model
reaction to access racemic threo-4-iodo-ritalinol.

5.1.2.3.

Attempted Reductive Ring Opening of a Racemic threo-3-Iodo-β-Lactam
Building Block with LiAlH4 to Access Racemic threo-3-Iodo-Ritalinol: a
Model Reaction for the Synthesis of Racemic threo-4-Iodo-Ritalinol as a
Desired Compound
At this stage of the project, an optimized small scale synthesis of 4-iodo-MP

((±)-3.31 via Scheme 5.5) via methanolysis of racemic threo-4-iodo-β-lactam (±)-5.4 was
developed.

In this regard, reductive lactam ring opening (conditions adapted from

D’hooghe et al., 2009) using 3-iodo-β-lactam (±)-5.14 with LiAlH4 was envisioned as an
appropriate model system to circumvent the previously described deiodination problem
(Scheme 5.15). Attempted reductive ring opening of 3-iodo-β-lactam (±)-5.14 with solid
LiAlH4 (2 equivalents) in diethyl ether under reflux conditions resulted in the recovery of
starting material. However, repeating this reaction with one equivalent of a 1.0 M
solution of LiAlH4 in THF gave a mixture of deiodinated β-lactam ((±)-3.11) alongside
starting material (±)-5.14. Given this unsuccessful reaction, this synthetic strategy was
abandoned in favor of using milder reducing agents.
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Scheme 5.15. Attempted reductive ring opening of a racemic threo-3-iodo-β-lactam building block
with LiAlH4 as a model reaction to access racemic threo-4-iodo-ritalinol.

5.1.2.4.

Borane Reduction of Racemic threo-3-Iodo-Ritalinic Acid as a Model
Reaction to Access Racemic threo-4-Iodo-Ritalinol
Given the failed attempts of reducing the methyl ester of 3-iodo-MP ((±)-4.18)

and reductive ring opening of 3-iodo-β-lactam (±)-5.14, borane reduction of 3-iodoritalinic acid ((±)-5.31) was attempted next as a model reaction to potentially access
racemic threo-4-iodo-ritalinol. This strategy began with acidic hydrolysis of 3-iodo-βlactam (±)-5.14 to provide 3-iodo-ritalinic acid ((±)-5.31) in 80% yield (Scheme 5.16).
The carboxylic acid of (±)-5.31 was then successfully reduced with 5 equivalents of
BH3•THF (conditions adapted from Bosch et al., 2004) to access crude 3-iodo-ritalinol
((±)-5.30) in low yield (20%). Irrespective of the low yield, lack of deiodinated side
product ritalinol (±)-5.27 was very encouraging and made this synthetic strategy
appropriate for accessing 4-iodo-ritalinol ((±)-5.25).
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Scheme 5.16. Borane reduction of racemic threo-3-iodo-ritalinic acid as a model reaction
to access racemic threo-4-iodo-ritalinol.

5.1.2.5.

Borane Reduction of Racemic threo-4-Iodo-Ritalinic Acid Towards the
Synthesis of Racemic threo-p-Azido-N-Benzyl-4-Iodo-Ritalinol

Scheme 5.17. Synthesis of racemic threo-p-azido-N-benzyl-4-iodo-ritalinol via
borane reduction of racemic threo-4-iodo-ritalinic acid.

Given the successful borane reduction of 3-iodo-ritalinic acid ((±)-5.31) to 3iodo-ritalinol ((±)-5.30), this prompted me to hydrolyze 4-iodo-β-lactam (±)-5.4 (from
Scheme 5.7) to produce 4-iodo-ritalinic acid ((±)-3.30) in 99% yield (Scheme 5.17).
Subsequent reduction of the carboxylic acid to the primary alcohol with borane
(conditions from Scheme 5.16) provided 4-iodo-ritalinol ((±)-5.25) in 43% yield. The
crude ritalinol (±)-5.25 was then taken forward and N-alkylated with para-azido benzyl
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bromide (5.3 from Scheme 5.9) to provide racemic threo-p-azido-N-benzyl-4-iodoritalinol ((±)-4.33) in 50% yield as a potential photoaffinity ligand for DAT structurefunction studies.
5.1.3. Synthesis of Racemic threo-MP-Based Analogs Containing the Traditional 3Iodo-4-Azido Labeling Motif as Potential Photoaffinity Ligands for DAT
Structure-Function Studies
As previously described in Section 4.6.3, since photoaffinity ligands based on 3iodo-MP ((±)-4.18) and 4-iodo-MP ((±)-3.31) had poor DAT binding affinity, we desired
racemic threo-MP-based analogs containing the traditional 3-iodo-4-azido labeling motif
as potential photoaffinity ligands with improved DAT binding affinity relative to
previously described successful DAT probe [125I]-(±)-4.26 (Lapinsky et al., 2011). In
particular, we envisioned the synthesis of these photoprobes via N-alkylation of either
racemic threo-MP ((±)-1.10; Axten et al., 1998; Gutman et al., 2004) or ritalinol ((±)5.27; Kim et al., 2007) with 3-iodo-4-azido benzyl chloride (5.32; Murray et al., 2005)
(Scheme 5.18). As a result, syntheses of racemic threo-MP ((±)-1.10), ritalinol ((±)5.27), and 3-iodo-4-azido benzyl chloride (5.32) were pursued in parallel.

Scheme 5.18. Proposed retrosynthesis of racemic threo-MP analogs containing the traditional 3-iodo4-azido labeling motif as potential photoaffinity ligands for DAT structure-function studies.

5.1.3.1.

Synthesis of 3-Iodo-4-Azido Benzyl Chloride in Order to Access Racemic
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threo-MP Analogs Containing the Traditional 3-Iodo-4-Azido Labeling
Motif
In order to produce desired target racemic threo-MP-based photoaffinity
ligands containing the traditional 3-iodo-4-azido labeling motif (Scheme 5.18), 3-iodo-4azido benzyl chloride (5.32) was needed for N-alkylation of racemic threo-MP and
ritalinol. 3-Iodo-4-azido benzyl chloride (5.32) was synthesized according to the known
chemical literature (Murray et al., 2005).

Scheme 5.19. Synthesis of 3-iodo-4-azido benzyl chloride needed to produce racemic threo-MPbased analogs containing the traditional 3-iodo-4-azido labeling motif as potential photoaffinity
ligands for DAT structure-function studies.

Briefly, commercially available aniline 5.33 was subjected to electrophilic
iodination to provide iodide 5.34 in 67% yield (Scheme 5.19). Next, the amino group of
5.34 was diazotized and displaced with azide to provide methyl ester 5.35 in 99% yield.
Subsequent hydrolysis of ester 5.35 under basic conditions provided the carboxylic acid
5.36 in 97% yield, which in turn was reduced to the primary alcohol (5.37) in 70% yield
via a mixed anhydride intermediate (Shu et al., 1996).
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Finally, alcohol 5.37 was

converted to 3-iodo-4-azido benzyl chloride (5.32) upon treatment with mesyl chloride
wherein the benzylic mesylate is displaced by chloride anion.
5.1.3.2.

N-Alkylation of Racemic threo-MP with 3-Iodo-4-Azido Benzyl Chloride
To Produce a MP-Based Photoaffinity Ligand Containing the Traditional
3-Iodo-4-Azido Labeling Motif
Target racemic threo-MP-based photoaffinity probe (±)-4.35 was synthesized

in 28% yield by reacting the secondary amine of racemic threo-MP ((±)-1.10 from
Scheme 5.2) with 3-iodo-4-azido benzyl chloride (5.32 from Scheme 5.19) (Scheme
5.20).

Scheme 5.20. Synthesis of a racemic threo-MP-based photoaffinity ligand containing the traditional
3-iodo-4-azido labeling motif.

5.1.3.3.

N-Alkylation of Racemic threo-Ritalinol with 3-Iodo-4-Azido Benzyl
Chloride To Produce a Racemic threo-MP-Based Photoaffinity Ligand
Containing the Traditional 3-Iodo-4-Azido Labeling Motif
In order to access an additional racemic threo-MP-based photoaffinity ligand

containing the traditional 3-iodo-4-azido labeling motif, racemic threo-MP ((±)-1.10
from Scheme 5.2) was first treated with 1M aqueous NaOH to provide the free base
compound (±)-5.38 in 70% yield (Scheme 5.21). Subsequent reduction of the methyl
ester with LiAlH4 then provided racemic threo-ritalinol ((±)-5.27) in 90% yield (Kim et
al., 2007). Finally, the piperidine of (±)-5.27 was N-alkylated with 3-iodo-4-azido benzyl
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chloride (5.32 from Scheme 5.19) to provide target ritalinol-based photoaffinity probe
(±)-4.36 in 19% yield.

Scheme 5.21. Synthesis of a racemic threo-ritalinol-based photoaffinity ligand
containing the traditional 3-iodo-4-azido labeling motif.

5.1.4. Synthesis of

(R,R)-MP-Based

Photoaffinity Ligands Containing the

Traditional 3-Iodo-4-Azido Labeling Motif for DAT Structure-Function
Studies
In order to avoid photoprobes as racemic mixtures as previously described in
Section 4.6.3, we desired enantiomerically pure (R,R)-MP-based analogs containing the
traditional 3-iodo-4-azido labeling motif as potential photoaffinity ligands for DAT
structure-function studies.

In particular, we envisioned the synthesis of these

enantiomerically pure photoprobe compounds via N-alkylation of (R,R)-MP ((+)-1.10;
Prashad et al., 1999a) and (R,R)-ritalinol (5.27; Prashad et al., 1999b) with 3-iodo-4azido benzyl chloride (5.32; Murray et al., 2005) (Scheme 5.22). With this synthetic
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strategy in mind, parallel syntheses of target photoaffinity ligands (-)-4.35 and (-)-4.36
were pursued.

Scheme 5.22. Proposed retrosynthesis for enantiomerically pure (R,R)-MP-based photoaffinity
ligands containing the traditional 3-iodo-4-azido labeling motif.

5.1.4.1.

N-Alkylation of (R,R)-MP with 3-Iodo-4-Azido Benzyl Chloride Towards
an Enantiomerically Pure MP-Based Photoaffinity Ligand Containing the
Traditional 3-Iodo-4-Azido Labeling Motif
Target enantiomerically pure (R,R)-MP-based photoaffinity probe (-)-4.35

was synthesized in 19% yield by N-alkylation of (R,R)-MP ((+)-1.10; provided by retired
Professor Howard M. Deutsch (Georgia Tech University)) with 3-iodo-4-azido benzyl
chloride (5.32 from Scheme 5.19) (Scheme 5.23).

Scheme 5.23. Synthesis of an enantiomerically pure (R,R)-MP-based photoaffinity ligand containing
the traditional 3-iodo-4-azido labeling motif.
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5.1.4.2.

N-Alkylation of (R,R)-Ritalinol with 3-Iodo-4-Azido Benzyl Chloride To
Access an Additional (R,R)-MP-Based Photoaffinity Ligand Containing
the Traditional 3-Iodo-4-Azido Labeling Motif

Scheme 5.24. Synthesis of a (R,R)-ritalinol-based photoaffinity ligand for DAT structure-function
studies containing the traditional 3-iodo-4-azido labeling motif.

In order to access an additional enantiomerically pure (R,R)-MP-based
photoaffinity ligand for potential DAT structure-function studies, (R,R)-MP ((+)-1.10;
provided by retired Professor Howard M. Deutsch (Georgia Tech University) was first
treated with aqueous 1M NaOH in order to provide the free base compound 5.38 in 72%
yield (Scheme 5.24). The methyl ester of this enantiomerically pure compound was then
reduced with LiAlH4 (using conditions adapted from Kim et al., 2007) to provide
enantiomerically pure (R,R)-ritalinol (5.27) in 93% yield. Finally, the piperidine nitrogen
of enantiomerically pure 5.27 was alkylated under basic conditions with 3-iodo-4-azido
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benzyl chloride (5.32 from Scheme 5.19) to provide access target ritalinol-based
photoaffinity probe (-)-4.36 in 46% yield.

This potential DAT photoprobe was

subsequently converted to its oxalate salt (5.39) in 34% yield for pharmacological
evaluation.
5.1.4.3.

Stannylation

of

(-)-3-Iodo-4-Azido-N-Benzyl-Ritalinol

Towards

Radioiodination and DAT Covalent Ligation Via Photoaffinity Labeling
Given (-)-3-iodo-4-azido-N-benzyl-ritalinol ((-)-4.36) displayed the highest
DAT binding affinity (Ki = 218 ± 29 nM) of the enantiopure MP-based photoaffinity
ligands synthesized during this work, further development of this compound into a
potential DAT photoprobe was pursued. Once again, given that wash-resistant binding
experiments involving nonradioactive azido compounds frequently give false positives in
the assessment of covalent attachment (Agoston et al., 1997), synthesis of a
radioiodinated (i.e., [125I]) version of enantiopure (-)-3-iodo-4-azido-N-benzyl-ritalinol
((-)-4.36) was pursued to determine if photoactivation could produce covalent ligation to
the DAT. In this regard, enantiopure (-)-3-iodo-4-azido-N-benzyl-ritalinol ((-)-4.36) was
subjected to Stille coupling (conditions adapted from Shu et al., 1996) with
bis(tributyltin) to provide stannyl derivative (-)-5.40 in 40% yield (Scheme 5.25). This
compound was then converted to radioactive iodide derivative [125I]-4.36 by Dr. John
Lever at the University of Missouri-Columbia (see Section A.2 in Appendix).
Subsequently, the DAT was irreversibly labeled (5.41, Scheme 5.25) succesfully with
[125I]-4.36 by Dr. Roxanne Vaughan’s group at the University of North Dakota (see
Section A.2 in Appendix). In summary, [125I]-4.36 represents the first successful example
of an enantiopure DAT photoaffinity ligand based on a MP scaffold, thus representing an
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important contribution to the arsenal of chemical probes useful for characterizing DAT
function and 3-D structure.

Scheme 5.25. Stannylation of an enantiomerically pure ritalinol-based probe towards radioiodination
by Dr. John Lever and DAT covalent ligation by Dr. Roxanne Vaughan.

5.1.5. Synthesis of Racemic threo-3,4-Dichloro-MP-Based Photoaffinity Ligands
Containing the Traditional 3-Iodo-4-Azido Labeling Motif for DAT
Structure-Function Studies
As previously described in Section 4.6.4, racemic threo-3,4-dichloro-MP analogs
containing the traditional 3-iodo-4-azido labeling motif ((±)-4.37 and (±)-4.38) were
desired as potential photoaffinity ligands for DAT structure-function studies. As a result
and analogous to the synthesis of MP-based photoprobes previously described in this
dissertation, N-alkylation of racemic threo-3,4-dichloro-MP ((±)-3.53; Deutsch et al.,
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1996) or 3,4-dichloro-ritalinol ((±)-5.42; Kim et al., 2007) with 3-iodo-4-azido benzyl
chloride (5.32; Murray et al., 2005) was envisioned as a synthetic strategy (Scheme 5.26)
to access potential DAT photoprobes with higher binding affinity versus that of probes
previously described.

With this strategy in mind, parallel syntheses of target

photoaffinity ligands (±)-4.37 and (±)-4.38 were pursued.

Scheme 5.26. Proposed retrosynthesis of racemic threo-3,4-dichloro-MP-based analogs as potential
photoaffinity ligands containing the traditional 3-iodo-4-azido labeling motif.

5.1.5.1.

N-Alkylation of Racemic threo-3,4-Dichloro-MP with 3-Iodo-4-Azido
Benzyl Chloride Towards Photoaffinity Ligands Containing the
Traditional 3-Iodo-4-Azido Labeling Motif

Scheme 5.27. Synthesis of a racemic threo-3,4-dichloro-MP-based photoaffinity
ligand containing the traditional 3-iodo-4-azido labeling motif.

Analogous to that previously described, target racemic threo-3,4-dichloroMP-based photoaffinity probe (±)-4.37 was synthesized in 24% yield by reacting racemic
threo-3,4-dichloro-MP ((±)-3.53; provided by retired Professor Howard M. Deutsch
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(Georgia Tech University)) with 3-iodo-4-azido benzyl chloride (5.32 from Scheme 5.19)
under basic conditions (Scheme 5.27).
5.1.5.2.

N-Alkylation of Racemic threo-3,4-Dichloro-Ritalinol with 3-Iodo-4-Azido
Benzyl Chloride Towards an Additional MP-Based DAT Photoaffinity
Ligand Containing the Traditional 3-Iodo-4-Azido Labeling Motif

Scheme 5.28. Synthesis of a racemic threo-3,4-dichloro-ritalinol-based photoaffinity ligand
containing the traditional 3-iodo-4-azido labeling motif.

Given that N-benzyl-ritalinol derivatives tend to possess higher DAT binding affinity
than their methyl ester counterparts (previously described in Section 4.6.4), a synthesis of
a racemic threo-3,4-dichloro-ritalinol analog containing the traditional 3-iodo-4-azido
labeling motif was pursued.

In particular, racemic threo-3,4-dichloro-MP ((±)-3.53;

provided by retired Professor Howard M. Deutsch (Georgia Tech University)) was first
converted to its free base form by treatment with 1M aqueous NaOH (Scheme 5.28). The
methyl ester of compound (±)-5.43 was then reduced with LiAlH4 to provide racemic
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threo-3,4-dichloro-ritalinol ((±)-5.42; Kim et al., 2007) in 80% yield.

Finally, the

piperidine nitrogen of (±)-5.42 was selectively alkylated under basic conditions via
reaction with 3-iodo-4-azido benzyl chloride (5.32 from Scheme 5.19) in order to provide
target 3,4-dichloro-ritalinol-based photoaffinity probe (±)-4.38 in 23% yield.
5.2.

Synthesis of GBR-12909-Based Photoprobes Suitable for DAT StructureFunction Studies

5.2.1. Synthesis of a Clickable Benzophenone-Alkyne-Based GBR-12909 Analog as
a Potential Photoprobe for DAT Structure-Function Studies
In an effort to transition away from radioiodinated-based compounds, several
DAT photoprobes were envisioned employing terminal alkynes or aliphatic azides as
click chemistry handles for application of a tandem photoaffinity labeling-bioorthogonal
conjugation strategy (Lapinsky, 2012; see Section 4.7). In particular, we envisioned
synthesis of a clickable benzophenone-alkyne-based GBR-12909 photoprobe (4.40) for
DAT structure-function studies via Sonogashira coupling of iodobenzophenone 5.44 with
trimethylsilyl acetylene (3.67) followed by silyl group deprotection (Scheme 5.29). This
synthetic strategy appeared to be particularly attractive since iodobenzophenone 5.44
could also represent a potential radioactive GBR-12909-based DAT photoaffinity probe
via pursuit of its 125I form. In particular, we envisioned iodobenzophenone 5.44 could be
obtained via N-alkylation of known mono-substituted piperazine derivative 3.58 (Van der
zee et al., 1980) with alkyl bromide 5.45. In turn, the synthesis of alkyl bromide 5.45
was envisioned via Friedel-Craft’s acylation of commercially available 1-phenyl-3bromopropane (3.59) with 4-iodobenzoyl chloride (5.46).
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Scheme 5.29. Proposed retrosynthesis of a clickable benzophenone-alkyne-based GBR-12909
analog as a potential photoprobe for DAT structure-function studies.

With this retrosynthetic strategy in mind, 4,4’-difluorobenzhydrol (3.54) was first
treated with 2-chloroethanol (3.55) under acidic conditions to provide known chloride
3.56 (Ironside et al., 2002) in moderate yield (85%) (Scheme 5.30). Next, displacement
of the primary chloride within 3.56 by reacting with excess piperazine (3.57) provided
the known mono-substituted piperazine derivative 3.58 (Van der zee et al., 1980) in 55%
yield. Subsequent alkylation of piperazine 3.58 with alkyl bromide 5.45, obtained via
Friedel-Craft’s acylation (conditions adapted from Tanaka et al., 1992) of 1-phenyl-3bromopropane (3.59) with 4-iodobenzoyl chloride (5.46), provided GBR-12909 analog
5.44 in 62% yield. In order to access the photoprobe containing the terminal alkyne click
chemistry handle, Sonogashira coupling (conditions adapted from Gangjee et al., 2000)
conditions were employed by reacting iodo benzophenone 5.44 with trimethylsilyl
acetylene (3.67) under palladium-catalyzed reaction conditions. Subsequent silyl group
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deprotection using tert-butyl ammonium fluoride (TBAF) provided target benzophenonealkyne-based GBR-12909 analog 4.40 in 37% yield.

Scheme 5.30. Synthesis of a clickable benzophenone-alkyne-based GBR-12909 analog as
a potential photoprobe for DAT structure-function studies.

5.2.2. Synthesis of a Diazido-Based GBR-12909 Analog as a Potential Photoprobe
for DAT Structure-Function Studies
5.2.2.1.

An Attempted β-Alkyl Suzuki-Miyaura Coupling Strategy Towards the
Synthesis of a Diazido-Based GBR-12909 Analog for DAT StructureFunction Studies
As previously described in Section 4.7.2, an alternative GBR-12909 DAT

photoprobe was desired containing the 1,3,5-disubstitued diazido phenyl motif commonly
used in tandem photoaffinity labeling-bioorthogonal conjugation (Lapinsky, 2012). In
this regard, we envisioned the synthesis of probe 4.43 for DAT structure-function studies
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via β-alkyl Suzuki-Miyaura coupling between known N-allyl alkene 5.47 (Hsin et al.,
2003) and known iodo diazide 5.48 (Hosoya et al., 2009) (Scheme 5.31). In particular,
this synthetic strategy was initially pursued given there are numerous examples of sp 2-sp2
carbon-carbon bond forming reactions involving 5.48 under Suzuki-Miyaura coupling
conditions (Hosoya et al., 2009), thus indicating both the aryl and aliphatic azide
functional groups survive this palladium-catalyzed reaction. Furthermore, this synthetic
strategy was selected with an objective to potentially develop a method for readily
arming any compound of interest with this common diazide motif upon attachment of
iodo diazide 5.48 to a terminal alkene.

Scheme 5.31. Envisioned β-alkyl Suzuki-Miyaura coupling strategy towards the synthesis of a
clickable diazido-based GBR-12909 DAT photoprobe.

With this strategy in mind, synthesis of GBR-12909 (1.12) itself via β-alkyl
Suzuki-Miyaura coupling of known alkene 5.47 (Hsin et al., 2003) with commercially
available iodobenzene (3.69) was initially pursued as a model reaction to see if this
chemistry would prove successful (Scheme 5.32).
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Scheme 5.32. Envisioned β-alkyl Suzuki-Miyaura coupling towards the synthesis of
GBR-12909 as a model reaction.

5.2.2.1.1. Synthesis of GBR-12909 via β-Alkyl Suzuki-Miyaura Coupling: a Model
Reaction
Before proceeding with the synthesis of target diazido-based GBR-12909
analog 4.43 via β-alkyl Suzuki-Miyaura coupling, a model reaction was performed using
commercially available iodobenzene (3.69) and readily accessible known alkene 5.47
(Hsin et al., 2003) in an attempt to synthesize GBR-12909 (1.12) by β-alkyl SuzukiMiyaura coupling (Scheme 5.33). This work began by reacting chloride 3.56 (from
Scheme 5.30) with allyl piperazine (5.49) to provide known terminal alkene 5.47 (Hsin et
al., 2003) in 55% yield. Next, β-alkyl Suzuki-Miyaura coupling (conditions adapted
from

Lapinsky

and

Bergmeier,

2001)

involving

alkene

5.47,

9-BBN,

PdCl2(dppf)•CH2Cl2, and iodobenzene (3.69) provided impure GBR-12909 (1.12) in 20%
yield (Scheme 5.33). Irrespective of the low yield of this reaction, successful formation
of GBR-12909 (1.12) by this chemistry prompted pursuit of known iodo diazide 5.48
(Hosoya et al., 2009), which would be required for application of this chemical strategy
to synthesize target diazido GBR-12909 analog 4.43.
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Scheme 5.33. Synthesis of GBR-12909 via β-alkyl Suzuki-Miyaura coupling: a model reaction.

5.2.2.1.2. Synthesis of a Known Aryl-Iodo Diazide Towards Generation of a
Clickable GBR-12909-Based DAT Photoprobe
In order to access diazido GBR-12909-based photoprobe 4.43 for DAT
structure-function studies, known iodo diazide 5.48 was synthesized according to the
chemical literature (Hosoya et al., 2009) (Scheme 5.34). Commercially available aniline
5.50 was first diazotized and reacted with potassium iodide to provide the known aryl
iodide 5.51 (Vaidyanathan et al., 2001) in 95% yield. The carboxylic acid of iodide 5.51
was then reduced with sodium borohydride in the presence of boron trifluoride diethyl
ether (conditions adapted from Cho et al., 2004) to provide the primary alcohol 5.52 in
71% yield. Next, the aromatic nitro group of 5.52 was reduced with tin (II) chloride
under acidic conditions to provide aniline 5.53 in 90% yield. Diazotization of the aniline
followed by displacement with sodium azide then provided aryl azide 5.54 (Hosoya et al.,
2002) in 93% yield. Finally, the primary alcohol of 5.54 was converted into a mesylate

122

leaving group and displaced with sodium azide to provide the aliphatic azide 5.48
(Hosoya et al., 2009) in 80% yield.

Scheme 5.34. Synthesis of a known aryl-iodo diazide building block towards a clickable GBR12909-based DAT photoprobe.

5.2.2.1.3. Attempted Synthesis of a Diazido-Based GBR-12909 Photoprobe for DAT
Structure-Function Studies Via β-Alkyl Suzuki-Miyaura Coupling
Based on successful β-alkyl Suzuki-Miyaura reaction conditions used to
synthesize GBR-12909 (1.12; Scheme 5.33), synthesis of target diazido-based GBR12909 photoprobe 4.43 was attempted by trying to couple terminal alkene 5.47 with iododiazide 5.48 (Scheme 5.35). This attempted coupling reaction resulted in multiple spots
on TLC.

In particular, 1H NMR of an isolated proposed target spot indicated

decomposition of one or more of the organic azides. As a result of this experiment, βalkyl Suzuki-Miyaura coupling between terminal alkene 5.47 and relatively stable aryl
iodide 5.55 (Giblin et al., 2005a; obtained via esterification of carboxylic acid 5.51 from
Scheme 5.34) was envisioned as a key reaction to access GBR-12909 analog 5.56 as an
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important synthetic intermediate. Sequential nitro and ester reductions of intermediate
5.56 followed by incorporation of both the aryl and aliphatic azides as previously
described was then envisioned to provide the target diazido-based GBR-12909 analog
4.43 (Scheme 5.35). However, attempted β-alkyl Suzuki-Miyaura coupling between
terminal alkene 5.47 and aryl iodide 5.55 produced multiple spots on TLC, none
indicative of target 5.56 upon chromatography and 1H NMR. Given the relative lack of
success of these two attempted β-alkyl Suzuki-Miyaura coupling reactions, this chemical
strategy towards target diazido-based GBR-12909 photoprobe 4.43 was dropped in favor
of pursuit of alternative synthetic routes (vide infra).

Scheme 5.35. Attempted synthesis of a diazido-based GBR-12909 photoprobe via
β-alkyl Suzuki-Miyaura coupling.
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5.2.2.2.

Reductive Amination Strategy Towards the Synthesis of a Diazido-Based
GBR-12909 Photoprobe for DAT Structure-Function Studies
Given the relative lack of success via a proposed β-alkyl Suzuki-Miyaura

coupling strategy, alternative synthetic strategies toward target diazido-based GBR12909 photoprobe 4.43 were pursued (Scheme 5.36). In particular, access to this target
photoprobe was envisioned via GBR-12909 analog 5.56 as a key synthetic intermediate,
wherein this compound could potentially be accessed through reductive amination of
novel aldehyde 5.57 with known piperazine 3.58 (Van der zee et al., 1980). In turn, the
requisite aldehyde 5.57 could potentially be obtained by via known alkene 5.58 (Ek et al.,
2002) by sequential hydroboration-oxidation followed by alcohol oxidation. With these
synthetic thoughts in mind, pursuit towards target diazido-based GBR-12909 photoprobe
4.43 was re-initiated.

Scheme 5.36. Proposed reductive amination strategy towards the synthesis of a
diazido-based GBR-12909 photoprobe.
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With Scheme 5.36 in mind, synthesis of GBR-12909 (1.12) by reductive
amination of piperazine 3.58 (from Scheme 5.30) with commercially available 3phenylpropanal (5.59) was first envisioned as a model reaction to determine whether this
chemistry could proceed successfully (Scheme 5.37).

Scheme 5.37. Envisioned reductive amination strategy towards the synthesis of GBR-12909 as a
model reaction towards a target diazido-based GBR-12909 photoprobe.

5.2.2.2.1. Synthesis of GBR-12909 by Reductive Amination as a Model Reaction
Towards a Target Diazido-Based GBR-12909 Photoprobe

Scheme 5.38. Synthesis of GBR-12909 by reductive amination.

Before pursuit of novel aldehyde 5.57 for the envisioned reductive amination
strategy towards target diazido-based GBR-12909 photoprobe 4.43 (Scheme 5.36), a
reductive amination reaction was attempted involving known piperazine 3.58 (from
Scheme 5.30) and commercially available 3-phenylpropanal (5.59) using conditions from
Abdel-Magid et al., 1996 (Scheme 5.38).

This model reaction proved successful

providing GBR-12909 (1.12) in 70% yield. Given the success of this particular model
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reaction, pursuit of novel aldehyde 5.57 for reductive amination to access key
intermediate 5.56 required for the synthesis of target diazido-based GBR-12909 analog
4.43 was initiated.
5.2.2.2.2. Synthesis of a Novel Aldehyde in Order To Access a Key Synthetic
Intermediate for the Synthesis of a Diazido-Based GBR-12909 DAT
Photoprobe
Novel aldehyde 5.57 was required in relatively large amounts in order to
access key intermediate 5.56 for the synthesis of target diazido-based GBR-12909
photoprobe 4.43. Initial strategy for synthesis of aldehyde 5.57 began with conversion of
aniline 5.60 to terminal alkene 5.58 (Scheme 5.39; Ek et al., 2002, red color) via
diazotization and free radical allylation. Next, terminal alkene 5.58 was subjected to
hydroboration-oxidation (conditions adapted from Kim et al., 2008) to provide primary
alcohol 5.62 in 40% yield. Subsequently, primary alcohol 5.62 was oxidized to its
corresponding aldehyde (5.57) using pyridinium chlorochromate (PCC), followed by
reductive amination with piperazine 3.58 (Van der zee et al., 1980) to provide GBR12909 analog 5.56 in good yield (70%). However, synthesis of aldehyde 5.57 by this
hydroboration-oxidation route was rather low yielding (Scheme 5.39, red color, 3 steps,
7% overall yield, 0.4 mmol scale). In particular, this chemistry was much lower yielding
on a larger scale (1 mmol) and attempts utilizing BH3•Me2S as a hydroboration reagent
did not result in a significant improvement. As a result, a more practical, alternative
route was pursued in order to generate aldehyde 5.57 on a larger scale (Scheme 5.39, blue
color).
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This alternative strategy to aldehyde 5.57 began with subjection of aniline
5.60 to diazotization and iodide displacement conditions to provide aryl iodide 5.55 in
70% yield (Scheme 5.39, blue color, Giblin et al., 2005b). Subsequent Heck-coupling
(conditions adapted from Deng et al., 2009) of this aryl iodide with allyl alcohol (5.63)
then provided direct access to target aldehyde 5.57 in 57% yield (Scheme 5.39, blue
color). This chemistry proved very practical even on a relatively large scale (7 mmol).
Additionally, a significant improvement in the yield of aldehyde 5.57 was observed using
this strategy and also involved fewer synthetic steps (Scheme 5.39, blue color, 2 steps,
40% overall yield versus Scheme 5.39, red color, 3 steps, 7% overall yield).

Scheme 5.39. Synthesis of a novel aldehyde and a key GBR-12909 analog as an intermediate
needed for the synthesis of a diazido-based GBR-12909 dopamine photoprobe.
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5.2.2.2.3. Further Modifications of a GBR-12909 Analog Towards the Synthesis of
a Diazido-Based GBR-12909 Photoprobe for DAT Structure-Function
Studies

Scheme 5.40. Further successful modifications of a GBR-12909 analog to produce a diazido-based
GBR-12909 photoprobe for DAT structure-function studies.

With large quantities of GBR-12909 analog 5.56 as a synthetic intermediate in
hand, the nitro group of this compound was reduced with tin (II) chloride dihydrate to
provide aniline 5.64 in 74% yield (Scheme 5.40). The ethyl ester of 5.64 was then
reduced with LiAlH4 to provide the corresponding primary alcohol (5.65) in 81% yield.
Next, the aniline of intermediate 5.65 was subjected to diazotization and azide
displacement to provide access to aryl azide 5.66 in 70% yield. Finally, the primary
alcohol of intermediate 5.66 was converted into a mesylate leaving group to provide 5.67
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in 40% yield, then subsequently displaced with sodium azide to produce diazido-based
GBR-12909 target photoprobe 4.43 in 40% yield.
5.3.

Synthesis of Irreversible mGlu5 NAMs as Chemical Probes Suitable for
mGlu5 Structure-Function Studies

5.3.1. Synthesis of Lead mGlu5 NAMs as Controls for mGlu5 Pharmacological
Evaluation
Given known lead mGlu5 NAMs 4.44 and 4.45 were required as positive controls
for pharmacological comparison to novel probe compounds, these compounds were
synthesized according to the known chemical literature (Iso et al., 2006; Mishra et al.,
2012). In this regard, condensation of acid chloride 3.72 with bis(trimethylsilyl)acetylene
(3.73) first provided α-chloroketone derivative 3.74 in 70% yield (Scheme 5.41).
Subsequent

cyclization

with

thioacetamide

(3.75)

provided

alkyne-protected

methylthiazole derivative 3.76 (Cosford et al., 2003) in 60% yield.

In turn, this

trimethylsilyl protected alkyne was subjected to one-pot desilylation and Sonogashira
coupling with either iodobenzene (3.69) or 3-iodo-phenol (5.68) to provide known lead
mGlu5 NAMs 4.44 (Iso et al., 2006) and 4.45 (Mishra et al., 2012) in 80% and 50%
yield, respectively. Additionally, with the objective of pursuing novel benzylic ether 4.46
as a potential lead compound (i.e., should this compound display appreciable mGlu5
binding affinity and retain NAM function), trimethylsilyl-protected alkyne 3.76 was
subjected to one-pot desilylation and Sonogashira coupling (conditions adapted from Iso
et al., 2006) with aryl iodide 5.69 to give benzyl ether 4.46 in 70% yield. With these
control compounds in hand, synthesis of novel mGlu5 irreversible NAMs as chemical
probes for mGlu5 structure-function studies were subsequently initiated.
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Scheme 5.41. Synthesis of several lead mGlu5 NAMs as control
compounds for mGlu5 pharmacological studies.

5.3.2. Synthesis of a Clickable Benzophenone Propargyl Ether mGlu5 NAM
Photoprobe for mGlu5 Structure-Function Studies
As previously described in Section 4.8.1, we desired clickable benzophenone
propargyl ether mGlu5 NAM 4.49 (RVDU-3-130) as a potential photoprobe suitable for
mGlu5 structure-function studies. The synthesis of target photoprobe 4.49 (RVDU-3130) was envisioned via O-alkylation of known phenol 4.45 (Mishra et al., 2012) with
alkyl bromide 5.70, which in turn we believed could be accessed via O-alkylation of
known phenol 5.72 (Tae et al., 2010) with dibromoethane (5.71) (Scheme 5.42). It is
known that phenol 5.72 can be obtained by monopropargylation of bis-phenol 5.74 (Tae
et al., 2010).
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Scheme 5.42. Proposed retrosynthesis of a clickable benzophenone propargyl ether
mGlu5 NAM photoprobe.

With this retrosynthesis in mind, commercially available bis-phenol 5.74 was first
mono-alkylated with propargyl bromide (5.73) to provide benzophenone derivative 5.72
(Tae et al., 2010) in 40% yield (Scheme 5.43).

Subsequent alkylation with

dibromoethane (5.71) then provided alkyl bromide 5.70 in 28% yield.

Next, alkyl

bromide 5.70 was treated with phenol 4.45 (from Scheme 5.41) under basic conditions to
provide target probe 4.49 (RVDU-3-130) in 70% yield. Given clickable benzophenone
propargyl ether mGlu5 NAM 4.49 (RVDU-3-130) displays improved mGlu5 binding
affinity (Ki = 11 ± 0.8 nM) versus lead compounds 4.45 (Ki = 59 ± 0.9 nM) and 4.46 (Ki
= 48 ± 0.8 nM), and retained mGlu5 NAM functional potency, this photoprobe is
currently being evaluated in mGlu5 tandem photoaffinity labeling-bioorthogonal
conjugation experiments in Dr. Karen Gregory’s laboratory at Monash University (see
Section A.3 in Appendix)
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Scheme 5.43. Synthesis of a clickable benzophenone propargyl ether mGlu5 NAM photoprobe
suitable for mGlu5 structure-function studies.

5.3.3. Synthesis of a Clickable MPEP-Binding Site Diazido mGlu5 NAM
Photoprobe for mGlu5 Structure-Function Studies
As previously discussed in Section 4.8.2, a MPEP-binding site diazido mGlu5
NAM thiazole (4.50) was desired as a clickable photoprobe for mGlu5 structure-function
studies. We envisioned the synthesis of this target compound via O-alkylation of known
phenol 4.45 (Mishra et al., 2012) with known diazido mesylate 5.79 (Hosoya et al., 2005)
(Scheme 5.44).

Scheme 5.44. Proposed retrosynthesis of a MPEP-binding site diazido mGlu5 NAM as a clickable
photoprobe for mGlu5 structure-function studies.
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With this synthetic strategy in mind, commercially available dimethyl 5aminoisophthalate (5.80) was first reduced with excess lithium aluminum hydride to
provide diol 5.81 in 55% yield (Scheme 5.45). Aniline 5.81 was then subjected to
diazotization and azide displacement to provide aryl azide 5.82 in 70% yield, which upon
treatment with bis(2,4-dichlorophenyl chlorophosphate) and sodium azide provided
known diazido alcohol 5.83 (Neelarapu et al., 2011) in 56% yield. In turn, the remaining
primary alcohol of 5.83 was converted into a mesylate leaving group (5.79; Hosoya et al.,
2005) then displaced with phenol 4.45 (from Scheme 5.41) under basic conditions to
provide target clickable photoprobe 4.50 in 50% yield.

Scheme 5.45. Synthesis of a clickable MPEP-binding site diazido mGlu5 NAM photoprobe for
mGlu5 structure-function studies.

5.3.4. Synthesis of an Azido-Iodo Thiazole mGlu5 MPEP-Binding Site NAM
Photoprobe for mGlu5 Structure-Function Studies
As previously described in Section 4.8.3, an azido-iodo thiazole mGlu5 MPEPbinding site NAM photoprobe (4.52) was envisioned and desired for mGlu5 structure
function studies. In order to access this target photoprobe, we envisioned 4-((3-fluoro-5nitrophenyl)ethynyl)thiazol-2-amine (5.84) could be subjected to a sequence of
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diazotization followed by iodide displacement, nitro reduction, then diazotization
followed

by

azide

displacement

(Scheme

5.46).

In

turn,

4-((3-fluoro-5-

nitrophenyl)ethynyl)thiazol-2-amine (5.84) was envisioned by Sonogashira coupling
known TMS-protected alkyne 5.85 (Simeon et al., 2011) with commercially available 1fluoro-3-iodo-5-nitrobenzene (5.86).

Scheme 5.46. Proposed retrosynthesis of an azido-iodo thiazole mGlu5 MPEP-binding site NAM
photoprobe for mGlu5 structure function studies.

With this retrosynthetic strategy in mind, α-chloro ketone 3.74 (Cosford et al.,
2003) was first cyclized with thiourea (5.87) to provide amino thiazole 5.85 (Simeon et
al., 2011) in 70% yield (Scheme 5.47). Subsequent one-pot desilylation and Sonogashira
coupling (conditions adapted from Simeon et al., 2011) with commercially available aryl
iodide 5.86 provided impure disubstituted alkyne 5.84 in 25% yield after silica gel
chromatography. Next, impure thiazoloaniline 5.84 was directly converted to heteroaryl
iodide 5.88 in 70% yield using diazotization and iodide displacement conditions from
Simeon et al., 2011. Subsequent reduction of the nitro group within intermediate 5.88
using tin (II) chloride under strong acidic conditions resulted in the deiodinated analog of
intermediate 5.89. Alternatively, the nitro group of intermediate 5.88 was reduced with
solid iron under weak acidic conditions (adapted from Gamble et al., 2007) to provide
aniline 5.89 in 20% yield. Finally, aniline 5.89 was subjected to diazotization and
displacement with sodium azide to provide target azido-based photoprobe 4.52 in 15%
yield.
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Scheme 5.47. Synthesis of an azido-iodo thiazole mGlu5 MPEP-binding site NAM photoprobe for
mGlu5 structure function studies.

5.3.5. Synthesis of a Clickable Azido-Propargyl Ether mGlu5 MPEP-Binding Site
NAM Photoprobe for mGlu5 Structure-Function Studies
As previously described in Section 4.8.4, a mGlu5 MPEP-binding site NAM
(4.54) containing an aryl azide photoreactive group and a propargyl ether click chemistry
handle was envisioned as a photoprobe for mGlu5 structure function studies.

The

synthesis of this target photoprobe was envisioned by subjecting 2-((3-methoxy-5nitrophenyl)ethynyl)-6-methylpyridine

(5.90)

to

a

sequence

of

demethylation,

propargylation, nitro reduction, then diazotization followed by azide displacement
(Scheme 5.48). In turn, 2-((3-methoxy-5-nitrophenyl)ethynyl)-6-methylpyridine (5.90)
was envisioned by Sonogashira coupling TMS-protected alkyne 3.68 (Alagille et al.,
2005) with 1-iodo-3-methoxy-5-nitrobenzene (5.91) (Jorgensen et al., 2011).
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Scheme 5.48. Proposed retrosynthesis of a clickable azido-propargyl ether mGlu5 MPEP-binding site
NAM photoprobe for mGlu5 structure function studies.

With this synthetic strategy in mind, 2-bromo-6-methyl pyridine (3.64) was first
reacted with trimethylsilyl acetylene (3.67) under Sonogashira coupling conditions to
provide known TMS-protected alkyne 3.68 (Alagille et al., 2005) in 70% yield (Scheme
5.49).

Scheme 5.49. Synthesis of a clickable azido-propargyl ether mGlu5 MPEP-binding site NAM
photoprobe for mGlu5 structure function studies.

In parallel, 3,5-dinitro-iodobenzene (5.94) was reacted with sodium methoxide in
MeOH according to Jorgensen et al., 2011 to provide 1-iodo-3-methoxy-5-nitrobenzene
5.91 in 77% yield.

Next, protected terminal alkyne 3.68 was subjected to one-pot
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desilylation and Sonogashira coupling (conditions adapted from Iso et al., 2006) with 1iodo-3-methoxy-5-nitrobenzene 5.91 to provide disubstituted alkyne 5.90 in 78% yield.
Deprotection of methoxy ether 5.90 followed by propargylation provided ether 5.92 in
35% yield. Finally, the nitro group of intermediate 5.92 was reduced under acidic
conditions to provide aniline 5.93 in 91% yield, which was then subjected to
diazotization and displacement with sodium azide to provide target clickable photoprobe
4.54 in 30% yield.
5.3.6. Synthesis of a Methanethiosulfonate-Containing mGlu5 MPEP-Binding Site
NAM Thiol-Reactive Chemical Probe for mGlu5 Engineered Affinity
Labeling Experiments
As previously described in Section 4.8.5, a methanethiosulfonate-containing
mGlu5 MPEP-binding site NAM thiol-reactive chemical probe (4.55) was envisioned and
desired for mGlu5 engineered affinity labeling experiments.

The synthesis of this

particular affinity labeling probe was envisioned via S-alkylation of bromide 5.96 with
sodium methanethiosulfonate (5.95) (Scheme 5.50). In turn, we believed alkyl bromide
5.96 could be obtained by O-alkylation of known phenol 4.45 (Mishra et al., 2012) with
dibromethane (5.71).

Scheme 5.50. Proposed retrosynthesis of a methanethiosulfonate-containing mGlu5 MPEP-binding
site NAM thiol-reactive chemical probe for mGlu5 engineered affinity labeling experiments.

Given this retrosynthesis, previously obtained phenol 4.45 (from Scheme 5.41)
was alkylated with 1,2-dibromoethane (5.71) to provide alkyl bromide 5.96 in 32% yield
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(Scheme 5.51).

Subsequent displacement of this alkyl bromide with sodium

methanethiosulfonate (5.95) provided target thiol-reactive affinity labeling probe 4.55 in
85% yield. Given methanethiosulfonate-containing mGlu5 MPEP-binding site NAM
thiol-reactive chemical probe 4.55 retained appropriate mGlu5 binding affinity (Ki = 13 ±
0.8 nM, ~2-fold lower than parent compound 4.44) and NAM functional potency, this
probe has been subjected to prelimary docking experiments in a mGlu5 homology model
developed by Dr. Jens Meiler’s group (Vanderbilt University) to suggest rational cysteine
mutations for proposed mGlu5 engineered affinity labeling experiments (see Section A.4
in Appendix).

Scheme 5.51. Synthesis of a methanethiosulfonate-containing mGlu5 MPEP-binding site NAM thiolreactive chemical probe for mGlu5 engineered affinity labeling experiments.

5.3.7. Synthesis of a Maleimide-Based mGlu5 MPEP-Binding Site NAM ThiolReactive Chemical Probe for mGlu5 Engineered Affinity Labeling
Experiments
As previously described in Section 4.8.6, we envisioned and desired a maleimidebased mGlu5 MPEP-binding site NAM thiol-reactive chemical probe (4.56) for mGlu5
engineered affinity labeling experiments. The synthesis of this affinity labeling probe
was anticipated via condensation of 3-((2-methylthiazol-4-yl)ethynyl)aniline (5.98) with
maleic anhydride (5.97) (Scheme 5.52). In turn, we believed 3-((2-methylthiazol-4yl)ethynyl)aniline (5.98) could be obtained by Sonogashira coupling of known TMSprotected alkyne 3.76 (Cosford et al., 2003) with bromo aniline 5.99.
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Scheme 5.52. Proposed retrosynthesis of a maleimide-based mGlu5 MPEP-binding site thiol-reactive
chemical probe for mGlu5 engineered affinity labeling experiments.

Initial one-pot desilylation of TMS-protected alkyne 3.76 (from Scheme 5.41) and
Sonogashira coupling (conditions adapted from Iso et al., 2006) with bromo aniline 5.99
failed to provide disubstitued alkyne 5.98 (Scheme 5.53). As a result, one-pot desilylation
of TMS-protected alkyne 3.76 and Sonogashira coupling with 3-iodo-nitrobenzene
(5.100) provided disubstitued alkyne 5.101 (Alagille et al., 2004) in 70% yield.
Subsequent reduction of the nitro group in intermediate 5.101 with solid iron under acidic
conditions gave aniline 5.98 in 91% yield. Finally, treatment of aniline 5.98 with maleic
anhydride (5.97) and condensation with acetic anhydride provided target maleimidebased probe 4.56 in 70% yield.

Scheme 5.53. Synthesis of a maleimide-based mGlu5 MPEP-binding site thiol-reactive chemical
probe for mGlu5 engineered affinity labeling experiments.
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5.4.

Summary of Significance, Innovation, and Research Accomplishments
Associated With This Dissertation Work
Despite decades of committed research, no agents are clinically available to

combat psychostimulant abuse and addiction. This prodigious void can be linked in part
to sparse information on the 3-D structure and function of the DAT (DAT), which
pharmacological and behavioral studies indicate is the brain receptor chiefly responsible
for the reinforcing / reward properties associated with amphetamines and cocaine.
Specifically, there is a fundamental gap in understanding the mechanism of inhibitors and
the structural elements and conformational states associated with the DAT.
One of the long-term goals of the Lapinsky research group is to develop chemical
entities towards understanding how abused and therapeutic compounds interact with the
DAT at the amino acid level. In particular, the initial objective of this dissertation work
was to develop non-tropane irreversible ligands for mapping drug-binding pockets within
the DAT.

The hypothesis was that non-tropane irreversible ligands could serve as

complimentary probes to existing tropane-based (e.g., cocaine, benztropine) irreversible
ligands for high-resolution elucidation of DAT 3-D structure. Guided by the literature,
identification of the structural elements of MP- and GBR-12909-based irreversible
ligands essential for successful labeling of the DAT was pursued. In particular, the
specific hypothesis for this part of dissertation work tested whether these non-tropanebased inhibitor scaffolds could be structurally modified to covalently label the DAT via a
photoaffinity labeling experiment. Specifically, MP and GBR-12909 were modified to
contain a tag (i.e., I125, a terminal alkyne, or an aliphatic azide) and a photoreactive
functional group (i.e., an aryl azide or a benzophenone). The synthesized analogs were

141

then pharmacologically evaluated at the DAT by the Surratt laboratory in order to
identify candidate probes for irreversible DAT labeling experiments performed by the
Vaughan lab. In particular, an innovative, systematic design approach towards MP-based
DAT irreversible ligands was explored in order to address noted shortcomings associated
with previously established tropane-based DAT irreversible ligands. This portion of
research is significant because the binding sites and conformational preferences for MP
and GBR-12909 as non-tropane therapeutically relevant compounds are unknown relative
to tropane-based DAT ligands. Furthermore, a battery of developed probes based on
these chemical scaffolds is expected to advance the field towards rational structure-based
drug design for a myriad of DAT-implicated disorders besides drug addiction (e.g.,
Parkinson’s disease, schizophrenia, ADHD, depression). In this regard and as previously
described in Section 5.1, synthesis of racemic threo-p-azido-N-benzyl-4-iodo-MP ((±)4.26) and (R,R)-3-iodo-4-azido-N-benzyl-ritalinol ((-)-4.36) represent the first successful
examples of DAT photoaffinity ligands based on MP. Moreover, racemic threo-p-azidoN-benzyl-4-iodo-MP ((±)-4.26) represents the first successful example of a DAT
photoaffinity ligand wherein the photoreactive azide and iodine tag are on different parts
of the chemical scaffold (Lapinsky et al., 2011).
In terms of practical organic synthesis troubleshooting and as previously
described in Section 5.1.1.2.2, a novel, efficient large-scale synthesis of racemic threo-4iodo-MP ((±)-3.31) was developed in order to synthesize a series of racemic threo-Nazidobenzyl-4-iodo-MP photoaffinity ligands ((±)-4.24 to (±)-4.26) as potential
candidates for DAT structure-function studies. This optimized synthesis of racemic
threo-4-iodo-MP (Scheme 5.7) utilizes 6 steps and produces the target compound in 26%
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overall yield (Lapinsky et al., 2011). This represents a significant improvement in terms
of number of synthetic steps and overall product yield when compared to the previously
known synthetic route for racemic threo-4-iodo-MP (Pan et al., 1996; 10 steps, 9%
overall yield, Schemes 5.2 and 5.3). Additionally and as previously described in Section
5.1.2, synthesis of racemic threo-4-iodo-ritalinol ((±)-5.25) was needed towards racemic
threo-p-azido-N-benzyl-4-iodo-ritalinol ((±)-4.33) as a potential photoprobe for DAT
structure-function studies. However, the synthesis of racemic threo-4-iodo-ritalinol ((±)5.25) was problematic wherein ester reduction of racemic threo-4-iodo-MP ((±)-3.31)
using LiAlH4 routinely resulted in formation of the dehalogenated side product, racemic
threo-ritalinol ((±)-5.27).

In order to overcome this problem, borane reduction of

racemic threo-4-iodo-ritalinic acid ((±)-3.30) was employed in order to successfully
access racemic threo-4-iodo-ritalinol ((±)-5.25) without formation of any dehalogenated
side product, racemic threo-ritalinol ((±)-5.27).

Finally, as previously described in

Section 5.2.2.2.2, an efficient, large-scale synthesis of aldehyde 5.57 was needed in order
to synthesize diazido-based GBR-12909 photoprobe 4.43 for DAT structure-function
studies. An initial route featuring hydroboration-oxidation of a terminal alkene (Scheme
5.39, red color) was not optimal due to low yield of the target aldehyde. In turn, a unique
Heck coupling was employed (Scheme 5.39, blue color) in order to produce target
aldehyde 5.57 with improved yield and fewer steps when compared to the hydroborationoxidation route (Scheme 5.39, blue color, 2 steps, 40% overall yield versus Scheme 5.39,
red color, 3 steps, 7% over all yield).
To date, it should be noted that the development of DAT photoprobes has been
limited and traditionally involves the use of radioisotope tags. However, such tags have

143

limited utility and are no longer necessary for sensitive detection. Instead, photoprobe
development is rapidly and routinely moving to compounds bearing “clickable handles”
(e.g., aliphatic azides, terminal alkynes).

These handles allow click chemistry

derivatization of a probe after covalent photoligation to a protein of interest. In theory,
“clicked” DAT-photoprobe complexes can be purified, proteolyzed, and used in mass
spectrometric (MS) studies in order to sensitively identify specific sites of crosslinking.
This powerful and innovative tandem photoaffinity labeling-bioorthogonal conjugation
chemical proteomics approach using MS to identify distinct covalent crosslinks is
expected to directly map the binding sites of promising anti-addiction compounds within
the DAT (or mGlu5 (vide infra)).

In particular, the click chemistry approach is

advantageous in that it allows secondary attachment of a wide variety of tags (e.g., biotin
for easy enrichment, isolation, and detection, or fluorophores for sensitive detection and
imaging applications). Most importantly, it should be noted that previous attempts to
determine adduction sites of radioisotope-based phenyltropane photoprobes in the DAT
have relied on labor intensive peptide mapping strategies or construction of mutant
proteins, constraints which limit the utility and resolution of analysis. The ability to
attach biotin as a purification and detection handle to the probe via click chemistry after
photoligation is expected to permit microlevel analysis of probe-labeled protein
fragments when coupled to sequential LC-MS/MS. In this regard and as previously
described in Section 5.2, benzophenone-alkyne GBR-12909 analog 4.40 and diazido
GBR-12909 analog 4.43 represent the first clickable photoaffinity ligands synthesized for
potential DAT structure-function studies, thus representing an important contribution to
the growing arsenal of irreversible chemical probes useful for determining the binding
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site(s) and pose(s) of anti-addiction compounds upon coupling photoaffinity labeling with
molecular modeling studies.
Analogous to DAT inhibitors, numerous studies also indicate allosteric
modulation of mGlu5 as a promising pharmacological approach for treating drug abuse.
In particular, mGlu5 NAMs are currently being pursued as drug abuse therapeutics given
their ability to reduce conditioned reward, self-administration, and reinstatement of drug
seeking.

However, numerous challenges are associated with the discovery and

optimization of mGlu5 allosteric modulators as potential therapeutics including biased
pharmacology, difficult SAR, and molecular switches. Collectively these challenges are
linked to a lack of understanding around the specific molecular determinants that govern
mGlu5 allosteric modulator affinity, selectivity, and cooperativity (i.e., the magnitude and
direction of their effect). Towards addressing this knowledge gap, 3-D molecular models
of mGlu5’s 7-TM-spanning domain have been generated based on crystal structures from
related 7TM-spanning domain receptors. In turn these models are capable of predicting
critical residues that control the pharmacological profile of these modulators, yet lack
appropriate atomic level resolution for definitive conclusions to be drawn. Thus, there
remains a critical need to further refine and experimentally validate these molecular
models in order to aid rational drug design efforts.
The overall objective of the second portion of this dissertation work was to
develop mGlu5 NAM irreversible ligands as chemical probes to map their corresponding
binding sites and poses within mGlu5. The hypothesis for this portion of the work was
that chemically distinct mGlu5 NAMs could be derivatized with a functional group
capable of forming a covalent bond to mGlu5 and, if necessary, a tag functional group.
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These irreversible mGlu5 NAM chemical probes would then be expected to allow the
Gregory group to couple mGlu5 affinity or photoaffinity labeling experiments with
computational modeling studies performed by the Meiler group in order to directly map
the ligand-binding poses and sites of NAMs within mGlu5. The rationale behind this
research is that it will become possible to accurately predict the pharmacological profile
of existing and novel mGlu5 allosteric modulators, as well as their metabolites. In
particular, a deeper understanding of the specific molecular interactions that underlie
mGlu5 allosteric modulation is expected to facilitate vertical advancement of the field
from ligand- to rational structure-based drug design, as well as improve virtual / in silico
screening approaches to identify novel mGlu5 allosteric modulator chemotypes.
The specific aim of the second portion of this dissertation was to test the
hypothesis that mGlu5 NAMs could be structurally modified without significant loss in
pharmacological activity to contain a functional group capable of forming a covalent
bond to mGlu5 and, if necessary, a tag functional group. In particular, the creation of
irreversible chemical probes based on mGlu5 NAMs is expected to aid in mapping the
binding sites and poses of these compounds within mGlu5 via affinity or photoaffinity
labeling performed by the Gregory group. Subsequently, several probes were rationally
designed, chemically synthesized, and pharmacologically evaluated by the Gregory group
in order to identify appropriate candidates for mGlu5 irreversible labeling studies.
In particular, it should be noted that SAR for mGlu5 allosteric modulators are
notoriously difficult wherein minimal changes to the structure can result in complete loss
of activity. Furthermore, numerous mGlu5 modulator chemotypes display a “molecular
switch” phenomenon whereby a PAM arises from a NAM scaffold (or vice versa) or
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mGlu selectivity may be altered. As a result, molecular switches raise concern over the
pharmacology of putative metabolites and represent a true nightmare for medicinal
chemists trying to develop SAR to drive a program towards a clinical candidate with a
single mode of pharmacology. Collectively these challenges may be attributed to the
affinity and / or cooperativity of mGlu5 allosteric modulators dictated via specific
modulator-mGlu5 interactions within distinct mGlu5 binding sites.

Despite recent

identification of point mutations that engender a molecular switch in mGlu5 PAM
pharmacology, understanding of mechanistic and / or conformational mGlu5 structurefunction relationships remains in its infancy. mGlu5 molecular models provide powerful
tools for hypothesis generation and prediction of ligand-binding modes; however,
experimental strategies that further refine and validate such models are sorely needed
given the current absence of a class C GPCR crystal structure. Elucidation of the
molecular determinants for mGlu5 allosteric modulator affinity versus cooperativity
represents a key knowledge gap that must be resolved if we are to understand the inherent
complexities of these compounds that hinder their rational development into therapeutics.
In this regard, the mGlu5 NAM compounds described in Section 5.3 represent the first
potentially irreversible chemical probes directed at this therapeutically significant protein
to be used in critical structure-function studies.

In particular, the mGlu5 research

approach proposed by the Lapinsky and Gregory groups is expected to contribute the
finest level of structural information available for mGlu5 by coupling affinity or
photoaffinity labeling with molecular modeling studies, thus shedding light on the direct
interactions mGlu5 allosteric modulators form with mGlu5. This contribution is expected
to vertically advance the field towards accurate prediction of mGlu5 allosteric modulator
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pharmacology, and, ideally, preempt undesirable molecular switches associated with
these compounds and their metabolites.
In conclusion, since the basis of medicinal chemistry is the interactions of ligands
with a target structure, a key component in pharmacophore research and drug
development is precise knowledge of ligand-binding sites. In particular, the research
being performed by the Lapinsky group in collaboration with numerous research groups
is expected to refine established DAT and mGlu5 molecular models to improve current
virtual screening / medicinal chemistry drug discovery efforts. As a consequence, the
synthesis and utilization of the irreversible chemical probes described in this dissertation
is ultimately expected to transition the design and development of DAT inhibitors and
mGlu5 allosteric modulators from a ligand- to structure-based perspective, with the
ultimate aim to develop effective medications to treat drug abuse and prevent relapse.
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5.5.

Summary of Final Compounds Synthesized for This Dissertation Work
Table 5.3. Final compounds synthesized for this dissertation work.

Compound Name

Novel/

Scale

Known
(±)-threo-MP hydrochloride ((±)-1.10)

Known

Large

(±)-threo-4-Iodo-MP hydrochloride ((±)-3.31)

Known

Large

(±)-threo-o-Azido-N-benzyl-4-iodo-MP ((±)-4.24)

Novel

Small

(±)-threo-m-Azido-N-benzyl-4-iodo-MP ((±)-4.25)

Novel

Small

(±)-threo-p-Azido-N-benzyl-4-iodo-MP ((±)-4.26)

Novel

Small

±)-threo-o-Azido-N-benzyl-3-iodo-MP ((±)-4.27)

Novel

Small

(±)-threo-m-Azido-N-benzyl-3-iodo-MP ((±)-4.28)

Novel

Small

(±)-threo-p-Azido-N-benzyl-3-iodo-MP ((±)-4.29)

Novel

Small

(±)-threo-p-Azido-N-benzyl-4-iodo-ritalinol ((±)-4.33)

Novel

Small

(±)-threo-3-Iodo-4-azido-N-benzyl-MP ((±)-4.35)

Novel

Small

(R,R)-3-Iodo-4-azido-N-benzyl-MP ((-)-4.35)

Novel

Small

(±)-threo-3-Iodo-4-azido-N-benzyl-ritalinol ((±)-4.36)

Novel

Small

(R,R)-3-Iodo-4-azido-N-benzyl-ritalinol ((-)-4.36)

Novel

Small

(R,R)-3-Iodo-4-azido-N-benzyl-ritalinol oxalate (5.39)

Novel

Small

(±)-threo-3-Iodo-4-azido-N-benzyl-

Novel

Small

Novel

Small

GBR-12909 (1.12)

Known

Large

(4-(3-(4-(2-(Bis(4-fluorophenyl)methoxy)ethyl)piperazin-1-

Novel

Small

Novel

Small

2-methyl-4-(phenylethynyl)thiazole (4.44)

Known

Small

3-((2-methylthiazol-4-yl)ethynyl)phenol (4.45)

Known

Large

3,4-dichloro-MP ((±)-4.37)
(±)-threo-3-Iodo-4-azido-N-benzyl3,4-dichloro-ritalinol ((±)-4.38)

yl)propyl)phenyl)(4-ethynyl phenyl) methanone (4.40)
1-(3-(3-Azido-5-(azidomethyl)phenyl)propyl)-4-(2-(bis(4fluorophenyl)methoxy) ethyl) piperazine (4.43)

149

Compound Name

Novel/

Scale

Known
4-((3-(Benzyloxy)phenyl)ethynyl)-2-methylthiazole (4.46)

Novel

Small

(4-(2-(3-((2-Methylthiazol-4-

Novel

Small

Novel

Small

4-((3-Azido-5-fluorophenyl)ethynyl)-2-iodothiazole (4.52)

Novel

Small

2-((3-Azido-5-(prop-2-yn-1-yloxy)phenyl)ethynyl)-6-

Novel

Small

Novel

Small

Novel

Small

yl)ethynyl)phenoxy)ethoxy)phenyl)(4-(prop-2-yn-1yloxy)phenyl)methanone (4.49)
4-((3-((3-Azido-5-(azidomethyl)benzyl)oxy)phenyl)ethynyl)-2methylthiazole (4.50)

methylpyridine (4.54)
S-(2-(3-((2-Methylthiazol-4-yl)ethynyl)phenoxy)ethyl)
methanesulfonothioate (4.55)
1-(3-((2-Methylthiazol-4-yl)ethynyl)phenyl)-1H-pyrrole-2,5dione (4.56)
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CHAPTER SIX
Experimental
Reaction conditions and yields were not optimized. All reactions were performed using
ﬂame-dried glassware under an inert atmosphere of argon unless otherwise noted. All
solvents and chemicals were purchased from Aldrich Chemical Co. or Fisher Scientiﬁc
and used without further puriﬁcation unless otherwise noted.

Flash column

chromatography was performed according to the method of Still et al., 1978 using Fisher
S826-25 silica gel sorbent (70–230 mesh) and eluting solvent mixtures as speciﬁed.
Thin-layer chromatography (TLC) was performed using TLC Silica Gel 60 F254 plates
obtained from EMD Chemicals, Inc. and compounds were visualized under UV light
and/or I2 stain. Proportions of solvents used for TLC are by volume. 1H and 13C NMR
spectra were recorded on either a Bruker 400 or 500 MHz spectrometer. Chemical shifts
for 1H and

13

C NMR spectra are reported as parts per million (δ ppm) relative to

tetramethylsilane (0.00 ppm) as an internal standard. Coupling constants are measured in
hertz (Hz). HRMS samples were analyzed at Old Dominion University (Norfolk, VA) by
positive ion electrospray on a Bruker 12 Tesla APEX-Qe FTICR-MS with an Apollo II
ion source.

Combustion analyses of selected solid compounds were performed by

Atlantic Microlab, Inc. (Norcross, GA) and are in agreement within 0.4% of calculated
values. Melting point determinations were conducted using a Thomas-Hoover melting
point apparatus and are uncorrected. Infrared spectra were recorded using a Perkin–
Elmer Spectrum RZ I FT-IR spectrometer. Optical rotation was recorded using AutoPol
IV, Automatic Polarimeter. On the basis of NMR and combustion data, all compounds
were ≥ 95% pure.
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1-(4-Iodophenylglyoxylyl)piperidine (5.7)
A solution of ethyl 2-(4-iodophenyl)-2-oxoacetate (5.6, Kiesewetter, 1993) (230 mg, 0.75
mmol) in EtOH (3 mL) was added to a stirred mixture of piperidine (3.8) (0.22 mL, 2.25
mmol) in EtOH (3 mL). The reaction mixture was stirred at 70 ˚C for 3 hrs, cooled to
room temperature, diluted with H2O then 1M aq. HCl, and extracted with EtOAc. The
organic layer was dried (MgSO4), ﬁltered, concentrated, and chromatographed
(EtOAc:hexanes, 1:9) to provide 220 mg of keto amide 5.7 as a colorless oil (63%). Rf =
0.23 (EtOAc:hexanes, 1:9). 1H NMR (CDCl3, 400 MHz): δ 7.82 (d, 2H, J = 8.2 Hz), 7.59
(d, 2H, J = 8.2 Hz), 3.63 (t, 2H, J = 5.6 Hz), 3.21 (t, 2H, J = 5.5 Hz), 1.63-1.59 (m, 4H),
1.50-1.45 (m, 2H).

13

C NMR (CDCl3, 100 MHz): δ 191.0, 164.8, 138.3, 132.5, 130.7,

103.2, 47.0, 42.2, 26.2, 25.4, 24.3. HRMS calcd for C13H14INO2Na+ 365.9961, found
365.9962.
1-(4-Iodophenylglyoxylyl)piperidine (5.7) (Alternative Method)
A solution of 4-nitrophenylglyoxylate (5.9) (2.23 g, 10 mmol) in EtOH (12 mL) was
treated with piperidine (3.8) (3 mL, 30 mmol).

The mixture was stirred at 70 ˚C

overnight then cooled to room temperature, diluted with 1M aq. HCl, and extracted with
EtOAc. The combined organic extracts were washed with H2O and brine, then dried
(MgSO4), filtered, and concentrated to provide 2.49 g of 1-(4-nitrophenyl)-2-(piperidin-1yl)ethane-1,2-dione (5.10) as a yellow solid (95%). 1H NMR data proved identical to that
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previously reported (Song et al., 2007). 1-(4-nitrophenyl)-2-(piperidin-1-yl)ethane-1,2dione (5.10) (2.49 g, 9.5 mmol) was added to MeOH (25 mL) at 0 ˚C followed by
concentrated HCl (7 mL) and SnCl2 (5.87 g, 30.97 mmol). The mixture was allowed to
stir at room temperature overnight then quenched with H2O (50 mL). The pH was then
adjusted to 11 with 1 M aq. NaOH and then the mixture was extracted with EtOAc. The
organic layer was washed with brine, dried (MgSO4), filtered, concentrated, and
chromatographed (CHCl3:MeOH, 9.5:0.5) to give 1.54 g of 1-(4-aminophenyl)-2(piperidin-1-yl)ethane-1,2-dione (5.11) as a colorless oil (70%).

1

H NMR data proved

identical to that previously reported (Song et al., 2007). 1-(4-aminophenyl)-2-(piperidin1-yl)ethane-1,2-dione (5.11) (1.54 g, 6.62 mmol) was added to a solution of p-TsOH
(3.42 g, 19.89 mmol) in acetonitrile at 0 ˚C. NaNO2 (1.37 g, 19.89 mmol) was carefully
added to this solution and the mixture was stirred for 15 min. Finally, KI (3.3 g, 19.89
mmol) was added and the reaction mixture was allowed to stir at room temperature for 12
hrs. The reaction mixture was then diluted with water, extracted with EtOAc, washed
with brine, dried (MgSO4), filtered, concentrated, and chromatographed (EtOAc:hexanes,
1:9) to give 1.77 g of iodide 5.7 as a colorless oil (78%). Rf = 0.23 (EtOAc:hexanes, 1:9).
1

H NMR (CDCl3, 400 MHz): δ 7.82 (d, 2H, J = 8.2 Hz), 7.59 (d, 2H, J = 8.2 Hz), 3.63 (t,

2H, J = 5.6 Hz), 3.21 (t, 2H, J = 5.5 Hz), 1.63-1.59 (m, 4H), 1.50-1.45 (m, 2H).

13

C

NMR (CDCl3, 100 MHz): δ 191.0, 164.8, 138.3, 132.5, 130.7, 103.2, 47.0, 42.2, 26.2,
25.4, 24.3. HRMS calcd for C13H14INO2Na+ 365.9961, found 365.9962.
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1-(4-Iodophenylglyoxylyl)piperidine p-toluenesulfonylhydrazone (5.8)
A solution of ketone 5.7 (930 mg, 2.71 mmol) in EtOH (10 mL) was added to a stirred
mixture of p-toluenesulfonyl hydrazide (550 mg, 2.93 mmol) in ethanol (10 mL)
containing H2SO4 (4 mg, 2 µL, 0.04 mmol).

The reaction was reﬂuxed at 85 ˚C

overnight then cooled to room temperature. The white solid that formed was ﬁltered,
washed with cold MeOH and cold hexanes, then dried under reduced pressure to give 1.1
g of tosylhydrazone (5.8) as a white solid (85%). Rf = 0.45 (EtOAc:hexanes, 4:6).

1

H

NMR (CDCl3, 400 MHz): δ 8.40 (s, 1H), 7.83 (d, 2H, J = 8.3 Hz), 7.71 (d, 2H, J = 8.7
Hz), 7.31 (d, 2H, J = 8.6 Hz), 7.26 (d, 2H, J = 8.1 Hz), 3.70-3.66 (m, 2H), 3.17 (t, 2H, J =
5.6 Hz), 2.38 (s, 3H), 1.66-1.64 (m, 4H), 1.50-1.40 (m, 2H).

13

C NMR (CDCl3, 100

MHz): δ 161.5, 149.5, 144.2, 137.9, 135.0, 131.7, 129.6, 127.9, 127.7, 97.2, 47.3, 42.3,
26.3, 25.5, 24.1, 21.6. HRMS calcd for C20H22IN3O3SNa+ 534.0319, found 534.0318.
Anal. Calcd for: C20H22IN3O3S: C, 46.97; H 4.34; N, 8.22; I, 24.82; S, 6.27. Found: C,
46.92; H 4.31; N, 8.23; I, 24.63; S, 6.42. MPt: 137-138 ˚C.
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(±)-7-(4-Iodophenyl)-1-azabicyclo[4.2.0]octan-8-one ((±)-5.4)
Hydrazone 5.8 (1 g, 2 mmol) was added to a stirred mixture of 50% aq. NaOH (170 µL,
2.08 mmol) and Aliquat 336 (8 mg, 9 µL, 0.02 mmol) in toluene (20 mL). The reaction
was reﬂuxed at 130 ˚C overnight then cooled to room temperature, diluted with H2O, and
extracted with toluene. The organic layer was dried (MgSO4), ﬁltered, concentrated, and
chromatographed (EtOAc:hexanes, 2:8) to afford bicyclic lactam (±)-5.4 as a yellow
solid. Recrystallization from Et2O provided 390 mg of bicyclic lactam (±)-5.4 (60%). Rf
= 0.20 (EtOAc:hexanes, 2:8). 1H NMR (CDCl3, 500 MHz): δ 7.64 (d, 2H, J = 8.3 Hz),
7.03 (d, 2H, J = 8.4 Hz), 3.92 (d, 1H, J = 4.3 Hz), 3.91-3.88 (m, 1H), 3.34-3.30 (m, 1H),
2.82-2.76 (m, 1H), 2.18-2.14 (m, 1H), 1.94-1.91 (m, 1H), 1.71-1.67 (m, 1H), 1.45-1.38
(m, 3H).

13

C NMR (CDCl3, 100 MHz): δ 165.5, 137.7, 135.3, 129.3, 92.6, 62.8, 56.5,

39.0, 30.4, 24.4, 22.1. HRMS calcd for C13H14INONa+ 350.0012, found 350.0009. Anal.
Calcd for: C13H14INO: C, 47.73; H 4.31; N, 4.28; I, 38.79. Found: C, 47.84; H, 4.29; N,
4.23; I, 38.57. MPt: 127-128 ˚C.
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(±)-threo-4-Iodo-MP hydrochloride ((±)-3.31)
(±)-threo-β-Lactam (±)-5.4 (90 mg, 0.28 mmol) was reﬂuxed in 1.25 M HCl in MeOH
(10 mL) at 85 ˚C for 7 hrs then concentrated under reduced pressure to afford 107 mg of
methyl ester (±)-3.31 as a yellow solid (99%).

1

H NMR proved identical to that

previously reported (Pan et al., 1996). This threo-iodo-MP was determined to be ≥95%
diastereomerically pure by

1

H NMR upon comparison to the known data for

enantiomerically pure threo- and erythro-MP and its para-substituted derivatives (Thai et
al., 1998). 1H NMR (CD3OD, 400 MHz): δ 7.76 (d, 2H, J = 7.9 Hz), 7.11 (d, 2H, J = 8.0
Hz), 3.95 (d, 1H, J = 9.6 Hz), 3.83 (t, 1H, J = 9.9 Hz), 3.73 (s, 3H), 3.45 (d, 1H, J = 12.4
Hz), 3.10 (t, 1H, J = 11.8 Hz), 1.89-1.71 (m, 3H), 1.53-1.40 (m, 3H).

13

C NMR (CD3OD,

100 MHz): δ 172.8, 139.6, 134.9, 131.7, 95.0, 58.9, 54.7, 53.6, 46.7, 27.6, 23.3, 22.8.
HRMS calcd for C14H18INO2Na+ 382.0274, found 382.0275. MPt: 188-189 ˚C.
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(±)-threo-o-Azido-N-benzyl-4-iodo-MP ((±)-4.24)
(±)-threo-4-Iodo-MP hydrochloride ((±)-3.31) (80 mg, 0.2 mmol) was added to a
suspension of K2CO3 (110 mg, 0.81 mmol) in DMF (5 mL). The mixture was stirred at
room temperature for 10 minutes then o-azido-N-benzyl bromide (5.1; Mornet et al.,
1984) (42 mg, 0.2 mmol) was added.

The reaction was allowed to stir at room

temperature in the dark for 30 hrs. Et2O (20 mL) was then added and the mixture was
decanted followed by rinsing with Et2O (2 × 20 mL). The combined organic layers were
washed with H2O, dried (MgSO4), filtered, concentrated, and chromatographed (100%
hexanes) to give 48 mg of tertiary amine (±)-4.24 as a colorless oil (50%). Rf = 0.28
(100% hexanes).

1

H NMR (CDCl3, 400 MHz): δ 7.63 (d, 2H, J = 8.4 Hz), 7.38 (d, 1H,

J = 7.6 Hz), 7.29–7.25 (m, 1H), 7.14–7.09 (m, 4H), 4.09 (d, 1H, J = 11.5 Hz), 3.92 (d,
1H, J = 14.4 Hz), 3.68 (d, 1H, J = 14.4 Hz), 3.59 (s, 3H), 3.43–3.38 (m, 1H), 2.99–2.93
(m, 1H), 2.58–2.52 (m, 1H), 1.62–1.46 (m, 4H), 1.38–1.33 (m, 1H), 1.06–1.03 (m, 1H).
13

C NMR (CDCl3, 100 MHz): δ 173.4, 138.0, 137.7, 136.6, 131.5, 130.7, 130.3, 127.9,

124.6, 117.8, 93.0, 62.4, 52.6, 51.9, 50.7, 45.5, 21.3, 20.7, 19.9. HRMS calcd for
C21H23IN4O2H+ 491.0938, found 491.0930. IR: azide, 2116 cm−1.

(±)-threo-m-Azido-N-benzyl-4-iodo-MP ((±)-4.25)
(±)-threo-4-Iodo-MP hydrochloride ((±)-3.31) (150 mg, 0.38 mmol) was added to a
suspension of K2CO3 (130 mg, 0.9 mmol) in DMF (5 mL). The mixture was stirred at
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room temperature for 10 minutes then m-nitro-N-benzyl bromide (5.22) (82 mg,
0.38 mmol) was added. The reaction was allowed to stir at room temperature in the dark
for 30 hrs. Et2O (20 mL) was then added and the mixture was decanted followed by
rinsing with Et2O (2 × 20 mL). The combined organic layers were washed with H2O,
dried (MgSO4), filtered, concentrated, and chromatographed (CHCl3:hexanes, 1:1) to
give 130 mg of (±)-threo-m-nitro-N-benzyl-4-iodo-MP as a yellow oil (69%). Rf = 0.21
(CHCl3:hexanes, 1:1).

1

H NMR (CDCl3, 400 MHz): δ 8.18 (s, 1H), 8.10 (d, 1H,

J = 8.1 Hz), 7.65–7.60 (m, 3H), 7.47 (t, 1H, J = 7.9 Hz), 7.16 (d, 2H, J = 8.4 Hz), 4.13 (d,
1H, J = 11.6 Hz), 4.05 (d, 1H, J = 14.3 Hz), 3.86 (d, 1H, J = 14.3 Hz), 3.72 (s, 3H), 3.48–
3.44 (m, 1H), 3.03–2.96 (m, 1H), 2.54–2.51(m, 1H), 1.60–1.50 (m, 4H), 1.37–1.34 (m,
1H), 1.10–1.06 (m, 1H).

13

C NMR (CDCl3, 100 MHz): δ 173.6, 148.4, 142.7, 137.8,

136.4, 134.5, 130.7, 128.9, 123.3, 122.0, 93.2, 62.7, 56.0, 52.4, 52.1, 44.9, 21.2, 20.5,
19.5. HRMS calcd for C21H23IN2O4Na+ 517.0594, found 517.0594. (±)-threo-m-NitroN-benzyl-4-iodo-MP (100 mg, 0.2 mmol) was added to MeOH (5 mL) at 0 ˚C followed
by concentrated HCl (1 mL) and SnCl2 (150 mg, 0.78 mmol). The mixture was allowed
to stir at room temperature overnight then quenched with H2O (5 mL). The pH was then
adjusted to 11 with 1 M aq. NaOH and the mixture was extracted with EtOAc. The
organic layer was washed with brine, dried (MgSO4), filtered, concentrated, and
chromatographed (CHCl3:MeOH, 9:1) to give 90 mg of (±)-threo-m-amino-N-benzyl-4iodo-MP as a colorless oil (81%). Rf = 0.29 (CHCl3:MeOH, 9:1).

1

H NMR (CDCl3,

400 MHz): δ 7.63 (d, 2H, J = 8.4 Hz), 7.15 (d, 2H, J = 8.4 Hz), 7.09 (t, 1H, J = 7.7 Hz),
6.68–6.65 (m, 2H), 6.56 (d, 1H, J = 7.8 Hz), 4.10 (d, 1H, J = 11.4 Hz), 3.82 (d, 1H,
J = 13.5 Hz), 3.69 (d, 1H, J = 13.4 Hz), 3.66 (s, 3H), 3.48–3.40 (m, 1H), 2.97–2.91 (m,
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1H), 2.57–2.52 (m, 1H), 1.54–1.42 (m, 4H), 1.32–1.29 (m, 1H), 1.05–1.02 (m, 1H).

13

C

NMR (CDCl3, 100 MHz): δ 173.6, 146.3, 141.4, 137.7, 136.8, 130.8, 128.9, 118.9, 115.4,
113.7, 93.0, 62.5, 56.4, 52.7, 51.9, 45.1, 21.3, 20.9, 19.6.

HRMS calcd for

C21H25IN2O2Na+ 487.0852, found 487.0859. A solution of (±)-threo-m-amino-N-benzyl4-iodo-MP (62 mg, 0.13 mmol) in concentrated HCl (0.5 mL) and H2O (5 mL) at 0 ˚C
was treated with NaNO2 (10 mg, 0.15 mmol). The mixture was stirred in the dark for
10 minutes at 0 ˚C then carefully treated with NaN3 (18 mg, 0.27 mmol). The reaction
was allowed to stir in the dark for 2 hrs at 0 ˚C then diluted with H2O and CHCl3. The
organic layer was separated, washed with brine, dried (MgSO4), filtered, concentrated,
and chromatographed (100% CHCl3) to give 65 mg of azide (±)-4.25 as a yellow oil
(85%).

Rf = 0.30 (100% CHCl3).

1

H NMR (CDCl3, 400 MHz): δ 7.63 (d, 2H,

J = 8.4 Hz), 7.29–7.25 (m, 1H), 7.14 (d, 2H, J = 8.4 Hz), 7.05–7.01 (m, 2H), 6.89 (d, 1H,
J = 7.9 Hz), 4.11 (d, 1H, J = 11.5 Hz), 3.91 (d, 1H, J = 13.8 Hz), 3.76 (d, 1H,
J = 13.8 Hz), 3.68 (s, 3H), 3.45–3.41 (m, 1H), 2.99–2.93 (m, 1H), 2.55–2.50 (m, 1H),
1.64–1.48 (m, 4H), 1.33–1.25 (m, 1H), 1.06–1.03 (m, 1H).

13

C NMR (CDCl3,

100 MHz): δ 173.3, 142.4, 139.9, 137.7, 136.6, 130.7, 129.3, 125.1, 119.0, 117.6, 93.1,
62.5, 56.3, 52.5, 52.0, 44.9, 21.1, 20.6, 19.5. HRMS calcd for C21H23IN4O2H+ 491.0938,
found 491.0940. IR: azide, 2109 cm−1.

(±)-threo-p-Azido-N-benzyl-4-iodo-MP ((±)-4.26)
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(±)-threo-4-Iodo-MP hydrochloride ((±)-3.31) (110 mg, 0.27 mmol) was added to a
suspension of K2CO3 (150 mg, 1.08 mmol) in DMF (6 mL). The resulting suspension
was stirred at room temperature for 10 minutes then p-azido-N-benzyl bromide (5.3;
Mornet et al., 1984) (60 mg, 0.29 mmol) was added and the mixture was allowed to stir
at room temperature in the dark for 30 hrs. Et2O (20 mL) was then added and the mixture
was decanted followed by rinsing with Et2O (2 × 20 mL). The combined organic layers
were washed with H2O, dried (MgSO4), filtered, concentrated, and chromatographed
(EtOAc:hexanes, 5:95) to give 90 mg of tertiary amine (±)-4.26 as a yellow solid (67%).
1

Rf = 0.26 (EtOAc:hexanes, 5:95).

H NMR (CDCl3, 400 MHz): δ 7.64 (d, 2H,

J = 8.3 Hz), 7.27 (d, 2H, J = 8.3 Hz), 7.14 (d, 2H, J = 8.4 Hz), 6.97 (d, 2H, J = 8.4 Hz),
4.11 (d, 1H, J = 11.5 Hz), 3.89 (d, 1H, J = 13.6 Hz), 3.74 (d, 1H, J = 13.6 Hz), 3.65 (s,
3H), 3.45–3.41 (m, 1H), 2.97–2.91 (m, 1H), 2.55–2.50 (m, 1H), 1.58–1.47 (m, 4H), 1.33–
1.25 (m, 1H), 1.06–1.02 (m, 1H).

13

C NMR (CDCl3, 100 MHz): δ 173.5, 138.4, 137.7,

137.1, 136.6, 130.7, 129.9, 118.7, 93.1, 62.3, 55.9, 52.6, 51.9, 44.8, 21.1, 20.7, 19.5.
HRMS calcd for C21H23IN4O2H+ 491.0938, found 491.0930.

Anal. Calcd for:

C21H23IN4O2: C, 51.44; H 4.73; N, 11.43; I, 25.88. Found: C, 51.72; H 4.67; N, 11.48; I,
25.62. MPt: 108–110 ˚C. IR: azide, 2109 cm−1.
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(±)-threo-o-Azido-N-benzyl-3-iodo-MP ((±)-4.27)
(±)-threo-3-Iodo-MP hydrochloride ((±)-4.18, Lapinsky et al., 2011) (100 mg,
0.27 mmol) was added to a suspension of K2CO3 (150 mg, 1.08 mmol) in DMF (5 mL).
The mixture was stirred at room temperature for 10 min then o-azido-N-benzyl bromide
(5.1; Mornet et al., 1984) (58 mg, 0.27 mmol) was added. The reaction was allowed to
stir at room temperature in the dark for 30 hrs. Et2O (20 mL) was then added and the
mixture was decanted followed by rinsing with Et2O (2 × 20 mL). The combined organic
layers were washed

with

H2O, dried (MgSO4), filtered, concentrated, and

chromatographed (CH2Cl2:hexanes, 1:1) to give 67 mg of tertiary amine (±)-4.27 as a
yellow oil (51%). Rf = 0.23 (CH2Cl2:hexanes, 7:3). 1H NMR (CDCl3, 400 MHz): δ 7.74
(t, 1H, J = 1.7 Hz), 7.59 (d, 1H, J = 7.9 Hz), 7.39 (t, 2H, J = 8.3 Hz), 7.32–7.27 (m, 1H),
7.14–7.09 (m, 2H), 7.03 (t, 1H, J = 7.8 Hz), 4.07 (d, 1H, J = 11.5 Hz), 3.93 (d, 1H,
J = 14.5 Hz), 3.67 (d, 1H, J = 14.5 Hz), 3.60 (s, 3H), 3.44–3.40 (m, 1H), 2.99–2.92 (m,
1H), 2.57–2.51 (m, 1H), 1.58–1.52 (m, 4H), 1.39–1.33 (m, 1H), 1.07–1.03 (m, 1H).

13

C

NMR (CDCl3, 100 MHz): δ 173.3, 139.3, 137.9, 137.6, 136.5, 131.5, 130.3, 128.0, 127.9,
124.6, 117.8, 94.5, 62.5, 52.6, 51.9, 50.7, 45.4, 21.3, 20.7, 19.8. HRMS calcd for
C21H23IN4O2H+ 491.0938, found 491.0932. IR: azide, 2115 cm−1.

161

(±)-threo-m-Azido-N-benzyl-3-iodo-MP ((±)-4.28)
(±)-threo-3-Iodo-MP hydrochloride ((±)-4.18, Lapinsky et al., 2011) (300 mg,
0.76 mmol) was added to a suspension of K2CO3 (250 mg, 1.8 mmol) in DMF (5 mL).
The mixture was stirred at room temperature for 10 minutes then m-nitro-N-benzyl
bromide (5.22) (160 mg, 0.76 mmol) was added. The reaction was allowed to stir at
room temperature in the dark for 30 hrs. Et2O (20 mL) was then added and the mixture
was decanted followed by rinsing with Et2O (2 × 20 mL). The combined organic layers
were washed with H2O, dried (MgSO4), filtered, concentrated, and chromatographed
(CHCl3:hexanes, 1:1) to give 260 mg of (±)-threo-m-nitro-N-benzyl-3-iodo-MP as a
yellow oil (70%). Rf = 0.31 (CHCl3:hexanes, 1:1). 1H NMR (CDCl3, 400 MHz): δ 8.18
(s, 1H), 8.10 (d, 1H, J = 8.1 Hz), 7.76 (s, 1H), 7.60 (d, 2H, J = 7.9 Hz), 7.47 (t, 1H,
J = 7.9 Hz), 7.37 (d, 1H, J = 7.8 Hz), 7.06 (t, 1H, J = 7.8 Hz), 4.10 (d, 1H, J = 11.6 Hz),
4.05 (d, 1H, J = 14.3 Hz), 3.86 (d, 1H, J = 14.3 Hz), 3.72 (s, 3H), 3.48–3.45 (m, 1H),
3.01–2.96 (m, 1H), 2.54–2.50 (m, 1H), 1.61–1.52 (m, 4H), 1.38–1.34 (m, 1H), 1.10–1.07
(m, 1H).

13

C NMR (CDCl3, 100 MHz): δ 173.4, 148.3, 142.6, 138.9, 137.4, 136.7, 134.4,

130.4, 128.9, 127.9, 123.2, 122.0, 94.6, 62.8, 56.0, 52.4, 52.1, 44.7, 21.2, 20.5, 19.4.
HRMS calcd for C21H23IN2O4H+ 495.0775, found 495.0780.

(±)-threo-m-Nitro-N-

benzyl-3-iodo-MP (260 mg, 0.53 mmol) was added to MeOH (5 mL) at 0 ˚C then treated
with concentrated HCl (2 mL) and SnCl2 (390 mg, 2.05 mmol).

The mixture was

allowed to stir at room temperature overnight then quenched with H2O (5 mL). The pH
was adjusted to 11 with 1 M aq. NaOH and then the mixture was extracted with EtOAc.
The organic layers were washed with brine, dried (MgSO4), filtered, concentrated, and
chromatographed (CHCl3:MeOH, 95:5) to give 200 mg of (±)-threo-m-amino-N-benzyl-
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3-iodo-MP as a colorless oil (81%). Rf = 0.27 (CHCl3:MeOH, 95:5). 1H NMR (CDCl3,
400 MHz): δ 7.75 (s, 1H), 7.59 (d, 1H, J = 8.5 Hz), 7.37 (d, 1H, J = 7.8 Hz), 7.09–7.02
(m, 2H), 6.68–6.65 (m, 2H), 6.56 (d, 1H, J = 7.9 Hz), 4.08 (d, 1H, J = 11.4 Hz), 3.82 (d,
1H, J = 13.6 Hz), 3.69 (d, 1H, J = 13.7 Hz), 3.66 (s, 3H), 3.48–3.42 (m, 1H), 2.97–2.90
(m, 1H), 2.57–2.52 (m, 1H), 1.56–1.46 (m, 4H), 1.33–1.28 (m, 1H), 1.06–1.02 (m, 1H).
13

C NMR (CDCl3, 100 MHz): δ 173.4, 146.3, 141.3, 139.2, 137.5, 136.4, 130.2, 128.8,

127.9, 118.7, 115.2, 113.5, 94.5, 62.5, 56.3, 52.6, 51.0, 44.8, 21.2, 20.8, 19.5. HRMS
calcd for C21H25IN2O2H+ 465.1033, found 465.1026. A solution of (±)-threo-m-aminoN-benzyl-3-iodo-MP (180 mg, 0.39 mmol) in 2 N HCl (6 mL) at 0 ˚C was treated with
NaNO2 (30 mg, 0.43 mmol). The mixture was stirred in the dark for 10 minutes at 0 ˚C,
carefully treated with NaN3 (50 mg, 0.78 mmol), stirred in the dark at 0 ˚C for 2 h, then
diluted with H2O and CHCl3. The organic layer was separated, washed with brine, dried
(MgSO4), filtered, concentrated, and chromatographed (100% CHCl3) to give 160 mg of
azide (±)-4.28 as a yellow oil (95%). Rf = 0.35 (100% CHCl3).

1

H NMR (CDCl3,

400 MHz): δ 7.75 (s, 1H), 7.59 (d, 1H, J = 8.4 Hz), 7.37 (d, 1H, J = 7.9 Hz), 7.29–7.25
(m, 1H), 7.06–7.01 (m, 3H), 6.89 (d, 1H, J = 7.9 Hz), 4.08 (d, 1H, J = 11.5 Hz), 3.93 (d,
1H, J = 13.8 Hz), 3.76 (d, 1H, J = 13.8 Hz), 3.68 (s, 3H), 3.46–3.41 (m, 1H), 2.98–2.92
(m, 1H), 2.55–2.50 (m, 1H), 1.64–1.48 (m, 4H), 1.35–1.31 (m, 1H), 1.07–1.03 (m, 1H).
13

C NMR (CDCl3, 100 MHz): δ 173.3, 142.4, 139.9, 139.1, 137.5, 136.6, 130.3, 129.3,

127.9, 125.0, 118.9, 117.5, 94.5, 62.5, 56.2, 52.5, 52.0, 44.7, 21.1, 20.6, 19.4. HRMS
calcd for C21H23IN4O2Na+ 513.0757, found 513.0763. IR: azide, 2113 cm−1.
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(±)-threo-p-Azido-N-benzyl-3-iodo-MP ((±)-4.29)
(±)-threo-3-Iodo-MP hydrochloride ((±)-4.18, Lapinsky et al., 2011) (140 mg,
0.35 mmol) was added to a suspension of K2CO3 (190 mg, 1.43 mmol) in DMF (7 mL).
The mixture was stirred at room temperature for 10 minutes then p-azido-N-benzyl
bromide (5.3; Mornet et al., 1984) (80 mg, 0.39 mmol) was added. The reaction was
allowed to stir at room temperature in the dark for 30 hrs. Et2O (20 mL) was then added
and the mixture was decanted followed by rinsing with Et2O (2 × 20 mL). The combined
organic layers were washed with H2O, dried (MgSO4), filtered, concentrated, and
chromatographed (EtOAc:hexanes, 5:95) to give 110 mg of tertiary amine (±)-4.29 as a
yellow gum (65%). Rf = 0.23 (EtOAc:hexanes, 5:95).

1

H NMR (CDCl3, 400 MHz): δ

7.74 (s, 1H), 7.60 (d, 1H, J = 7.9 Hz), 7.36 (d, 1H, J = 7.8 Hz), 7.26 (d, 2H, J = 8.6 Hz),
7.05 (t, 1H, J = 7.8 Hz), 6.97 (d, 2H, J = 8.4 Hz), 4.08 (d, 1H, J = 11.5 Hz), 3.89 (d, 1H,
J = 13.6 Hz), 3.74 (d, 1H, J = 13.6 Hz), 3.66 (s, 3H), 3.46–3.42 (m, 1H), 2.97–2.90 (m,
1H), 2.53–2.49 (m, 1H), 1.58–1.48 (m, 5H), 1.07–1.03 (m, 1H).

13

C NMR (CDCl3,

100 MHz): δ 173.4, 139.2, 138.4, 137.0, 136.6, 130.3, 129.9, 128.0, 118.7, 94.5, 62.5,
55.9, 52.5, 51.9, 44.6, 21.1, 20.6, 19.4. HRMS calcd for C21H23IN4O2H+ 491.0938, found
491.0945. IR: azide, 2111 cm−1.
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(±)-threo-p-Azido-N-benzyl-4-(tri-n-butylstannyl)-MP ((±)-5.23)
A mixture of (±)-threo-p-azido-N-benzyl-4-iodo-MP ((±)-4.26) (105 mg, 0.21 mmol),
Pd(PPh3)2Br2 (10 mg, 0.02 mmol), and bis(tri-n-butyltin) (0.15 mL, 0.39 mmol) in
toluene (10 mL) was heated at 105 ˚C for 6 hrs. The mixture was then cooled to room
temperature, diluted with saturated aq. K2CO3 solution, and then extracted with EtOAc.
The organic phase was washed with brine, dried (MgSO4), filtered, concentrated, and
chromatographed (EtOAc:hexanes, 1:9) to give 49 mg of organostannane (±)-5.23 as a
colorless oil (41%). Rf = 0.35 (EtOAc/hexanes, 1:9).

1

H NMR (CDCl3, 400 MHz): δ

7.39 (d, 2H, J = 7.9 Hz), 7.32 (d, 2H, J = 7.9 Hz), 7.28 (d, 2H, J = 8.4 Hz), 6.97 (d, 2H,
J = 8.4 Hz), 4.11 (d, 1H, J = 11.5 Hz), 3.90 (d, 1H, J = 13.6 Hz), 3.76 (d, 1H,
J = 13.6 Hz), 3.65 (s, 3H), 3.49–3.45 (m, 1H), 2.99–2.94 (m, 1H), 2.54–2.51 (m, 1H),
1.56–1.49 (m, 9H), 1.34–1.29 (m, 9H), 1.03 (t, 6H, J = 8.0 Hz), 0.88 (t, 9H, J = 7.3 Hz).
13

C NMR (CDCl3, 100 MHz): δ 174.1, 141.0, 138.3, 137.3, 136.7, 136.4, 129.9, 128.2,

118.7, 62.5, 55.8, 53.1, 51.8, 44.8, 29.0, 27.4, 21.1, 20.8, 19.5, 13.7, 9.5. HRMS calcd
for C33H50N4O2SnH+ 655.3029, found 655.3033. IR: azide, 2110 cm−1.
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(±)-threo-p-Azido-N-benzyl-4-iodo-ritalinol ((±)-4.33)
A mixture of (±)-threo-4-iodo-β-lactam (±)-5.4 (200 mg, 0.62 mmol) and 6N HCl (5 mL)
was stirred at room temperature for 12 hrs. The reaction mixture was then concentrated
under reduced pressure to afford 235 mg of (±)-threo-4-iodo-ritalinic acid ((±)-3.30) as a
white solid (99%).

1

H NMR data was comparable to that previously described (Pan et

al., 1996). (±)-threo-4-iodo-ritalinic acid ((±)-3.30) (180 mg, 0.52 mmol) was added to
BH3•THF (1.4 mL, 2.68 mmol) in THF (5 mL) at 0 ˚C, and then the mixture was allowed
to stir at room temperature overnight. The reaction mixture was treated with MeOH and
concentrated under reduced pressure. The crude mixture was then dissolved in Et2O and
washed with 1M aq. NaOH to afford 70 mg of (±)-threo-4-iodo-ritalinol ((±)-5.25) as oil
(43%), which was used further without any purification. Rf = 0.2 (CHCl3:MeOH, 1:1).
1

H NMR (CD3OD, 400MHz): δ 7.62 (d, 2H, J = 8.3 Hz), 6.99 (d, 2H, J = 8.3 Hz), 3.89-

3.85 (m, 1H), 3.80-3.76 (m, 1H), 3.03 (d, 1H, J = 12.3 Hz), 2.85 (td, 1H, J = 10.9, 2.2
Hz), 2.70-2.60 (m, 2H), 1.69-1.65 (m, 1H), 1.56-1.52 (m, 1H), 1.40 (s, 1H), 1.36-1.26 (m,
3H), 1.01-0.91 (m, 1H). A mixture of (±)-threo-4-iodo-ritalinol ((±)-5.25) (70 mg, 0.2
mmol), p-azido-N-benzyl bromide (5.3; Mornet et al., 1984) (40 mg, 0.2 mmol) and
K2CO3 (50 mg, 0.4 mmol) in DMF (3 mL) was stirred at room temperature under argon
for 3 hrs. The mixture was then diluted with H2O and extracted with Et2O (2 × 10 mL).
The combined organic layers were washed with brine, dried (MgSO4), filtered,
concentrated, and chromatographed (EtOAc:hexanes, 2:8) to give 40 mg of tertiary amine
(±)-4.33 as an oil (50%). Rf = 0.24 (EtOAc:hexanes, 2:8). 1H NMR (CDCl3, 400 MHz):
δ 7.59 (d, 2H, J = 8.3 Hz), 7.35 (d, 2H, J = 8.4 Hz), 7.04 (d, 2H, J = 8.4 Hz,), 6.79 (d, 2H,
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J = 8.3 Hz), 6.65 (br s, 1H), 3.94 (s, 2H), 3.72 (t, 1H, J = 10.1 Hz), 3.63 (dd, 1H, J = 10.8
Hz, 3.5 Hz), 3.40 (td, 1H, J = 10.0, 3.4 Hz), 3.22 (td, 1H, J = 11.6, 3.0 Hz), 3.10 (d, 1H, J
= 11.6 Hz), 2.72 (d, 1H, J = 14.4 Hz), 1.73-1.49 (m, 4H), 1.35 (d, 1H, J = 13.6 Hz), 0.93
(d, 1H, J = 13.2 Hz).

13

C NMR (CDCl3, 100 MHz): δ 140.4, 139.3, 137.8, 135.1, 130.5,

129.8, 119.3, 91.9, 69.7, 62.7, 56.6, 45.5, 44.6, 20.6, 19.9, 18.6. HRMS calcd for
C20H23IN4ONa+ 485.0808, found 485.0807.

(±)-threo-3-Iodo-4-azido-N-benzyl-MP ((±)-4.35)
A mixture of (±)-threo-MP ((±)-1.10, provided by retired Professor Howard M. Deutsch
(Georgia Tech)) (140 mg, 0.51 mmol), 3-iodo-4-azido benzyl chloride (5.32, Murray et
al., 2005) (220 mg, 0.76 mmol), and K2CO3 (170 mg, 1.21 mmol) in DMF (5 mL) was
stirred at room temperature for 36 hrs. The mixture was then diluted with H2O and
extracted with EtOAc (2 × 20 mL). The combined organic layers were washed with
brine, dried (MgSO4), filtered, concentrated, and chromatographed (EtOAc:hexanes,
5:95) to give 69 mg of tertiary amine (±)-4.35 as a yellow solid (28%). Rf = 0.20
(EtOAc:hexanes, 5:95).

1

H NMR (CDCl3, 400 MHz): δ 7.74 (d, 1H, J = 1.8 Hz), 7.40-

7.38 (m, 2H), 7.33-7.25 (m, 4H), 7.06 (d, 1H, J = 8.1 Hz,), 4.14 (d, 1H, J = 11.6 Hz),
3.87 (d, 1H, J = 13.9 Hz), 3.73-3.70 (m, 1H), 3.69 (s, 3H), 3.49-3.45 (m, 1H), 3.01-2.95
(m, 1H), 2.54-2.48 (m, 1H), 1.64-1.47 (m, 4H), 1.35-1.25 (m, 1H), 1.08-1.04 (m, 1H).
13

C NMR (CDCl3, 100 MHz): δ 174.0, 140.0, 139.9, 139.2, 136.8, 129.6, 128.7, 128.6,
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127.5, 117.9, 87.6, 62.7, 55.3, 53.0, 52.0, 44.8, 21.1, 20.6, 19.4. HRMS calcd for
C21H23IN4O2H+ 491.0938, found 491.0938. Anal calcd for C21H23IN4O2: C, 51.44; H,
4.73; N, 11.43; I, 25.88. Found: C, 51.48; H, 4.73; N, 11.17; I, 25.65. MPt: 147-148 ˚C.

(R,R)-3-Iodo-4-azido-N-benzyl-MP ((-)-4.35)
A mixture of enantiopure (R,R)-MP hydrochloride ((+)-1.10, Deutsch et al., 1996,
provided by retired Professor Howard M. Deutsch (Georgia Tech)) (90 mg, 0.33 mmol),
3-iodo-4-azido benzyl chloride (5.32, Murray et al., 2005) (150 mg, 0.5 mmol), and
K2CO3 (110 mg, 0.8 mmol) in DMF (3 mL) was stirred at room temperature for 48 hrs.
The mixture was then diluted with H2O and extracted with EtOAc (2 × 20 mL). The
combined organic layers were washed with brine, dried (MgSO4), filtered, concentrated,
and chromatographed (DCM:hexanes, 7:3) to give 30 mg of tertiary amine (-)-4.35 as an
oil (19%). Rf = 0.10 (DCM:hexanes, 7:3). 1H NMR (CDCl3, 400 MHz): δ 7.74 (d, 1H, J
= 1.8 Hz), 7.40-7.38 (m, 2H), 7.33-7.25 (m, 4H), 7.06 (d, 1H, J = 8.1 Hz), 4.14 (d, 1H, J
= 11.6 Hz,), 3.87 (d, 1H, J = 13.9 Hz), 3.73-3.72 (m, 1H), 3.70 (s, 3H), 3.49-3.44 (m,
1H), 3.01-2.94 (m, 1H), 2.54-2.49 (m, 1H), 1.59-1.46 (m, 4H), 1.35-1.32 (m, 1H), 1.081.04 (m, 1H).

13

C NMR (CDCl3, 100 MHz): δ 174.0, 140.0, 139.9, 139.2, 136.7, 129.6,

128.7, 128.6, 127.5, 117.9, 87.6, 62.7, 55.3, 53.0, 52.0, 44.8, 21.1, 20.6, 19.4. HRMS
calcd for C21H23IN4O2Na+ 513.0757, found 513.0765. IR: azide, 2115 cm-1. [α]D21.8 = 34.25˚, c = 0.94 (CHCl3).

168

(±)-threo-3-Iodo-4-azido-N-benzyl-ritalinol ((±)-4.36)
A mixture of (±)-threo-ritalinol ((±)-5.27, Kim et al., 2007) (120 mg, 0.58 mmol), 3iodo-4-azido benzyl chloride (5.32, Murray et al., 2005) (260 mg, 0.87 mmol), and
K2CO3 (160 mg, 1.17 mmol) in DMF (6 mL) was stirred at room temperature for 12 hrs.
The mixture was then diluted with H2O and extracted with Et2O (2 × 20 mL). The
combined organic layers were washed with brine, dried (MgSO4), filtered, concentrated,
and chromatographed (EtOAc:hexanes, 2:8) to give 50 mg of tertiary amine (±)-4.36 as a
yellow oil (19%). Rf = 0.24 (EtOAc:hexanes, 2:8). 1H NMR (CDCl3, 500 MHz): δ 7.74
(d, 1H, J = 2 Hz), 7.46 (d, 1H, J = 8.1 Hz), 7.29-7.26 (m, 2H), 7.22-1.19 (m, 1H), 7.15 (d,
1H, J = 8.2 Hz), 7.05 (d, 2H, J = 7.1 Hz), 6.36 (br s, 1H), 3.92 (s, 2H), 3.84 (t, 1H, J =
10.1 Hz), 3.71 (dd, 1H, J = 10.9 Hz, 3.6 Hz), 3.46 (td, 1H, J = 9.9 Hz, 3.4 Hz), 3.27 (t,
1H, J = 12.0 Hz), 3.14 (d, 1H, J = 11.1 Hz), 2.71 (d, 1H, J = 14.6 Hz), 1.70-1.58 (m, 3H),
1.49-1.47 (m, 1H), 1.37 (d, 1H, J = 12.3 Hz), 0.98-0.96 (m, 1H).

13

C NMR (CDCl3, 100

MHz): δ 140.8, 140.5, 140.3, 137.1, 130.1, 128.7, 127.8, 126.7, 118.5, 87.6, 69.8, 63.1,
55.7, 45.4, 45.0, 20.5, 19.9, 18.9. HRMS calcd for C20H23IN4OH+ 463.0989, found
463.0989.
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(R,R)-Ritalinol (5.27)
(R,R)-MP hydrochloride ((+)-1.10, provided by retired Professor Howard M. Deutsch
(Georgia Tech)) (1 g, 3.71 mmol) was treated with 1M aq. NaOH to provide 800 mg of
the free base form of 5.38 (72 %). To a solution of 5.38 (800 mg, 3.43 mmol) in Et2O (7
mL) was added 1.0 M lithium aluminum hydride in Et2O (2.2 mL, 2.2 mmol) at 0 ˚C.
The mixture was stirred from 0 ˚C to room temperature for 3 hrs. The reaction mixture
was then diluted with H2O slowly and extracted with Et2O (2 X 10 mL). The combined
organic layers were washed with brine, dried (MgSO4), filtered, and concentrated to give
650 mg of (R,R)-alcohol 5.27 (93%).

1

H NMR data proved identical to that previously

reported (Prashad et al., 1999b).

(R,R)-3-Iodo-4-azido-N-benzyl-ritalinol ((-)-4.36)
A mixture of (R,R)-ritalinol (5.27) (270 mg, 1.31 mmol), 3-iodo-4-azido benzyl chloride
(5.32, Murray et al., 2005) (310 mg, 1.04 mmol), and K2CO3 (724 mg, 5.24 mmol) in
DMF (6 mL) was stirred at room temperature for 12 hrs. The mixture was then diluted
with H2O and extracted with Et2O (2 × 20 mL). The combined organic layers were
washed with brine, dried (MgSO4), filtered, concentrated, and chromatographed
(EtOAc:hexanes, 2:8) to give 150 mg of tertiary amine (-)-4.36 as an oil (46 %). Rf =
0.24 (EtOAc:hexanes, 2:8). 1H NMR (CDCl3, 400 MHz): δ 7.73 (d, 1H, J = 1.9 Hz), 7.46
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(dd, 1H, J = 8.2, 1.9 Hz), 7.29-7.26 (m, 2H), 7.22-7.19 (m, 1H), 7.15 (d, 1H, J = 8.2 Hz),
7.05 (d, 2H, J = 8.3 Hz), 6.46 (br s, 1H), 3.92 (s, 2H), 3.84 (t, 1H, J = 10.0 Hz), 3.70 (dd,
1H, J = 10.8 Hz, 3.6 Hz), 3.46 (td, 1H, J = 10.0, 3.4 Hz), 3.27 (t, 1H, J = 12.0 Hz,), 3.14
(d, 1H, J = 10.9 Hz,), 2.71 (d, 1H, J = 14.9 Hz,), 1.71-1.55 (m, 3H), 1.49-1.47 (m, 1H),
1.37 (d, 1H, J = 12.8 Hz), 0.98-0.96 (m, 1H).

13

C NMR (CDCl3, 100 MHz): δ 140.9,

140.6, 140.4, 137.2, 130.2, 128.8, 127.9, 126.9, 118.7, 87.7, 69.9, 63.2, 55.9, 45.5, 45.2,
20.7, 20.0, 18.9. HRMS calcd for C20H23IN4OH+ 463.0989, found 463.0999. IR azide
2114.9 cm-1. [α]D 21.7 = -58.63˚, c = 5.168 (MeOH).

(R,R)-3-Iodo-4-azido-N-benzyl-ritalinol oxalate (5.39)
A mixture of (R,R)-3-iodo-4-azido-N-benzyl-ritalinol (-)-4.36 (150 mg, 0.32 mmol) and
oxalic acid (30 mg, 0.32 mmol) in EtOAc (4 mL) was refluxed for 1 hr. The mixture was
then cooled to room temperature and concentrated to provide a white foam/solid, which
was washed with Et2O to provide 60 mg of oxalate salt 5.39 (34%). 1H NMR (CD3OD,
400 MHz): δ 8.06 (d, 1H, J = 1.8 Hz), 7.66 (dd, 1H, J = 8.3, 1.8 Hz), 7.36-7.29 (m, 4H),
7.20 (d, 2H, J = 7.0 Hz,), 4.65 (d, 1H, J = 13.1 Hz), 4.53 (d, 1H, J = 13.2 Hz,), 4.00 (t,
1H, J = 10.5 Hz), 3.87-3.83 (m, 2H), 3.63 (td, 1H, J = 10.4, 3.5 Hz), 3.43-3.40 (m, 1H),
3.17-3.11 (m, 1H), 1.85-1.70 (m, 4H), 1.53-1.42 (m, 2H). Anal Calcd for C22H25IN405:
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C, 47.84; H, 4.56; N, 10.14; I, 22.97. Found: C, 48.17; H, 4. 62; N, 9.92; I, 22.59. IR:
azide, 2070 cm-1. MPt: 90-92 ˚C.

(R,R)-3-(tri-n-Butylstannyl)-4-azido-N-benzyl-ritalinol ((-)-5.40)
A mixture of (R,R)-3-iodo-4-azido-N-benzyl-ritalinol ((-)-4.36) (93 mg, 0.2 mmol),
Pd(PPh3)2Br2 (10 mg, 0.02 mmol), bis(tributytin) (140 µL, 0.36 mmol) in toluene (10
mL) was heated at 105 ˚C for 6 hrs. The mixture was then cooled to room temperature,
diluted with saturated aq. K2CO3 solution, then extracted with EtOAc (2 × 20 mL). The
combined organic layers were washed with brine, dried (MgSO4), ﬁltered, concentrated,
and chromatographed (EtOAc:hexanes, 2:8) to give 50 mg of organostannane (-)-5.40 as
a colorless oil (40%). Rf = 0.25 (EtOAc:hexanes, 2:8). 1H NMR (CDCl3, 400 MHz): δ
7.40 (dd, 1H, J = 8.1, 2.0 Hz), 7.34 (d, 1H, J = 2.0 Hz), 7.27-7.15 (m, 4H), 7.22-7.02 (d,
2H, J = 6.9 Hz), 6.71 (br s, 1H), 3.94 (d, 2H, J = 3.8 Hz), 3.77 (t, 1H, J = 10.3 Hz), 3.65
(dd, 1H, J = 10.7, 3.3 Hz), 3. 46 (td, 1H, J = 10.3, 3.3 Hz), 3.28 (t, 1H, J = 11.5 Hz), 3.17
(d, 1H, J = 11.4 Hz), 2.74 (d, 1H, J = 14.6 Hz,), 1.56-1.51 (m, 8H), 1.35-1.30 (m, 8H),
1.13-1.09 (m, 6H), 0.87 (t, 11H, J = 7.3 Hz).

13

C NMR (CDCl3, 100 MHz): δ 145.1,

141.0, 138.3, 134.6, 134.4, 130.6, 128.7, 127.8, 126.7, 117.3, 70.0, 62.7, 56.7, 45.5, 45.0,
29.1, 27.3, 20.5, 20.0, 19.0, 13.7, 10.1. HRMS calcd for C32H50N4OSnH+ 627.3079,
found 627.3084. IR: azide, 2108 cm-1. [α]D 21.7 = -55.69˚, c = 1.57 (CHCl3).
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(±)-threo-3-Iodo-4-azido-N-benzyl-3,4-dichloro-MP ((±)-4.37)
A mixture of (±)-threo-3,4-dichloro-MP hydrochloride ((±)-3.53, Deutsch et al., 1996,
provided by retired Professor Howard M. Deutsch (Georgia Tech)) (130 mg, 0.38 mmol),
3-iodo-4-azido benzyl chloride (5.32, Murray et al., 2005) (190 mg, 0.57 mmol), and
K2CO3 (120 mg, 0.90 mmol) in DMF (8 mL) was stirred at room temperature for 24 hrs.
The mixture was then diluted with H2O and extracted with Et2O (2 × 20 mL). The
combined organic layers were washed with brine, dried (MgSO4), filtered, concentrated,
and chromatographed (CHCl3:hexanes, 2:8) to provide 50 mg of tertiary amine (±)-4.37)
as a colorless oil (24%). Rf = 0.20 (CHCl3:hexanes, 2:8). 1H NMR (CDCl3, 500 MHz): δ
7.71-7.70 (m, 1H), 7.51-7.50 (m, 1H), 7.4-7.38 (m, 1H), 7.28-7.22 (m, 2H), 7.06 (d, 1H, J
= 8.1 Hz), 4.11 (d, 1H, J = 11.6 Hz), 3.85 (d, 1H, J = 13.9 Hz), 3.71 (s, 3H), 3.68-3.65
(m, 1H), 3.40-3.38 (m, 1H), 2.96-2.91 (m, 1H), 2.52-2.49 (d, 1H, J = 14.2 Hz,), 1.54-1.52
(m, 4H), 1.32-1.31 (m, 1H), 1.06-1.04 (m, 1H).

13

C NMR (CDCl3, 100 MHz): δ 173.2,

140.1, 140.0, 139.9, 138.8, 136.9, 132.7, 131.7, 130.6, 129.6, 128.0, 117.9, 87.6, 62.7,
55.4, 52.3, 52.0, 44.7, 21.1, 20.5, 19.4. HRMS calcd for C21H21ICl2N4O2H+ 559.0159,
found 559.0165.
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(±)-threo-3-Iodo-4-azido-N-benzyl-3,4-dichloro-ritalinol ((±)-4.38)
A mixture of (±)-threo-3,4-dichloro-ritalinol ((±)-5.42; Kim et al., 2007) (110 mg, 0.41
mmol), 3-iodo-4-azido benzyl chloride (5.32; Murray et al., 2005) (180 mg, 0.62 mmol),
and K2CO3 (130 mg, 1.17 mmol) in DMF (8 mL) was stirred at room temperature for 12
hrs. The mixture was then diluted with H2O and extracted with Et2O (2 × 20 mL). The
combined organic layers were washed with brine, dried (MgSO4), filtered, concentrated,
and chromatographed (EtOAc:hexanes, 2:8) to provide 50 mg of tertiary amine (±)-4.38
as a colorless oil (23%). Rf = 0.20 (EtOAc:hexanes, 2:8). 1H NMR (CDCl3, 400 MHz): δ
7.74 (d, 1H, J = 1.8 Hz), 7.41 (dd, 1H, J = 8.2, 1.8 Hz), 7.35 (d, 1H, J = 8.2 Hz), 7.16 (m,
2H), 6.90 (dd, 1H, J = 8.2, 2.0 Hz), 6.19 (br s, 1H), 3.92 (s, 2H), 3.77 (t, 1H, J = 10.7
Hz,), 3.68 (dd, 1H, J = 10.8, 3.6 Hz), 3.41 (td, 1H, J = 9.7, 3.6 Hz), 3.22 (td, 1H, J = 11.9,
3.0Hz), 3.08 (d, 1H, J = 11.2 Hz), 2.70 (d, 1H, J = 14.6 Hz,), 1.71-1.51 (m, 4H), 1.37 (d,
1H, J = 13.7 Hz), 0.97 (d, 1H, J = 10.8 Hz).

13

C NMR (CDCl3, 100 MHz): δ 141.0,

140.9, 140.3, 136.9, 132.7, 130.8, 130.7, 130.1, 129.7, 127.2, 118.6, 87.7, 69.2, 62.9,
55.8, 45.5, 44.6, 20.7, 20.0, 18.8. HRMS calcd for C20H21Cl2N4OH+ 531.0209, found
531.0216. IR: azide, 2118 cm-1.

(4-(3-Bromopropyl)phenyl)(4-iodophenyl)methanone (5.45)
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AlCl3 (870 mg, 6.5 mmol) was slowly added to a stirring mixture of 4-iodo-benzoyl
chloride (5.46) (1.73 g, 6.5 mmol) in DCM (6 mL) at 0 ˚C for 10 min.

(3-

Bromopropyl)benzene (3.59) (1.0 g, 5.0 mmol) was then added dropwise at 0 ˚C. The
reaction mixture was refluxed overnight, cooled to room temperature, diluted with
CHCl3, and poured into ice cold concentrated HCl (4 mL). The organic layer was
separated, washed with 1M aq. NaOH, brine, dried (MgSO4), filtered, concentrated, and
chromatographed (EtOAc:hexanes, 1:9) to give 1.3 g of ketone 5.45 as a light yellow
solid (61%). Rf = 0.20 (EtOAc:hexanes, 1:9).

1

H NMR (CDCl3, 400 MHz): δ 7.85 (d,

2H, J = 8.5 Hz), 7.72 (d, 2H, J = 8.3 Hz), 7.51 (d, 2H, J = 8.5 Hz), 7.32 (d, 2H, J = 8.1
Hz), 3.41 (t, 2H, J = 6.5 Hz), 2.87 (t, 2H, J = 7.5 Hz), 2.22 (quin, 2H, J = 8.0 Hz).

13

C

NMR (CDCl3, 100 MHz): δ 195.5, 146.0, 137.5, 137.0, 135.1, 131.4, 130.4, 128.6, 99.9,
34.0, 33.7, 32.7. HRMS calcd for C16H14BrIONa+ 450.9164, found 450.9162. MPt: 8586 ˚C.

(4-(3-(4-(2-(Bis(4-fluorophenyl)methoxy)ethyl)piperazin-1-yl)propyl)phenyl)(4iodophenyl) methanone (5.44)
A mixture of 1-(2-(bis(4-fluorophenyl)methoxy)ethyl)piperazine (3.58; Van der zee et
al., 1980) (200 mg, 0.63 mmol), alkyl bromide 5.45 (300 mg, 0.69 mmol), and K2CO3
(260 mg, 1.89 mmol) in EtOH (5 mL) was refluxed overnight. The mixture was then
cooled to room temperature, diluted with H2O, and extracted with CHCl3 (2 × 20 mL).
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The combined organic layers were washed with brine, dried (MgSO4), filtered,
concentrated, and chromatographed (CHCl3:MeOH, 98:2) to give 270 mg of Ndialkylated piperazine 5.44 as an oil (62%). Rf = 0.10 (CHCl3:MeOH, 98:2).

1

H NMR

(CDCl3, 400 MHz): δ 7.82 (d, 2H, J = 8.5 Hz), 7.70 (d, 2H, J = 8.2 Hz), 7.49 (d, 2H, J =
8.5 Hz), 7.30-7.26 (m, 6H), 6.98 (d, 4H, J = 8.7 Hz), 5.3 (s, 1H), 3.57 (t, 2H, J = 6.0 Hz),
2.73-2.47 (m, 12H), 2.36 (t, 2H, J = 7.8 Hz), 1.84 (quin, 2H, J = 7.7 Hz).

13

C NMR

(CDCl3, 100 MHz): δ 195.5, 163.3, 160.8, 147.7, 137.8, 137.7, 137.4, 137.0, 134.7,
131.3, 130.2, 128.6, 128.5, 128.4, 115.3, 115.1, 99.8, 82.4, 66.8, 57.8, 57.7, 53.5, 53.1,
33.6, 28.2. HRMS calcd for C35H35F2IN2O2Na+ 703.1603, found 703.1586.

(4-(3-(4-(2-(Bis(4-fluorophenyl)methoxy)ethyl)piperazin-1-yl)propyl)phenyl)(4ethynyl phenyl) methanone (4.40)
A mixture of iodo-benzophenone 5.44 (150 mg, 0.22 mmol), Pd (3 mg, 0.02 mmol), 10%
Pd/C (30 mg, 0.09 mmol), PPh3 (30 mg, 0.09 mmol), CuI (14 mg, 0.06 mmol), NEt3 (1.0
mL, 7.5 mmol) and trimethylsilyl acetylene (3.67) (40 µL, 0.27 mmol) in CH3CN (4 mL)
was refluxed for 12 hrs. The mixture was then cooled to room temperature, diluted with
EtOAc, and filtered over Celite®. The organic phase/filtrate was washed with H2O, brine,
dried (MgSO4), ﬁltered, concentrated, and chromatographed (CHCl3:MeOH, 9.5:0.5) to
give

120

mg

of

(4-(3-(4-(2-(bis(4-fluorophenyl)methoxy)ethyl)piperazin-1-
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yl)propyl)phenyl)(4-((trimethylsilyl)ethynyl) phenyl)methanone as a colorless oil (82 %).
Rf = 0.2 (CHCl3:MeOH, 9.5:0.5).

1

H NMR (CDCl3, 400 MHz): δ 7.75-7.71 (m, 4H),

7.57 (d, 2H, J = 8.5 Hz), 7.32-7.27 (m, 6H), 7.00 (d, 4H, J = 8.7 Hz), 5.35 (s, 1H), 3.58
(t, 2H, J = 6.0 Hz), 2.75-2.48 (m, 12H), 2.38 (t, 2H, J = 7.8 Hz), 1.86 (quin, 2H, J = 7.6
Hz), 0.29 (s, 9H).

13

C NMR (CDCl3, 100 MHz): δ 196.1, 163.8, 161.4, 148.0, 138.3,

138.2, 137.7, 135.5, 132.2, 130.7, 130.2, 129.1, 129.0, 128.8, 127.5, 115.8, 115.6, 104.5,
98.1, 82.9, 67.3, 58.3, 58.2, 54.1, 53.6, 34.1, 28.7, 0.3.
C40H44F2N2O2SiNa+ 673.3032, found 673.3030.

HRMS calcd for

A mixture of (4-(3-(4-(2-(bis(4-

fluorophenyl)methoxy)ethyl)piperazin-1-yl)propyl)phenyl)(4-((trimethylsilyl)ethynyl)
phenyl) methanone (260 mg, 0.4 mmol) and TBAF (1.0 M in THF) (2 mL, 2 mmol) in
THF (5 mL) was stirred at room temperature for 5 hrs. The mixture was then diluted
with H2O and extracted with Et2O (2 × 30 mL). The combined organic layers were
washed with saturated aq. NH4Cl solution, brine, dried (MgSO4), filtered, concentrated,
and chromatographed (100% EtOAc) to give 60 mg of terminal alkyne 4.40 as an oil
(45%). Rf = 0.10 (100% EtOAc).

1

H NMR (CDCl3, 400 MHz): δ 7.78-7.72 (m, 4H),

7.60 (d, 2H, J = 8.5 Hz), 7.32-7.27 (m, 6H), 7.03 (d, 4H, J = 8.7 Hz), 5.35 (s, 1H), 3.593.56 (m, 2H), 3.26 (s, 1H), 2.75-2.47 (m, 12H), 2.38 (t, 2H, J = 7.7 Hz), 1.86 (quin, 2H, J
= 7.6 Hz).

13

C NMR (CDCl3, 100 MHz): δ 195.5, 163.4, 160.9, 147.7, 137.9, 137.8,

137.7, 134.9, 131.9, 130.3, 129.8, 128.6, 128.5, 128.4, 126.0, 115.4, 115.2, 82.8, 82.5,
80.0, 66.9, 57.8, 57.7, 53.7, 53.2, 33.7, 28.3.
579.2817, found 579.2809.
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HRMS calcd for C37H36F2N2O2H+

(3-Iodo-5-nitrophenyl)methanol (5.52)
A solution of BF3•Et2O (2.57 mL, 20.97 mmol) in THF (7 mL) was added dropwise to a
THF (5 mL) suspension of NaBH4 (190 mg, 5.15 mmol) and 3-iodo-5-nitrobenzoic acid
(5.51) (1 g, 3.41 mmol). The reaction mixture was stirred from 0 ˚C to room temperature
for 3 hrs, diluted with H2O slowly, then extracted with EtOAc (2 x 10 mL). The
combined organic layers were washed with brine, dried (MgSO4), filtered, and
concentrated to give 700 mg of benzyl alcohol 5.52 as an oil (71%). 1H NMR data was
identical to that previously reported for this compound (Vaidyanathan et al., 2001).

(3-Amino-5-iodophenyl)methanol (5.53)
(3-Iodo-5-nitrophenyl)methanol (5.52) (700 mg, 2.50 mmol) was added to MeOH (5 mL)
at 0 ˚C followed by concentrated HCl (1 mL) and SnCl2 (1.5 g, 8.15 mmol). The mixture
was allowed to stir at room temperature overnight then quenched with H2O (5 mL). The
pH was then adjusted to 11 with 1M aq. NaOH and the mixture was extracted with
EtOAc.

The organic layer was washed with brine, dried (MgSO4), filtered, and

concentrated to give 550 mg of aniline 5.53 as a yellow oil (90%).

1

H NMR data was

identical to that previously reported for this compound (Vaidyanathan et al., 2001).
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Ethyl 3-nitro-5-(3-oxopropyl)benzoate (5.57)
A mixture of ethyl 3-iodo-5-nitrobenzoate (5.55; Giblin et al., 2005b) (2 g, 6.23 mmol),
allyl alcohol (5.63; 0.43 mL, 6.23 mmol), Pd(OAc)2 (80 mg, 0.37 mmol), LiCl (260 mg,
6.23 mmol), LiOAc (1.03 g, 15.57 mmol) and tetrabutylammonium chloride (1.73 g, 6.23
mmol) in DMF (15 mL) was heated at 71 ˚C for 3 hrs. The mixture was then cooled to
room temperature, diluted with EtOAc, and filtered over Celite®. The organic phase was
washed with H2O, brine, dried (MgSO4), ﬁltered, concentrated, and chromatographed
(EtOAc:hexanes, 1:9) to give 860 mg of aldehyde 5.57 as a colorless oil (57%). Rf = 0.2
(EtOAc:hexanes, 1:9). 1H NMR (CDCl3, 400 MHz): δ 9.86 (t, 1H, J = 0.9 Hz), 8.68 (d,
1H, J = 1.9 Hz), 8.26 (t, 1H, J = 2.2 Hz), 8.24-8.23 (m, 1H) 4.44 (q, 2H, J = 7.2 Hz), 3.12
(t, 2H, J = 7.3 Hz), 2.93 (t, 2H, J = 7.3 Hz), 1.43 (t, 3H, J = 7.1 Hz).

13

C NMR (CDCl3,

100 MHz): δ 199.9, 164.5, 148.4, 143.1, 135.3, 132.3, 127.1, 122.5, 61.9, 44.4, 27.5,
14.3. HRMS calcd for C12H13NO5Na+ 274.0685, found 274.0691.

Ethyl 3-nitro-5-(3-oxopropyl)benzoate (5.57) (Alternative Method)
To a 0 ˚C solution of ethyl 3-allyl-5-nitrobenzoate (5.58; Ek et al., 2002) (500 mg, 2.12
mmol) in THF (5 mL) was added 9-BBN (1M in THF, 3 mL, 6.36 mmol). The mixture
was then stirred at room temperature for 4 hours, cooled to 0 ˚C, then treated with 1M aq.
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NaOH (5 mL) followed by 30% H2O2 (5 mL). The resulting mixture was warmed to
room temperature then stirred for 1 hour. The reaction was then diluted with H2O and
extracted with EtOAc (2 x 15 mL). The combined organic layers were washed with
brine, dried (MgSO4), filtered, concentrated, and chromatographed (EtOAc:hexanes, 4:6)
to provide 110 mg of primary alcohol 5.62 (40%). Rf = 0.2 (EtOAc:hexanes, 4:6).

1

H

NMR (CDCl3, 400 MHz): δ 8.68-8.67 (m, 1H), 8.26-8.25 (m, 1H), 8.23-8.21 (m, 1H)
4.45 (q, 2H, J = 7.2 Hz), 3.71 (t, 2H, J = 6.2 Hz), 2.91 (t, 2H, J = 8.0 Hz), 2.06 (br s, 1H),
2.03-1.3 (m, 2H), 1.43 (t, 3H, J = 7.1 Hz). A mixture of ethyl 3-(3-hydroxypropyl)-5nitrobenzoate (5.62) (110 mg, 0.44 mmol) and PCC (110 mg, 0.49 mmol) in DCM (5
mL) was stirred at room temperature for 4 hrs. The reaction mixture was diluted with
Et2O and filtered over Celite®. The organic phase was then washed with saturated aq.
NaHCO3 solution, dried (MgSO4), ﬁltered, concentrated, and chromatographed
(EtOAc:hexanes, 1:9) to give 50 mg of aldehyde 5.57 as a colorless oil (40%). Rf = 0.2
(EtOAc:hexanes, 1:9). 1H NMR (CDCl3, 400 MHz): δ 9.86 (t, 1H, J = 0.9 Hz), 8.68 (d,
1H, J = 1.9 Hz), 8.26 (t, 1H, J = 2.2 Hz), 8.24-8.23 (m, 1H) 4.44 (q, 2H, J = 7.2 Hz), 3.12
(t, 2H, J = 7.3 Hz), 2.93 (t, 2H, J = 7.3 Hz), 1.43 (t, 3H, J = 7.1 Hz).

13

C NMR (CDCl3,

100 MHz): δ 199.9, 164.5, 148.4, 143.1, 135.3, 132.3, 127.1, 122.5, 61.9, 44.4, 27.5,
14.3. HRMS calcd for C12H13NO5Na+ 274.0685, found 274.0691.
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Ethyl

3-(3-(4-(2-(bis(4-fluorophenyl)methoxy)ethyl)piperazin-1-yl)propyl)-5-

nitrobenzoate (5.56)
A mixture of 1-(2-(bis(4-fluorophenyl)methoxy)ethyl)piperazine (3.58; Van der zee et
al., 1980) (150 mg, 0.45 mmol), aldehyde 5.57 (110 mg, 0.45 mmol), and NaBH(OAc)3
in DCE (7 mL) was stirred at room temperature for 24 hrs. The reaction mixture was
diluted with DCM (20 mL) and 1M aq. NaOH (20 mL). The organic layer was separated,
dried (MgSO4), ﬁltered, concentrated, and chromatographed (CHCl3:MeOH, 9.5:0.5) to
give 180 mg of disubstituted piperazine 5.56 as a colorless oil (70%).
(CHCl3:MeOH, 9.5:0.5).

1

Rf = 0.25

H NMR (CDCl3, 400 MHz): δ 8.68-8.67 (m, 1H), 8.25-8.20

(m, 2H), 7.30-7.26 (m, 4H), 7.02-6.97 (m, 4H), 5.34 (s, 1H), 4.43 (q, 2H, J = 7.2 Hz),
3.58 (t, 2H, J = 6.0 Hz), 2.83 (t, 2H, J = 7.2 Hz), 2.66 (t, 2H, J = 6.1 Hz), 2.64-2.40 (m,
8H), 2.34 (t, 2H, J = 7.6 Hz), 1.86 (quin, 2H, J = 7.1 Hz), 1.42 (t, 3H, J = 7.2 Hz).

13

C

NMR (CDCl3, 100 MHz): δ 164.7, 163.3, 160.9, 148.3, 144.7, 137.9, 137.8, 135.4, 132.0,
128.6, 128.5, 127.2, 122.1, 115.4, 115.2, 82.5, 66.9, 61.8, 57.8, 57.0, 53.6, 53.1, 33.0,
27.9, 14.3. HRMS calcd for C31H35F2N3O5H+ 568.2617, found 568.2624.

Ethyl

3-amino-5-(3-(4-(2-(bis(4-fluorophenyl)methoxy)ethyl)piperazin-1-yl)propyl)

benzoate (5.64)
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A mixture of nitro derivative 5.56 (180 mg, 0.32 mmol) and SnCl2•2H2O (298 mg, 1.29
mmol) in EtOH (6 mL) was refluxed for 2 hrs. The reaction mixture was then cooled to
room temperature, diluted with saturated aq. NaHCO3 solution, and extracted with
EtOAc.

The organic phase was washed with brine, dried (MgSO4), ﬁltered, and

concentrated to give 130 mg of aniline 5.64 as a yellow oil (74%).
(CHCl3:MeOH:NEt3, 90:8:2).

1

Rf = 0.3

H NMR (CDCl3, 400 MHz): δ 7.29-7.25 (m, 5H), 7.19-

7.17 (m, 1H), 7.01-6.97 (m, 4H), 6.69-6.66 (m, 1H), 5.33 (s, 1H), 4.33 (q, 2H, J = 7.1
Hz), 3.78 (br s, 2H), 3.55 (t, 2H, J = 6.0 Hz), 2.66 (t, 2H, J = 6.0 Hz), 2.62-2.39 (m,
10H), 2.36 (t, 2H, J = 7.3 Hz), 1.79 (quin, 2H, J = 7.7 Hz), 1.35 (t, 3H, J = 7.1 Hz).

13

C

NMR (CDCl3, 100 MHz): δ 166.9, 163.3, 160.9, 146.5, 143.4, 137.9, 137.8, 131.4, 128.6,
128.5, 119.8, 119.4, 115.3, 115.1, 113.4, 82.5, 66.9, 60.8, 57.8, 53.5, 53.1, 33.4, 28.2,
14.3. HRMS calcd for C31H37F2N3O3H+ 538.2875, found 538.2869.

(3-Amino-5-(3-(4-(2-(bis(4-fluorophenyl)methoxy)ethyl)piperazin-1-yl)propyl)
phenyl) methanol (5.65)
LiAlH4 (1.0 M in THF) (530 µL, 0.53 mmol) was added slowly to a solution of ester 5.64
(140 mg, 0.27 mmol) in THF (6 mL) at -10 ˚C then warmed to room temperature for 4
hrs. The reaction mixture was cooled to 0 ˚C, sequentially treated with H2O (30 µL),
15% w/v NaOH (30 µL), and H2O (90 µL) to form a white solid that was filtered and
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washed with Et2O.

The organic layer/filtrate was dried (MgSO4), ﬁltered, and

concentrated to give 110 mg of benzyl alcohol 5.65 as an oil (81%).

Rf = 0.6

(CHCl3:MeOH:NEt3, 80:18:2). 1H NMR (CDCl3, 400 MHz): δ 7.28-7.24 (m, 4H), 7.016.97 (m, 4H), 6.54 (s, 1H), 6.48 (s, 1H), 6.39 (s, 1H), 5.32 (s, 1H), 4.57 (s, 2H), 3.61 (br
s, 1H), 3.53 (t, 2H, J = 6.0 Hz), 2.63 (t, 2H, J = 6.0 Hz), 2.60-2.36 (m, 10H), 2.32 (t, 2H,
J = 7.4 Hz), 1.74 (quin, 2H, J = 7.7 Hz).

13

C NMR (CDCl3, 100 MHz): δ 163.4, 160.9,

146.6, 143.5, 142.5, 137.8, 137.7, 128.6, 128.5, 117.2, 115.4, 115.2, 114.3, 111.3, 82.5,
66.8, 64.9, 58.06, 57.7, 53.4, 53.0, 33.6, 28.2.

HRMS calcd for C29H35F2N3O2H+

496.2770, found 496.2766.

(3-Azido-5-(3-(4-(2-(bis(4-fluorophenyl)methoxy)ethyl)piperazin-1-yl)propyl)
phenyl) methanol (5.66)
NaNO2 (45 mg, 0.65 mmol) was added to a stirring solution of aniline 5.65 (94 mg, 0.19
mmol) in MeOH (2 mL) and 0.33N aq. HCl (7 mL) at 0 ˚C. After 10 minutes, NaN3 (37
mg, 0.57 mmol) was added and then the reaction mixture was stirred at room temperature
overnight.

The mixture was then diluted with saturated aq. NaHCO3 solution and

extracted with CHCl3. The organic layer was washed with brine, dried (MgSO4), ﬁltered,
and concentrated to give 70 mg of azide 5.66 as an oil (70%).

Rf = 0.4

(CHCl3:MeOH:NEt3, 90:8:2). 1H NMR (CDCl3, 400 MHz): δ 7.28-7.24 (m, 4H), 6.98 (t,
4H, J = 8.6 Hz), 6.91 (s, 1H), 6.85 (s, 1H), 6.72 (s, 1H), 5.32 (s, 1H), 4.58 (s, 2H), 3.54 (t,
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2H, J = 5.9 Hz), 2.63 (t, 2H, J = 5.9 Hz), 2.60-2.33 (m, 10H), 2.29 (t, 2H, J = 7.9 Hz),
1.77 (quin, 2H, J = 7.2 Hz).

13

C NMR (CDCl3, 100 MHz): δ 163.4, 160.9, 144.2, 143.3,

140.1, 137.8, 137.7, 128.6, 128.5, 123.3, 117.9, 115.4, 115.2, 114.8, 82.5, 66.8, 64.2,
57.7, 53.4, 53.0, 33.4, 28.1.

HRMS calcd for C29H33F2N5O2H+ 522.2675, found

522.2671. IR: azide, 2105 cm-1.

1-(3-(3-Azido-5-(azidomethyl)phenyl)propyl)-4-(2-(bis(4-fluorophenyl)methoxy)
ethyl) piperazine (4.43)
Triethylamine (200 µL, 1.39 mmol) was added to a stirring solution of azide 5.66 (364
mg, 0.70 mmol) in DCM (4 mL) at 0 ˚C. After 10 minutes, MsCl (80 µL, 1.04 mmol)
was added and then the reaction mixture was allowed to stir at room temperature for 3
hrs. The mixture was then diluted with saturated aq. NaHCO3 solution and extracted with
DCM. The organic phase was washed with brine, dried (MgSO4), ﬁltered, concentrated,
and chromatographed (CHCl3:MeOH, 98:2) to give 130 mg of 3-azido-5-(3-(4-(2-(bis(4fluorophenyl)methoxy)ethyl)piperazin-1-yl)propyl)benzylmethane sulfonate (5.67) as an
oil (40%). This intermediate was used immediately for the next reaction since the
compound was not stable in the freezer overnight. Rf = 0.1 (CHCl3:MeOH, 98:2).

1

H

NMR (CDCl3, 400 MHz): δ 7.28-7.25 (m, 4H), 7.00-6.97 (m, 5H), 6.87-6.86 (m, 1H),
6.81-6.80 (m, 1H), 5.33 (s, 1H), 4.50 (s, 2H), 3.57-3.55 (m, 2H), 3.11 (s, 3H), 2.72-2.34
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(m, 14H), 1.83-1.80 (m, 2H). IR: azide, 2108 cm-1. A mixture of mesylate 5.67 (125 mg,
0.23 mmol) and NaN3 (70 mg, 0.92 mmol) in DMF (5 mL) was stirred at room
temperature for 4 hrs. The reaction mixture was then diluted with H2O and extracted
with EtOAc.

The organic phase was washed with brine, dried (MgSO4), ﬁltered,

concentrated, and chromatographed (CHCl3:MeOH, 98:2) to give 41 mg of diazide 4.43
as an oil (40%). Rf = 0.2 (CHCl3:MeOH, 98:2).

1

H NMR (CDCl3, 400 MHz): δ 7.29-

7.25 (m, 4H), 7.01-6.97 (m, 4H), 6.91 (s, 1H), 6.82 (s, 1H), 6.79 (s, 1H), 5.33 (s, 1H),
4.29 (s, 2H), 3.56-3.54 (m, 2H), 2.68-2.32 (m, 14H), 1.82-1.79 (m, 2H).

13

C NMR

(CDCl3, 100 MHz): δ 163.4, 160.9, 144.8, 140.5, 137.8, 137.3, 128.6, 128.5, 124.8,
118.8, 116.2, 115.4, 115.2, 82.5, 66.8, 57.8, 57.6, 54.3, 53.6, 53.1, 33.3, 28.2. HRMS
calcd for C29H32F2N8ONa+ 569.2559, found 569.2554. IR: azide, 2105 cm-1.

(4-(2-Bromoethoxy)phenyl)(4-(prop-2-yn-1-yloxy)phenyl)methanone (5.70)
A mixture of phenol 5.72 (Tae et al., 2010) (500 mg, 1.98 mmol), dibromoethane (5.71)
(3.95 g, 21.01 mmol), and K2CO3 (280 mg, 2.02 mmol) in acetone (25 mL) was refluxed
overnight. The mixture was then cooled to room temperature, diluted with H2O, and
extracted with DCM (2 × 30 mL). The combined organic layers were washed with 1M
aq. NaOH, brine, dried (MgSO4), filtered, concentrated, and chromatographed
(EtOAc:hexanes, 2:8) to give 200 mg of alkyl bromide 5.70 as a white solid (28%). Rf =
0.20 (EtOAc/hexanes, 2:8). 1H NMR (CDCl3, 500 MHz): δ 7.79 (d, 4H, J = 8.7 Hz), 7.04
(d, 2H, J = 8.8 Hz), 6.97 (d, 2H, J = 8.7 Hz), 4.77 (d, 2H, J = 2.3 Hz), 4.38 (t, 2H, J = 6.3
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Hz), 3.67 (t, 2H, J = 6.4 Hz), 2.56 (t, 1H, J = 2.4 Hz).

13

C NMR (CDCl3, 100 MHz): δ

194.2, 161.3, 160.7, 132.3, 132.1, 131.3, 131.1, 114.4, 114.1, 78.0, 76.3, 67.9, 55.9, 29.0.
HRMS calcd for C18H15BrO3Na+ 381.0096, found 381.0093. Anal calcd for C18H15BrO3:
C, 60.18; H, 4.21; Br, 22.24. Found: C, 60.37; H, 4.32; Br, 21.96. MPt: 91-92 ˚C.

(4-(2-(3-((2-Methylthiazol-4-yl)ethynyl)phenoxy)ethoxy)phenyl)(4-(prop-2-yn-1yloxy)phenyl)methanone (4.49)
A mixture of 3-((2-methylthiazol-4-yl)ethynyl)phenol (4.45; Mishra et al., 2012) (100
mg, 0.46 mmol), alkyl bromide 5.70 (180 mg, 0.51 mmol), and K2CO3 (190 mg, 1.39
mmol) in DMF (7 mL) was heated at 60 ˚C for 19 hrs. The mixture was then cooled to
room temperature, diluted with H2O, and extracted with EtOAc (2 × 20 mL). The
combined organic layers were washed with brine, dried (MgSO4), filtered, concentrated,
and chromatographed (CHCl3:MeOH, 97:3) to give 165 mg of conjugate 4.49 as a yellow
solid (70%). Rf = 0.24 (CHCl3:MeOH , 97:3). 1H NMR (CDCl3, 400 MHz): δ 7.79 (d,
4H, J = 8.7 Hz,), 7.37 (s, 1H), 7.30-7.24 (m, 1H), 7.19-7.17 (m, 1H), 7.15-7.11 (m, 1H),
7.05-6.99 (m, 4H), 6.96 (dd, 1H, J = 8.2, 2.5 Hz), 4.77 (d, 2H, J = 2.3 Hz), 4.37 (dd, 4H,
J = 18.4, 5.3 Hz), 2.73 (s, 3H), 2.57 (t, 1H, J = 2.3 Hz).

13

C NMR (CDCl3, 100 MHz): δ

194.2, 165.8, 161.8, 160.6, 158.2, 136.6, 132.2, 132.1, 131.3, 130.8, 129.5, 124.7, 123.4,
122.5, 117.0, 116.1, 114.3, 114.1, 88.6, 83.4, 77.9, 76.2, 66.5, 66.3, 55.8, 19.1. HRMS
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calcd for C30H23NO4SNa+ 516.1240, found 516.1234. Anal. calcd for C30H23NO4S •
0.4692 H2O: C, 71.77; H, 4.80; N, 2.79; S, 6.39. Found: C, 71.75; H, 4.66; N, 2.96; S,
6.42. MPt: 90-92 ˚C.

4-((3-(Benzyloxy)phenyl)ethynyl)-2-methylthiazole (4.46)
2-Methyl-4-(trimethylsilylethynyl)thiazole 3.76 (Cosford et al., 2003) (176 mg, 0.90
mmol) and 1-(benzyloxy)-3-iodobenzene (5.69) (310 mg, 0.99 mmol) were added to a
flask containing degassed DMF (5 mL). To this mixture, Pd(PPh3)4 (8 mg, 0.05 mmol),
CuI (25 mg, 0.09 mmol), and NEt3 (200 µL, 1.08 mmol) were added. The mixture was
then degassed again and warmed to 85 ˚C. TBAF (1.0 M in THF) (1 mL, 0.99 mmol)
was then added dropwise over 15 min. The reaction mixture was stirred at 85 ˚C for 1.5
hrs then cooled to room temperature. The mixture was then filtered through Celite® and
washed with EtOAc. The organic phase was washed with 0.1M aq. HCl, H2O, brine,
dried (MgSO4), filtered, concentrated, and chromatographed (EtOAc:hexanes, 1:9) to
give 140 mg of disubstituted alkyne 4.46 as an oil (70%). Rf = 0.20 (EtOAc:hexanes,
1:9).

1

H NMR (CDCl3, 400 MHz): δ 7.42-7.30 (m, 6H), 7.25-7.22 (m, 1H), 7.17-7.15

(m, 2H), 6.98-6.95 (m, 1H), 5.04 (s, 2H), 2.71 (s, 3H).

13

C NMR (CDCl3, 100 MHz): δ

165.6, 158.4, 136.8, 136.6, 129.4, 128.6, 128.0, 127.4, 124.5, 123.4, 122.2, 117.3, 116.2,
88.6, 83.3, 69.9, 19.2. HRMS calcd for C19H15NOSNa+ 328.0766, found 328.07636.
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4-((3-((3-Azido-5-(azidomethyl)benzyl)oxy)phenyl)ethynyl)-2-methylthiazole (4.50)
A mixture of 3-((2-methylthiazol-4-yl)ethynyl)phenol (4.45; Mishra et al., 2012) (88 mg,
0.41 mmol), diazido mesylate 5.79 (Hosoya et al., 2005) (111 mg, 0.41 mmol), and
K2CO3 (170 mg, 1.23 mmol) in acetone (6 mL) was stirred at room temperature for 20
hrs. The mixture was then diluted with H2O and extracted with EtOAc (2 × 20 mL). The
combined organic layers were washed with brine, dried (MgSO4), filtered, concentrated,
and chromatographed (EtOAc:hexanes, 2:8) to give 80 mg of benzyl ether 4.50 as an oil
(50%). Rf = 0.20 (EtOAc:hexanes, 2:8).

1

H NMR (CDCl3, 400 MHz): δ 7.36 (s, 1H),

7.28-7.24 (m, 1H), 7.19-7.17 (m, 1H), 7.13 (s, 2H), 7.06 (s, 1H), 6.97-6.95 (m, 1H), 6.93
(s, 1H), 5.03 (s, 2H), 4.36 (s, 2H), 2.73 (s, 3H).

13

C NMR (CDCl3, 100 MHz): δ 165.7,

158.1, 141.07, 139.5, 137.8, 136.7, 129.6, 124.9, 123.6, 123.1, 122.4, 118.0, 117.5, 117.2,
116.2, 88.5, 83.5, 69.1, 54.1, 19.2. HRMS calcd for C20H15N7OSNa+ 424.0951, found
424.0947.

4-((3-Fluoro-5-nitrophenyl)ethynyl)-2-iodothiazole (5.88)
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A degassed DME (10 mL) solution of 4-((trimethylsilyl)ethynyl)thiazol-2-amine (5.85;
Simeon et al., 2011) (750 mg, 3.82 mmol) was sequentially treated with 1-fluoro-3-iodo5-nitrobenzene (5.86) (1.3 g, 5.7 mmol), CuI (50 mg, 0.24 mmol), Pd(PPh3)4 (148 mg,
0.14 mmol), and Et3N (1.47 mL, 10.56 mmol). The reaction mixture was degassed again
then warmed to 70 ˚C. TBAF (1M in THF, 5 mL, 5 mmol) was added to the mixture
slowly for 5 min and then the reaction was heated at 70 ˚C for 3 hrs. The reaction
mixture was then cooled to room temperature, filtered over Celite®, and washed with
EtOAc (30 mL). The organic layer was washed with H2O, saturated aq. NH4Cl solution,
brine, dried (MgSO4), filtered, concentrated, and chromatographed (EtOAc:hexanes, 2:8)
to give 650 mg of impure 4-((3-fluoro-5-nitrophenyl)ethynyl)thiazol-2-amine (5.84). A
mixture of impure aminothiazole 5.84 (650 mg, 2.47 mmol), CuI (650 mg, 0.7 mmol) and
n-butyl nitrite (380 µL, 3.43 mmol) in CH3CN (20 mL) was heated at 60 ˚C for 45 min.
The mixture was then cooled to room temperature, diluted with 0.1M aq. NEt3 (50 mL)
and extracted with EtOAc (2 × 30 mL). The combined organic layers were filtered over
Celite®, washed with brine, dried (MgSO4), filtered, concentrated, and chromatographed
(EtOAc:hexanes, 0.5:9.5) to give 100 mg of iodide 5.88 as an oil (70 %). Rf = 0.20
(EtOAc:hexanes, 0.5:9.5).

1

H NMR (CDCl3, 400 MHz): δ 8.21 (s, 1H), 7.95-7.92 (m,

1H), 7.59 (s, 1H), 7.58-7.55 (m, 1H).

13

C NMR (CDCl3, 100 MHz): δ 162.0 (d, J = 252.8

Hz), 149.0 (d, J = 9.6 Hz), 138.5, 130.2, 125.3 (d, J = 10.2 Hz), 124.4 (d, J = 23.0 Hz),
122.6 (d, J = 3.6 Hz), 111.8 (d, J = 26.5 Hz), 100.7, 86.6 (d, J = 3.0 Hz), 85.1. HRMS
calcd for C11H4FIN2O2SNa+ 396.8914, found 396.8913.
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4-((3-Azido-5-fluorophenyl)ethynyl)-2-iodothiazole (4.52)
Fe (s) (94 mg, 1.7 mmol) was added to a solution of nitro analog 5.88 (127 mg, 2.47
mmol) in glacial AcOH (2 mL), H2O (1 mL), and EtOH (2 mL). The mixture was
sonicated for 1 hr, diluted with EtOAc, and filtered over Celite®.

The organic

phase/filtrate was washed with 2M aq. NaOH, brine, dried (MgSO4), filtered,
concentrated, and chromatographed (EtOAc:hexanes, 2:8) to give 30 mg of 3-fluoro-5((2-iodothiazol-4-yl)ethynyl)aniline (5.89) as an oil (20%). Rf = 0.20 (EtOAc:hexanes,
2:8). 1H NMR (CDCl3, 500 MHz): δ 7.45 (s, 1H), 6.63-6.61 (m, 2H), 6.40-6.37 (m, 1H),
3.84 (br s, 2H). NaNO2 (12 mg, 0.174 mmol) in ice cold H2O (1 mL) was slowly added
to a stirring mixture of 3-fluoro-5-((2-iodothiazol-4-yl)ethynyl)aniline (5.89) (30 mg,
0.09 mmol) and p-TsOH•H2O (50 mg, 0.26 mmol) in CH3CN (3 mL) at -10 ˚C. After 5
min, NaN3 (13 mg, 0.10 mmol) in ice cold H2O (1 mL) was added slowly and the mixture
was stirred from -10 ˚C to room temperature for 4 hrs. The mixture was then diluted with
H2O and cooled to 0 ˚C. Saturated aq. NaHCO3 solution was then added to adjust the pH
to 9 and the mixture was extracted with EtOAc. The organic phase was washed with
brine, dried (MgSO4), filtered, concentrated, and chromatographed (100% CHCl3) to give
30 mg of azide 4.52 as an oil (15%). Rf = 0.20 (100% CHCl3). 1H NMR (CDCl3, 400
MHz): δ 7.51 (s, 1H), 7.03-7.01 (m, 2H), 6.75-6.72 (m, 1H).

13

C NMR (CDCl3, 100

MHz): δ 162.9 (d, J = 248.5 Hz), 142.2 (d, J = 11.0 Hz), 139.0, 129.3, 124.9 (d, J = 11.7
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Hz), 117.9 (d, J = 3.3 Hz), 115.0 (d, J = 23.5 Hz), 107.7 (d, J = 25.4 Hz), 100.4, 88.1 (d,
J = 3.7 Hz), 83.3. HRMS calcd for C11H4FIN4SH+ 370.9258, found 370.9258.

2-((3-Methoxy-5-nitrophenyl)ethynyl)-6-methylpyridine (5.90)
A degassed DMF (8 mL) solution of 2-methyl-6-((trimethylsilyl)ethynyl)pyridine (3.68;
Alagille et al., 2005) (500 mg, 2.64 mmol) was sequentially treated with 1-iodo-3methoxy-5-nitrobenzene (5.91; Jorgensen et al., 2011) (884 mg, 3.16 mmol),
PdCl2(PPh3)4 (90 mg, 0.13 mmol), CuI (50 mg, 0.26 mmol), Et3N (1.47 mL, 10.56
mmol), and DMF (2 mL). The reaction mixture was degassed again then warmed to 70
˚C. TBAF (1M in THF, 2.9 mL, 2.9 mmol) was added to the mixture slowly for 5 min
and then the reaction was heated at 70 ˚C for 3 hrs. The reaction mixture was then cooled
to room temperature, filtered (Celite®), and washed with EtOAc (30 mL). The organic
layer was washed with H2O, saturated aq. NH4Cl solution, brine, dried (MgSO4), filtered,
concentrated, and chromatographed (EtOAc:hexanes, 2.5:7.5) to give 550 mg of
disubstituted alkyne 5.90 as a yellow solid (78%). Rf = 0.15 (EtOAc:hexanes, 2.5:7.5).
1

H NMR (CDCl3, 500 MHz): δ 7.98-7.97 (m, 1H), 7.66 (t, 1H, J = 2.2 Hz), 7.59 (d, 1H, J

= 7.7 Hz), 7.38-7.36 (m, 2H), 7.16 (d, 1H, J = 7.7 Hz), 3.88 (s, 3H), 2.58 (s, 3H).

13

C

NMR (CDCl3, 100 MHz): δ 159.7, 159.0, 148.8, 141.4, 136.4, 124.6, 124.5, 123.2, 123.0,
118.8, 109.3, 90.6, 85.7, 55.9, 24.4. HRMS calcd for C15H12N2O3Na+ 291.0740, found
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291.0740. Anal calcd for C15H12N2O3: C, 67.16; H, 4.51; N, 10.44. Found: C, 66.90; H,
4.54; N, 10.40. MPt: 102-103 ˚C.

2-Methyl-6-((3-nitro-5-(prop-2-yn-1-yloxy)phenyl)ethynyl)pyridine (5.92)
A 1.0 M BBr3 solution in DCM (3.72 mL, 3.72 mmol) was added dropwise to solution of
methoxy ether 5.90 (250 mg, 0.93 mmol) in DCM (6 mL) at -78 ˚C and then stirred at
this temperature for 1hr. The reaction was mixture was warmed to room temperature and
subsequently stirred for 5 hrs. The mixture was then cooled to -78 ˚C, slowly quenched
with MeOH (60 mL), and then stirred for 20 min. The mixture was then concentrated,
partitioned between EtOAc and cold saturated aq. NaHCO3 solution. The organic layer
was washed with brine, dried (MgSO4), filtered (Celite®), and concentrated to give 390
mg of 3-(6-methylpyridin-2-yl)ethynyl)-5-nitrophenol as a yellow solid. Rf = 0.3
(EtOAc:hexanes, 1: 1). The crude phenol was then directly treated with 80% propargyl
bromide (5.73) in toluene (420 µL, 2.78 mmol), K2CO3 (384 mg, 2.78 mmol), and DMF
(5 mL) then stirred at room temperature for 9 hrs. The reaction mixture was then diluted
with H2O and extracted with EtOAc (2 x 20 mL). The combined organic layers were
washed with saturated aq. NH4Cl solution, brine, dried (MgSO4), filtered, concentrated,
and chromatographed (EtOAc:hexanes, 2.5:7.5) to give 100 mg of propargyl ether 5.92 as
a yellow oil (35%). Rf = 0.3 (EtOAc:hexanes, 2.5:7.5). 1H NMR (CDCl3, 500 MHz): δ
8.08-8.07 (m, 1H), 7.81 (t, 1H, J = 2.2 Hz), 7.62 (t, 1H, J = 7.7 Hz), 7.50-7.49 (m, 1H),
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7.40 (d, 1H, J = 7.7 Hz), 7.17 (d, 1H, J = 7.7 Hz), 4.80 (d, 2H, J = 2.4 Hz), 2.62 (t, 1H, J
= 2.4 Hz), 2.60 (s, 3H).

13

C NMR (CDCl3, 100 MHz): δ 159.3, 157.7, 148.9, 141.6,

136.6, 124.8, 124.7, 124.0, 123.4, 119.9, 110.7, 90.9, 85.8, 77.5, 76.8, 56.5, 24.6. HRMS
calcd C17H12N2O3Na+ 315.0740, found 351.0740.

3-((6-Methylpyridin-2-yl)ethynyl)-5-(prop-2-yn-1-yloxy)aniline (5.93)
Fe (s) (105 mg, 1.88 mmol) was added to a solution of nitro analog 5.92 (100 mg, 0.34
mmol) dissolved in glacial AcOH (1 mL, 13.04 mmol), H2O (0.5 mL, 20.75 mmol), and
EtOH (1 mL, 12.73 mmol). The reaction mixture was sonicated for 1.5 hrs, diluted with
EtOAc, and then filtered (Celite®). The organic layer/filtrate was washed with 1M aq.
NaOH, brine, dried (MgSO4), filtered (Celite®), and concentrated to give 80 mg of aniline
5.93 as a black oil (91%). Rf = 0.20 (EtOAc:hexanes, 1:1). 1H NMR (CDCl3, 500 MHz):
δ 7.54 (t, 1H, J = 7.7 Hz), 7.32 (d, 1H, J = 7.7 Hz), 7.09 (d, 1H, J = 7.8 Hz), 6.61-6.60
(m, 1H), 6.55-6.54 (m, 1H), 6.30 (t, 1H, J = 2.2 Hz), 4.62 (d, 2H, J = 2.4 Hz), 3.83 (br s,
2H), 2.57 (s, 3H), 2.54 (t, 1H, J = 2.4 Hz).

13

C NMR (CDCl3, 100 MHz): δ 158.8, 158.3,

147.7, 142.5, 136.4, 124.4, 123.6, 122.6, 112.3, 107.8, 103.3, 88.9, 88.0, 78.4, 75.7, 55.7,
24.5. HRMS calcd for C17H14N2ONa+ 285.0998, found 285.0999.
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2-((3-Azido-5-(prop-2-yn-1-yloxy)phenyl)ethynyl)-6-methylpyridine (4.54)
NaNO2 (60 mg, 0.86 mmol) was slowly added to a solution of aniline 5.93 (76 mg, 0.29
mmol) in 0.5M aq. HCl (7 mL, 3.54 mmol) at 0 ˚C. After 10 minutes, NaN3 (90 mg, 1.38
mmol) was added slowly and the mixture was warmed from 0 ˚C to room temperature
and stirred for 1.5 hrs. The mixture was diluted with saturated aq. NaHCO 3 solution at 0
˚C to achieve a pH of ~7 and then extracted with EtOAc (2 x 20 mL). The combined
organic layers were washed with brine, dried (MgSO4), filtered (Celite®), concentrated,
and chromatographed (100% CHCl3) to give 37 mg of azide 4.54 as a brown oil (30%).
Rf = 0.20 (100% CHCl3). 1H NMR (CDCl3, 500 MHz): δ 7.57 (t, 1H, J = 7.7 Hz), 7.36
(d, 1H, J = 7.7 Hz), 7.13 (d, 1H, J = 7.8 Hz), 6.98-6.97 (m, 1H), 6.94-6.93 (m, 1H), 6.636.62 (m, 1H), 4.69 (d, 2H, J = 2.3 Hz), 2.59 (s, 3H), 2.57-2.56 (m,1H).

13

C NMR

(CDCl3, 100 MHz): δ 159.1, 158.3, 142.1, 141.5, 136.4, 124.6, 124.5, 123.0, 115.7,
114.3, 107.5, 89.5, 87.4, 77.7, 76.3, 56.0, 24.6.
311.0903, found 311.0903.
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HRMS calcd for C17H12N4ONa+

4-((3-(2-Bromoethoxy)phenyl)ethynyl)-2-methylthiazole (5.96)
A mixture of 3-((2-methylthiazol-4-yl)ethynyl)phenol (4.45; Mishra et al., 2012) (257
mg, 1.19 mmol), dibromoethane (5.71) (0.5 mL, 5.80 mmol), and K2CO3 (490 mg, 3.57
mmol) in DMF (7 mL) was heated at 60 ˚C for 20 hrs. The mixture was then cooled to
room temperature, diluted with H2O, and extracted with EtOAc (2 × 20 mL). The
combined organic layers were washed with brine, dried (MgSO4), filtered, concentrated,
and chromatographed (EtOAc:hexanes, 2:8) to give 100 mg of alkyl bromide 5.96 as a
yellow oil (32%). Rf = 0.20 (EtOAc:hexanes, 2:8). 1H NMR (CDCl3, 400 MHz): δ 7.377.36 (m, 1H), 7.27-7.22 (m, 1H), 7.18-7.16 (m, 1H), 7.08-7.07 (m, 1H), 6.92-6.89 (m,
1H), 4.28-4.24 (m, 2H), 3.64-3.60 (m, 2H), 2.73-2.71 (m, 3H).

13

C NMR (CDCl3, 100

MHz): δ 165.6, 157.7, 136.6, 129.5, 124.8, 123.5, 122.3, 117.1, 116.0, 88.4, 83.4, 67.7,
28.9, 19.2. HRMS calcd for C14H12BrNOSH+ 321.9895, found 321.9896.

S-(2-(3-((2-Methylthiazol-4-yl)ethynyl)phenoxy)ethyl) methanesulfonothioate (4.55)
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A mixture of alkyl bromide 5.96 (105 mg, 0.32 mmol) and sodium methanethiosulfonate
(5.95) (62 mg, 0.46 mmol) in DMF (7 mL) was heated at 50 ˚C for 20 hrs. The mixture
was then cooled to room temperature, diluted with H2O, and extracted with EtOAc (2 ×
20 mL). The combined organic layers were washed with brine, dried (MgSO4), filtered,
concentrated,

and

chromatographed

(100%

CHCl3)

to

give

100

methanethiosulfonate 4.55 as a yellow oil (85%). Rf = 0.15 (100% CHCl3).

mg
1

of

H NMR

(CDCl3, 400 MHz): δ 7.38 (s, 1H), 7.27-7.23 (m, 1H), 7.18-7.17 (m, 1H), 7.07-7.06 (m,
1H), 6.90-6.87 (m, 1H), 4.26 (t, 2H, J = 5.8 Hz), 3.54 (t, 2H, J = 5.8 Hz), 3.40 (s, 3H),
3.72 (s, 3H).

13

C NMR (CDCl3, 100 MHz): δ 165.8, 157.6, 136.5, 129.7, 125.0, 123.7,

122.6, 117.2, 115.6, 88.3, 83.7, 66.6, 50.8, 35.7, 19.2. HRMS calcd for C15H15NO3S3Na+
376.0106, found 376.0107.

3-((2-Methylthiazol-4-yl)ethynyl)aniline (5.98)
Fe (s) (340 mg, 6.10 mmol) was added to a solution of 2-methyl-4-((3nitrophenyl)ethynyl)thiazole (5.101; Alagille et al., 2004) (271 mg, 1.11 mmol) in glacial
AcOH (2.43 mL, 42.61 mmol), H2O (1.21 mL, 67.75 mmol), and EtOH (2.41 mL, 41.19
mmol). The mixture was sonicated for 1.5 hrs then diluted with EtOAc and filtered over
Celite®.

The organic phase/filtrate was washed with 2M aq. NaOH, brine, dried

(MgSO4), filtered, concentrated, and chromatographed (EtOAc:hexanes, 3.5:6.5) to give
214 mg of aniline 5.98 as an oil (91%). Rf = 0.25 (EtOAc:hexanes, 3.5:6.5).
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1

H NMR

(CDCl3, 400 MHz): δ 7.32 (s, 1H), 7.07 (t, 1H, J = 7.8 Hz), 6.93 (dt, 1H, J = 7.6, 1.2 Hz),
6.82 (t, 1H, J = 2.1 Hz), 6.63 (dd, 1H, J = 8.0, 0.9 Hz), 3.73 (br s, 2H), 2.69 (s, 3H).

13

C

NMR (CDCl3, 100 MHz): δ 165.7, 146.5, 136.9, 129.3, 122.9, 122.2, 121.9, 117.8, 115.7,
89.2, 82.8, 19.2. HRMS calcd for C12H10N2SH+ 215.0637, found 215.0637.

1-(3-((2-Methylthiazol-4-yl)ethynyl)phenyl)-1H-pyrrole-2,5-dione (4.56)
A mixture of aniline 5.98 (124 mg, 0.58 mmol) and maleic anhydride (5.97) (60 mg, 0.58
mmol) in THF (5 mL) was refluxed for 3 hrs. The reaction mixture was then cooled to
room temperature, diluted with Et2O, and concentrated under reduced pressure. NaOAc
(25 mg, 0.24 mmol) and acetic anhydride (7 mL) was then added to the previous reaction
flask and the mixture was heated at 100 ˚C for 40 min. The mixture was cooled to room
temperature, diluted with 5% aq. NaHCO3, and then extracted with CHCl3 (2 × 30 mL).
The combined organic layers were washed with brine, dried (MgSO4), filtered,
concentrated, and chromatographed (EtOAc:hexanes. 1:1) to give 120 mg of succinimide
4.56 as a yellow solid (70%). Rf = 0.40 (EtOAc:hexanes, 1:1).

1

H NMR (CDCl3, 400

MHz): δ 7.57-7.53 (m, 2H), 7.44 (t, 1H, J = 8.1 Hz), 7.39 (s, 1H), 7.37-7.34 (m, 1H), 6.87
(s, 2H), 2.74 (s, 3H).

13

C NMR (CDCl3, 100 MHz): δ 169.1, 165.8, 136.5, 134.2, 131.4,

130.9, 129.1, 128.9, 126.0, 123.5, 122.7, 87.6, 84.4, 19.2.
C16H10N2O2SNa+ 317.0355, found 317.0354.
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HRMS calcd for
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Appendix
A.1.

Stannylation, Radioiodination and DAT Covalent Ligation of Racemic threo-

p-Azido-N-Benzyl-4-Iodo-MP
With respect to identifying candidate probes for photoaffinity labeling
experiments, ideal compounds are those that are bioactive in the same range as the parent
compound. However, compounds with as much as 1000-fold lower activity can still be
useful (Dorman and Prestwich, 2000). Given racemic threo-p-azido-N-benzyl-4-iodoMP ((±)-4.26) displayed modest DAT binding affinity, and the highest DAT binding
affinity (Ki = 363 ± 28 nM) in the series of racemic threo-N-azidobenzyl-4-iodo/3-iodoMP compounds (4.24-4.29), further development of this compound into a potential DAT
photoprobe was pursued.

Given that wash-resistant binding experiments involving

nonradioactive azido compounds frequently give false positives in the assessment of
covalent attachment (Agoston et al., 1997), synthesis of a radioiodinated (i.e., [125I])
version of racemic threo-p-azido-N-benzyl-4-iodo-MP ((±)-4.26) was pursued to
determine if photoactivation could produce covalent ligation to the DAT. In this regard,
racemic p-azido-N-benzyl-4-iodo-MP ((±)-4.26) was subjected to Stille coupling
(conditions adapted from Shu et al., 1996) with bis(tributyltin) to provide stannyl
derivative (±)-5.23 in 40% yield (Scheme A.1). This compound was then converted to
radioactive iodide derivative [125I]-(±)-4.26 by Dr. John Lever at the University of
Missouri-Columbia. Briefly, Dr. Lever treated stannyl derivative (±)-5.23 with [125I]-NaI
(1.53 mCi) in the presence of Chloramine- T. This chemistry ended with reversed-phase
HPLC isolation to provide [125I]-(±)-4.26 in 61% isolated yield, high purity (98%), and
high specific activity (2099 mCi/umol).

Furthermore, this radioligand exhibited a
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chromatographic profile identical to that of non-radioactive (±)-4.26. Also, purified
[125I]-(±)-4.26 co-eluted with a fully characterized sample of non-radioactive (±)-4.26
under the same reverse-phase HPLC conditions (Lapinsky et al., 2011).

Scheme A.1. Stannylation, radioiodination and DAT covalent ligation of racemic threo-p-azido-Nbenzyl-4-iodo-MP

To determine if the DAT was able to be irreversibly labeled ((±)-5.24, Scheme
A.1) with [125I]-(±)-4.26, Dr. Roxanne Vaughan’s group (University of North Dakota)
performed photoaffinity labeling with rat striatal membranes and HEK 293 cells
expressing 6Xhis-DAT incubated with 30 nM [125I]-(±)-4.26 in the absence or presence
of 10 M or 100 M -CFT ((-)-2--carbomethoxy-3--(4-fluoro-phenyl)tropane, WIN35,428, a cocaine analog) or D-(+)-MP (D-MPH) (Scheme A.1). The membranes and
cells were then detergent-solubilized and the lystates were immunoprecipitated with DAT
antibody and analyzed by SDS-PAGE/autoradiography. Labeled proteins of ~80 kDa
were obtained from both rat striatal tissue (Figure A.1) and HEK hDAT cells,
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demonstrating the incorporation of [125I]-(±)-4.26 into the DAT. Incorporation of the
ligand was blocked by 75-90% by both -CFT and D-MPH, demonstrating the
appropriate pharmacological specificity of [125I]-(±)-4.26 attachment to the DAT. In
particular, [125I]-(±)-4.26 represents the first successful example of a DAT photoaffinity
ligand based on a MP scaffold, thus representing an important contribution to the arsenal
of probes for characterizing DAT function and 3-D structure (Lapinsky et al., 2011).

Figure A.1. Photoafﬁnity labeling of the DAT with [125I]-(±)-4.26 performed by the Vaughan group
(Lapinsky et al., 2011). Rat striatal membranes were photoaffinity labeled with 30 nM [125I]-(±)-4.26
in the absence or presence of 10 M or 100 M -CFT or D-MPH. Membranes were solubilized and
DATs were immunoprecipitated followed by analysis by SDS-PAGE and autoradiography. The
relevant portion of a representative autoradiograph is pictured followed by a histogram that quantitates
relative band intensities. Mean ± SE of three independent experiments is shown; ***P<0.001 versus
control.

A.2.

Stannylation, Radioiodination and DAT Covalent Ligation of (-)-3-Iodo-4-

Azido-N-Benzyl-Ritalinol
Given (-)-3-iodo-4-azido-N-benzyl-ritalinol ((-)-4.36) displayed the highest DAT
binding affinity (Ki = 218 ± 29 nM) of the enantiopure MP-based photoaffinity ligands
synthesized during this work, further development of this compound into a potential DAT
photoprobe was pursued. Once again, given that wash-resistant binding experiments
involving nonradioactive azido compounds frequently give false positives in the
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assessment of covalent attachment (Agoston et al., 1997), synthesis of a radioiodinated
(i.e., [125I]) version of enantiopure (-)-3-iodo-4-azido-N-benzyl-ritalinol ((-)-4.36) was
pursued to determine if photoactivation could produce covalent ligation to the DAT.

Scheme A.2. Stannylation, radioiodination and DAT covalent ligation of (-)-3-iodo-4-azido-Nbenzyl-ritalinol

In this regard, enantiopure (-)-3-iodo-4-azido-N-benzyl-ritalinol ((-)-4.36) was
subjected to Stille coupling (conditions adapted from Shu et al., 1996) with
bis(tributyltin) to provide stannyl derivative (-)-5.40 in 40% yield (Scheme A.2). This
compound was then converted to radioactive iodide derivative [125I]-4.36 by Dr. John
Lever at the University of Missouri-Columbia.

Briefly, Dr. Lever treated stannyl

derivative (-)-5.40 with [125I]-NaI (1.53 mCi) in the presence of Chloramine- T. This
chemistry ended with reversed-phase HPLC isolation to provide [125I]-4.36 in 35%
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isolated yield with a high specific activity (2120 mCi/umol). This radioligand exhibited a
chromatographic profile identical to that of non-radioactive (-)-4.36.

Furthermore,

purified [125I]-4.36 co-eluted with a fully characterized sample of non-radioactive (-)-4.36
under the same reverse-phase HPLC conditions (Lapinsky et al., unpublished results).
To determine if the DAT could be irreversibly labeled (5.41, Scheme A.2) with
[125I]- 4.36, Dr. Roxanne Vaughan’s group (University of North Dakota) performed
photoaffinity labeling with rat striatal membranes and HEK 293 cells expressing 6XhisDAT incubated with 30 nM [125I]-4.36 in the absence or presence of 10 M -CFT ((-)-2-carbomethoxy-3--(4-fluoro-phenyl)tropane, WIN-35,428, a cocaine analog) or D-(+)MP (D-MPH) (Scheme A.2). The membranes and cells were then detergent-solubilized
and the lystates were immunoprecipitated with DAT antibody and analyzed by SDSPAGE/autoradiography.

Labeled proteins of ~80 kDa were obtained from both rat

striatal tissue (Figure A.2) and HEK hDAT cells, demonstrating the incorporation of
[125I]-4.36 into the DAT. Incorporation of the enantiomerically pure photoaffinity ligand
was blocked by 60-70% by both -CFT and D-MPH, demonstrating the appropriate
pharmacological specificity for [125I]-4.36 attachment to the DAT. In summary, [125I]4.36 represents the first successful example of an enantiopure DAT photoaffinity ligand
based on a MP scaffold, thus representing an important contribution to the arsenal of
chemical probes useful for characterizing DAT function and 3-D structure.
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Figure A.2. Photoafﬁnity labeling of the DAT with [125I]-4.36 performed by the Vaughan group
(Lapinsky et al., unpublished results). Rat striatal membranes were photoaffinity labeled with 30 nM
[125I]-4.36 in the absence or presence of 10 M or 100 M -CFT or D-MPH. Membranes were
solubilized and DATs were immunoprecipitated followed by analysis by SDS-PAGE and
autoradiography. The relevant portion of a representative autoradiograph is pictured followed by a
histogram that quantitates relative band intensities. Mean ± SE of three independent experiments is
shown; ***P<0.001 versus control.

A.3.

Tandem Photoaffinity Labeling-Bioorthogonal Conjugation of a Clickable

Thiazole Benzophenone Propargyl Ether mGlu5 NAM
Given clickable benzophenone propargyl ether mGlu5 NAM 4.49 (RVDU-3-130)
displays improved mGlu5 binding affinity (Ki = 11 ± 0.8 nM) versus lead compounds
4.45 (Ki = 59 ± 0.9 nM) and 4.46 (Ki = 48 ± 0.8 nM), and retained mGlu5 NAM
functional potency, this photoprobe is currently being evaluated in mGlu5 tandem
photoaffinity labeling-bioorthogonal conjugation experiments in Dr. Karen Gregory’s
laboratory at Monash University (Scheme A.3).
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Scheme A.3. mGlu5 tandem photoaffinity labeling-bioorthogonal conjugation of a clickable thiazole
benzophenone propargyl ether mGlu5 NAM photoprobe.

To determine if mGlu5 could be irreversibly labeled (5.75, Scheme A.3) with
photoprobe 4.49 (RVDU-3-130), Dr. Karen Gregory incubated membrane preparations
from nontransfected HEK293 cells or HEK-mGlu5 with 1 µM 4.49 (RVDU-3-130), or a
vehicle control (1% DMSO), for 2 hours with or without UV irradiation for 30 minutes at
4 ˚C.

After three washes, the cells were then resuspended in assay buffer and an

inhibition binding assay for MPEP was performed. These experiments indicate that
target probe 4.49 (RVDU-3-130) successfully irreversibly labels HEK-mGlu5 not only in
presence of UV light, but also, unexpectedly, in absence of UV light (Figure A.3).
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Figure A.3. Demonstration of irreversible labeling of HEK-mGlu5 in the presence or absence of UV
light with RVDU-3-130 (4.49), a clickable benzophenone propargyl ether mGlu5 NAM photoprobe.

Subsequently, non-transfected samples were then “clicked” with near-infrared
fluorescent Cy7.5 azide (Figure A.4 shown as green; 5.78, Figure A.5 for Cy7.5 azide
structure), while mGlu5 samples were “clicked” with near-infrared fluorescent Cy5.5
azide (Figure A.4 shown as red; 5.76, Scheme A.3 for Cy5.5 azide structure), then
separated by SDS-PAGE and visualized using an Odyssey Scanner (LICOR).

Figure A.4. mGlu5 photoaffinity labeling
experiments involving RVDU-3-130.

Figure A.5. Cy7.5 azide

The results of these experiments indicate no incorporation of either azide was evident in
the absence of RVDU-3-130 (Figure A.4, lanes 1-3). Furthermore, non-transfected (lane
4) and mGlu5 samples (lane 5) were combined, wherein yellow bands in lane 6 indicate
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non-specific binding of RVDU-3-130 and red bands indicate mGlu5 specific
incorporation of RVDU-3-130-Cy5.5.

Subsequent immunoblotting experiments

performed by Dr. Gregory revealed: A) Cy5.5-positive bands at high molecular weight
that co-localize with anti-Glu5 (consistent with mGlu5 dimers/oligomer), and B) a
mGlu5-specific band at ~70kDa that does not localize with anti-mGlu5; however, the size
of this band is consistent with that expected of a N- and C-terminal cleavage product. In
subsequent experiments, Dr. Gregory found that incorporation of RVDU-3-130+azide at
+250kDa and ~70kDa can be blocked by co-incubation with a competitive ligand (4.44)
at 10 µM (data not shown).

These preliminary efforts demonstrate successful

photolabeling of mGlu5 and incorporation of a near-infrared fluorescent tag utilizing
click chemistry, although further optimization is still required. As of the writing of this
dissertation, Dr. Gregory is currently working on improving photoaffinity labelingbiorthogonal conjugation protocols in order to progress towards purification/digestion for
characterization of mGlu5 3-D structure and function.
A.4.

Preliminary Docking Experiments of a Methanethiosulfonate-Containing

mGlu5 MPEP-Binding Site NAM Thiol-Reactive Chemical Probe for mGlu5
Engineered Affinity Labeling Experiments
Given methanethiosulfonate-containing mGlu5 MPEP-binding site NAM thiolreactive chemical probe 4.55 retained appropriate mGlu5 binding affinity (Ki = 13 ± 0.8
nM, ~2-fold lower than parent compound 4.44) and NAM functional potency, this probe
has been subjected to prelimary docking experiments (Figure A.6) in a mGlu5 homology
model developed by Dr. Jens Meiler’s group (Vanderbilt University) to suggest rational
cysteine mutations for proposed mGlu5 engineered affinity labeling experiments. These
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initial efforts indicate that methanethiosulfonate-containing mGlu5 MPEP-binding site
NAM thiol-reactive chemical probe 4.55 is binding in the same pocket as that of other
known MPEP-binding site modulators. In particular, Figure A.6 shows the top three
lowest energy poses identified. Based on these studies and as of the writing of this
dissertation, Dr. Gregory is currently making several rational cysteine mGlu5 mutations
for engineered affinity labeling experiements involving probe 4.55.

Figure A.6. The top three lowest energy poses upon docking of methanethiosulfonate containing
mGlu5 MPEP-binding site NAM thiol-reactive
chemical probe 4.55 (green, blue, magenta) in a mGlu5 homology model.

240

